Macrophage regulation in atherosclerosis by Falck-Hansen, Mika André




Macrophage Regulation in Atherosclerosis 
 
A thesis submitted to the Faculty of Medicine, Imperial College London  
for the degree of Doctor of Philosophy 
 
Mika André Falck-Hansen 
 
 
        SUPERVISORS 
          Professor Claudia Monaco 
          Kennedy Institute of Rheumatology 
         NDORMS, University of Oxford 
 
 Professor Rob Krams 
 Department of Bioengineering 
 Faculty of Engineering 
 Imperial College London 
 
 














“If you would be a real seeker after truth, it is necessary that at 
least once in your life you doubt, as far as possible, all things.” – René Descartes  
 
“Discovery consists of seeing what everybody has seen and 
thinking what nobody has thought.” 








Atherosclerosis is the leading cause of cardiovascular disease, topping the 
mortality list in the United Kingdom and the rest of the world. Macrophage 
activation and polarisation are key steps in host defence and chronic 
inflammatory diseases, including atherosclerosis. The myeloid glycoprotein 
receptor CD200R1 belongs to a family of four isoforms and signals after 
binding to its cognate ligand, CD200. The CD200/CD200R1 interaction 
blocks pro-inflammatory cytokines and has never before been studied in 
atherosclerosis. My work has demonstrated that CD200R is weakly 
expressed in atherosclerotic lesions during disease progression and 
significantly down-regulated in secondary lymphoid organs. Moreover, 
changes in shear stress had no effect on the expression of CD200R in 
plaques. During the steady state, the expression of CD200R on circulating 
monocytes was highest on the CD11b+CD115+Ly6Cint subset, revealing a 
potential mechanism for regulation of maturing monocytes. In vitro studies 
demonstrated that CD200R expression is sensitive to M1 macrophage 
polarising cytokine IFN-γ and MyD88-dependent TLR ligands. In contrast, 
non-MyD88-dependent TLR3 signalling had no effect on its expression, 
supporting previous findings in the literature. Moreover, CD200R1 mRNA 
expression was induced on alternatively activated M2a macrophage subsets 
following IL-4 and IL-13 cytokine treatment, whereas oxLDL had no effect. 
Immunotherapy with CD200-Fc in ApoE-/- mice exerted no significant 
changes on lesion size and phenotype compared to controls after nine weeks. 
My findings indicate that the type of inflammatory stimulus may play a role in 
dictating the ability of myeloid cells to terminate their own activation via 
CD200/CD200R1 signalling. Hence, chronic inflammation may be promoted 
by reduced presence of inhibitory signals leading to sustained, unresolved 
inflammation. In summary, my work has revealed new insight into the 
regulation of the inhibitory CD200R pathway in atherosclerosis, the molecular 
signals that may affect the regulation of inflammation through CD200R and 
possible future therapeutic strategies. 
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Atherosclerosis is derived from the Greek ‘gruel’ to describe the 
composition of a typical atheromatous plaque. The condition is a source of 
great mortality in the western world and is an important factor in the clinical 
outcome of coronary heart disease, cardiovascular disease and 
cerebrovascular disease (Loscalzo 2005). Atherosclerosis is a multifactorial 
inflammatory disease (Badimon, Fuster et al. 1993; Ross 1999), initiating 
from the accumulation and oxidation of lipids in the intima, the innermost 
layer of the vessel wall, leading to the activation of the immune system, the 
body’s mechanism of protection and handling foreign invasion (Hansson 
2001). Atherogenesis advances at early adolescence, but is frequently not 
apparent until the mid-forties. Atherosclerosis is no longer considered solely 
a disease of lipid accumulation, but a disease process that shares many 
features with prototypical inflammatory disease (Ross 1999). 
 
1.2 Clinical risk factors 
 
Atherosclerosis development involves a series of systemic risk factors. 
Complex immune reactions interact with metabolic risk factors at the 
systemic level, and local hemodynamic risk factors at the local level, leading 
to chronic inflammation that can begin already during childhood or early 
adolescence (Hansson 2005). Risk factors include hyperlipidaemia, body 
mass index (BMI), smoking, hypertension, diabetes type II and the 
metabolic syndrome, inflammation (Loscalzo 2005) and endothelial shear 




Michael S. Brown and Joseph Goldstein proposed the initial theories that 
arose concerning lipid storage and lipid accumulation for the development 
of atherosclerosis. Brown and Goldstein were studying familial 
hypercholesterolemia, a disease where patients lack the low-density 
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lipoprotein receptor and are incapable or severely impaired in their ability to 
remove LDL from the circulation. This observation led to the concept of 
cholesterol accumulation as an accelerating factor for atherogenesis 
(Goldstein and Brown 1973). However, this finding did not account for 
changes in the intima/media ratio of patients as patients with high and low 
levels of LDL had no differences in this diagnostic characteristic. This 
suggested that there was an additional contributing factor. Later on, further 
studies found macrophages with scavenger receptors (which can uptake 
lipoproteins) in both patient groups, indicating other mechanisms of 
cholesterol uptake could occur, in particular involving the immune system 
(Slavkin 1999). Later, a distinction between good and bad cholesterol was 
defined and associated with risk for developing CVD (i.e. low levels of high-
density lipoprotein (HDL) and high levels of low-density lipoprotein (LDL) 
have been associated with CVD risk) (Loscalzo 2005). 
1.2.2 Hypertension 
 
It has been described that the risk of CVD is greatly related to levels of 
blood pressure, and interestingly levels of systolic blood pressure are 
usually more correlated with the development of CVD, in comparison to 
levels of diastolic pressure. Hypertension usually adds a relative risk of 2.0 
for CVD, looking at systolic and diastolic combined (Kannel 2000; Basile 
2003). High blood pressure that does not meet the criteria for hypertension 
may increase the risk for CVD and may be as important as hypertension 
itself, on a population-wide basis (Vasan, Larson et al. 2001). A wide array 
of clinical studies have been conducted to lower blood pressure and have 
established that CHD risk is reduced when diet and other agents have 










Smoking, another important risk factor, has declined in recent years in the 
developed world (Dube, Asman et al. 2009; Simpson, Hippisley-Cox et al. 
2010). Cigarette smoking in general doubles the risk of CVD and passive 
smoking increases the risk of CHD by 30% compared to non-smokers. In 
fact, it has been reported that people exposed to environmental smoke have 
an augmented intima medial thickness of their carotid arteries (Steenland 




Obesity, another risk factor for atherosclerosis, is measured by the WHO’s 
body mass index (body weight in kg divided by height in m2) and may be 
used to indicate different levels of body weight. Overweight is defined as a 
BMI of 25-29.9 kg/m2 and obesity by a BMI > 30kg/m2. Obesity has 
increased dramatically over the past 50 years as lifestyle and eating habits 
have changed (WHO 2011). 
 
1.2.5 Diabetes type II and the metabolic syndrome 
 
Diabetes type II has been identified as another risk factor for atherosclerosis. 
Data from Finland in the late 90s’s has indicated that the risk for a heart 
attack in a person with diabetes is nearly identical to that in persons who 
have already had a heart attack, at risk for a second attack (Haffner, Lehto 
et al. 1998). The metabolic syndrome is a more recently described condition 
that embodies insulin resistance and a minimum of 3 of the following risk 
factors: high blood pressure, impaired fasting glucose, increased 
triglycerides, decreased HDL cholesterol and greater abdominal adiposity, 
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1.3 Haemodynamic components 	  
1.3.1 Blood constituents 
 
Blood is the only tissue in the body that flows. Blood is a concentrated 
suspension of cells with dimensions comparable to vessel diameters and 
these dimensions have a strong influence on blood flow. The main 
constituents are plasma, red blood cells (RBCs), white blood cells and 
platelets. Plasma is a straw coloured fluid in which the blood cells are 
suspended and makes up approximately 55% of the blood volume. Plasma 
is made up of approximately 90% water, glucose, fats, amino acids, 
electrolytes such as calcium, potassium and sodium, proteins such as 
fibrinogen (involved in blood clotting), albumin, antibodies and hormones 
some of which are able to regulate blood flow (e.g. adrenaline). 
Approximately 45% of blood is composed of RBCs. The RBC has a fluid 
interior, surrounded by a flexible membrane that can strongly resist area 
changes, but is flexible, bending easily (Secomb 1995; Secomb and Hsu 
1995). The size of white blood cells (leukocytes) is comparable, but they are 
much less abundant (only 5-10’000 WBC/µL blood) and are able to move by 
themselves. Finally, the platelets (thrombocytes) – are disc shaped cell 
fragments, which are involved in clotting the blood to prevent the excess 
loss of body fluids. The viscosity of blood is a principal property of blood 
related to its internal friction that causes blood to resist flow. The 
haematocrit (packed cell volume) is the main factor that determines the 
viscosity of blood (Chatzizisis, Coskun et al. 2007). 
1.3.2 Endothelial shear stress 
Shear stress, the drag force acting on the endothelium also defined as the 
component of stress coplanar with a material cross section is a key 
haemodynamic factor in atherosclerosis. Arterial-level shear stress (>15 
dyne/cm2) leads to the expression of protective genes, while low shear 
stress (<4 dyne/cm2) induces an atherogenic phenotype (Malek, Alper et al. 
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1999). This theory that mechanical irritation of the arterial wall is a cause of 
atherosclerosis was first proposed in the 1870’s (Caro 2009). During the 
mid-20th century, speculation arose that there might be a correlation 
between regions where shearing force was maximal and the commonest 
sites of atherogenesis (Duguid and Robertson 1957; McDonald 1960). 
Several studies have proposed that atherogenesis occurs at inner 
curvatures or branch-points such as bifurcations of the arteries (DeBakey, 










Figure 1.1 – Blood flow displays complex fluid behaviour. 
This figure illustrates the complex behaviour of blood flow at bifurcations with 50% stenosis. 
Figure adopted from (Hammer, Jeays et al. 2009). 
 
The risk factors for atherosclerosis are abundant in number and more is 
being understood each day as research is unfolding the mechanisms 
whereby risk factors act on a systemic and local level, tying inflammation 
together with systemic risk factors such as diabetes, lipid accumulation and 
shear stress, justifying the need for inter-disciplinary research that ties 
these different risk factors together. 
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1.3.3 Blood flow at branch points and bifurcations 
 
Blood may behave as a Newtonian fluid or as a non-Newtonian fluid. In 
large-sized arteries, such as the aorta, blood flows widely in a Newtonian 
fashion. In veins, small sized arteries and in the microcirculation, however, 
blood behaves in a non-Newtonian fashion, which is when the fluid viscosity 
is not constant (Chatzizisis, Coskun et al. 2007). The endothelium lining the 
inner region of the vessel is composed of a layer of ECs exposed to the 
blood flow and hemodynamic forces. These modulate the ECs functions 
and vascular biology by inducing changes in the endothelial phenotype, 
endothelial cell signalling, gene and protein expression leading to a pro-
inflammatory phenotype, disturbance of the extracellular matrix, reduced 
access of nitric oxide, leading to plaque development (Dhawan, Avati 
Nanjundappa et al. 2010). Hemodynamic factors are key contributors to the 
localisation of atherosclerotic lesions. Shear stress, the drag force acting on 
the endothelium as a result of blood flow, is a potent modulator of 
atherosclerotic plaque formation and progression (Garcia-Cardena, 
Comander et al. 2001). The patterns of flow are not homogeneous since at 
sites with complex geometries, e.g. branches and inner curvatures, there 
will be disturbed flow. Atherosclerotic plaque formation occurs preferentially 
in such areas, where shear stress is low (<1.5 N/m2 in humans), or near 
bifurcations, where shear stress is oscillatory. Shear stress arises from the 
difference in viscosity and motion between the two layers of a fluid inducing 
friction. The areas of the arterial tree that are exposed to unidirectional and 
constant laminar flow (regions with high shear stress) stem from areas with 
uniform geometry, whereas oscillatory and disturbed flow, exhibiting low 
shear stress at branch-points such as the aortic bifurcation, where the 
abdominal aorta bifurcates into the left and right common iliac arteries, and 
inner curvatures, such as the aortic arch (Davies 2009; Nakazawa, Yazdani 
et al. 2010; Cecchi, Giglioli et al. 2011). Here, recirculation or flow 
separation may occur (Nixon, Gunel et al. 2010). Thus, atherosclerosis 
occurs in a site-specific manner, predominantly at regions of low shear 
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stress in large and medium-sized arteries. Regions exposed to constant 
flow are protected (high shear stress regions) (Malek, Alper et al. 1999). 
During disturbed flow, there is often a rapid and random temporal and 
spatial variation of velocity at any given point. In conclusion, as blood flows 
through the arteries, the cellular components of the vascular system are 
exposed to different patterns of mechanical stimulus. The emergence of 
shear stress as an important risk factor for atherosclerosis development has 
become established (Malek, Alper et al. 1999). 
 
1.3.4 Low shear stress mechanotransduction 
 
Low shear stress (LSS) has been shown to have a variety of effects on the 
vessel wall. First, it attenuates nitric oxide (NO) dependent atheroprotection. 
As a main constituent of normal vascular tone, NO has also got strong anti-
inflammatory, anti-apoptotic, anti-thrombotic and anti-mitogenic 
characteristics (Harrison, Widder et al. 2006). Normal, physiological shear 
stress is the most significant contributor for continuous NO production by 
the endothelium. This effect is modulated at a transcriptional, gene 
expression or post-transcriptional level (Go, Boo et al. 2001; Lam, Peterson 
et al. 2006). Low shear stress also down-regulates prostacyclin, described 
as another vasodilator of the endothelium, while up-regulating endothelin-1, 
a strong constrictor involved in mitogenesis (Ziegler, Bouzourene et al. 
1998; Qiu and Tarbell 2000; Stone, Coskun et al. 2003). In essence, these 
factors accelerate atherosclerosis formation (Ziegler, Bouzourene et al. 
1998; Malek, Alper et al. 1999; Liu, Chen et al. 2002). The low shear stress 
also leads to the activation in a family of transcription factors termed the 
sterol regulatory elements binding proteins (SREBPs). These up-regulate 
the genes that encode the LDL receptor, which is able to uptake LDL 
particles. This eventually leads to LDL accumulating in the sub-endothelial 
layer (Chien 2003).  Low shear stress and disturbed flow leads to an 
augmented permeability of endothelial cells, further aiding the accumulation 
of LDL (Traub and Berk 1998; Buchanan, Kleinstreuer et al. 1999; Himburg, 
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Grzybowski et al. 2004). Other changes include the up-regulation of IFN-γ, 
TNF-α, IL-1 (Brooks, Lelkes et al. 2002; Dai, Kaazempur-Mofrad et al. 
2004), BMP-4 (Sorescu, Song et al. 2004; Cunningham and Gotlieb 2005), 
MMP2, MMP9 (Bassiouny, Song et al. 1998; Godin, Ivan et al. 2000; Magid, 
Murphy et al. 2003; Gambillara, Montorzi et al. 2005; Cheng, Tempel et al. 
2006), Cathepsin L (Platt, Ankeny et al. 2006), oxidative enzymes (NADPH 
oxidase (Hwang, Ing et al. 2003), Xanthine oxidase (McNally, Davis et al. 
2003) increased VSMC apoptosis induced by NO signalling (Slager, 
Wentzel et al. 2005), increased expression of chemoattractants (Collins and 
Cybulsky 2001; Brooks, Lelkes et al. 2002; Dai, Kaazempur-Mofrad et al. 
2004), adhesion molecules (VCAM-1, ICAM-1, E-Selectin) (Collins and 
Cybulsky 2001; Brooks, Lelkes et al. 2002; Hsiai, Cho et al. 2003; Mohan, 
Hamuro et al. 2003; Dai, Kaazempur-Mofrad et al. 2004; Orr, Sanders et al. 
2005; Cheng, Tempel et al. 2006). In addition to a down-regulation of 
vasodilatory molecules, there is a down-regulation in antioxidative enzymes 
and growth inhibitors (e.g. TGF-β). Consequentially, a number of factors 
activated by low shear stress attracts inflammatory cells, enhance the 
plaque uptake of leukocytes, degrades plaque and allows for an accelerated 
progression of disease. 
 
1.4 Principles of atherogenesis 
 
During atherogenesis, LDL molecules accumulate in the intima where they 
undergo oxidation by non-enzymatic reactive oxygen species (ROS) and 
enzymatic methods, such as exposure to myeloperoxidase in the arterial 
wall (Zhang, Brennan et al. 2002). Increasing evidence suggests that LDL 
induces endothelial activation after binding LOX-1, leading to the expression 
of adhesion molecules that lead to the recruitment of blood-borne 
mononuclear cells (Mehta, Chen et al. 2006). As described in more detail 
later, monocytes differentiate into macrophages. The activated 
macrophages produce inflammatory molecules such as cytokines, 
proteases, and reactive oxygen species (Moore and Tabas 2011). 
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Macrophages that ingest modified lipoproteins become foam cells, the 
hallmark of atherosclerotic lesions as reviewed by (Kruth 2001; Collot-
Teixeira, Martin et al. 2007). Later in the natural history of the disease, 
macrophages undergo apoptosis due to intracellular oxidised LDL (oxLDL) 
accumulation induced endoplasmic reticulum (ER) stress, and may become 
secondarily necrotic because of deficient clearance by phagocytosis (Tabas 
2010). The accumulation of necrotic macrophages and acellular lipids often 
gives rise to an atheromatous lipid-rich necrotic core (Tabas 2010).  
The necrotic core is surrounded by smooth muscle cells (SMCs) that build a 
fibrous cap (composed of collagen type I and III) (Wight 1989; Newby and 
Zaltsman 1999). The inflammatory process also involves other immune 
cells such as T lymphocytes and dendritic cells (DCs) which will have a role 
in immune events within the atherosclerotic plaque (Hansson 2005).   
The macrophage may therefore be considered an important mediator in the 
late-stage advanced atherosclerotic lesion build-up and rupture, when 
macrophages and other efferocytes are not able to function properly.  
For the build-up of plaque to occur, macrophages that become foam cells 
must first arrive at the lesions. This could occur through migratory 
monocytes that differentiate into macrophages. Below is an illustration of 













Figure 1.2 – The inflammatory atherosclerotic plaque.  
Monocyte migration and maturation form part of an inextricable atherosclerotic lesion 
formation process. The complex environment generated through the trapping and oxidation 
of lipids in the vessel wall initiates a response to injury, beginning with the recruitment of 
monocytes in areas with disturbed blood flow (1), leading to their extravasation (2) and to 
maturation into macrophages (3), dendritic cells (4) and formation of plaque resident foam 
cells that become necrotic and secondarily necrotic (5). The uptake of more cells is paired 
with the migration of growth factor producing smooth muscle cells from the adventitia and 
the media (6). Smooth muscle cells synthesize collagen under normal conditions. In a pro-
inflammatory environment they are less capable to do so. For instance the production of 
pro-inflammatory cytokine IFN-γ from inflammatory cells (e.g. NK cells) blocks collagen 
synthesis (7). Progressive destruction of fibrotic tissue, such as collagen can eventually 
lead to plaque rupture. Other cells identified in the plaque microenvironment include B cells 
(8), T cells (9) and more recently discovered for atherosclerosis, the NK T cells.  
 
1.4.1 The response to injury hypothesis 
 
The response to injury theory emanated with the studies conducted by 
Russell Ross, a dentist and doctor of experimental pathology working in 
Seattle, WA, USA who in the 1970’s proposed that atherosclerosis was 
caused by an excessive inflammatory response to injury and excessive 
healing of the injury (Slavkin 1999). Arising from a keen interest in the 
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the cells lining the inside of the blood vessel are subject to injury, platelets 
are recruited and secrete PDGF, stimulating smooth muscle cell (SMC) 
growth, which produce extracellular matrix, constituting a fatty streak (Ross 
1999; Slavkin 1999). The beginning for proof of his theory came about while 
studying SMCs under a variety of conditions in mice, rats, rabbits and 
primates. He observed with a transmission electron microscope that the 
SMCs had an extensive endoplasmic reticulum Golgi apparatus and were 
prone to forming extracellular matrices (Slavkin 1999). He identified PDGF 
as an important growth factor that stimulates the proliferation of SMCs 
(Ross, Glomset et al. 1974) and described that PDGF also can be produced 
by macrophages (Malden, Chait et al. 1991). It later became apparent that 
PDGF was only one of many growth factors contributing to cell proliferation 
in the response to atherosclerosis. In addition, Russell Ross and his team 
made the observation that SMCs also produce metalloproteinases as well 
as proteinase inhibitors leading to angiogenesis (Herren, Raines et al. 1997). 
Further studies conducted by Göran Hansson, Peter Libby and others tied 
atherosclerosis together with the response to injury and inflammation. 
 
1.4.2 The inflammation hypothesis 
 
Inflammation is the body’s response to injury. Evidence has emerged from 
various studies about the inflammatory aetiology of atherosclerosis - both 
innate and adaptive immune mediated inflammation (Libby, Ridker et al. 
2002; Hansson 2005). The incidence of cardiovascular events in other 
inflammatory and autoimmune disease such as systemic lupus 
erythematosus (SLE) and inflammatory arthritis are further evidence for the 
inflammatory link of atherosclerosis (Haque, Mirjafari et al. 2008; Full, 
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1.4.2.1 Inflammation and the innate immune system  
in atherosclerosis 
 
Low-grade chronic inflammation, as indicated by inflammatory markers such 
as C-reactive protein (CRP) is a predictor for a higher risk of developing 
atherosclerotic complications (Libby, Ridker et al. 2002). Further to this, 
treatments that reduce the risk of heart disease complication have been 
shown to reduce inflammation. This was evident in the JUPITER study, 
where statins, a gold-standard treatment used for lowering plasma 
cholesterol demonstrated anti-inflammatory effects (Kones 2009). 
Furthermore, in several different animal models of atherosclerosis (e.g. 
single, double and triple knockouts) it became evident that an important role 
was played by inflammatory leukocytes (Boring, Gosling et al. 1998; Abdi, 
Means et al. 2004; Kaikita, Hayasaki et al. 2004; Nahrendorf, Swirski et al. 
2007; Combadiere, Potteaux et al. 2008; Gautier, Jakubzick et al. 2009) and 
lymphocytes (Jonasson, Holm et al. 1986; Stemme, Holm et al. 1992; 
Stemme, Faber et al. 1995; Zhou, Stemme et al. 1996; Zhou, Paulsson et al. 
1998; Robertson, Rudling et al. 2003). The production of structure 
degrading mediators, such as matrix-degrading proteases and the blockage 
of wound-healing mechanisms such as collagen production ultimately lead 
to the development of an unstable cap, which may cause plaque rupture 
mediated by inflammation (Davies 1996). Macrophages also produce tissue 
factor, an important coagulant and trigger of thrombosis occurring in 
plaques (Libby, Ridker et al. 2002).  
1.4.2.2 Inflammation and the adaptive immune system  
in atherosclerosis 
 
T lymphocytes (Jonasson, Holm et al. 1986) and B lymphocytes contribute 
to lesion progression (Ait-Oufella, Herbin et al. 2010). Hansson and co-
workers showed that T lymphocytes and inflammatory cytokines play a key 
role in disease development. In 1986 they studied human atherosclerotic 
plaques using monoclonal antibodies against T lymphocyte markers and 
HLA-DR and showed that there was a regional accumulation of T 
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lymphocytes (in the fibrous cap), macrophages (lipid core) and SMCs 
(fibrous cap) in human atherosclerotic plaques (Jonasson, Holm et al. 1986). 
Later, in 1996, they showed that CD4+ T helper cells (also referred to as T 
helper lymphocytes) infiltrate lesions of ApoE-/- mice, giving evidence for a 
localized immune response in atherosclerosis (Zhou, Stemme et al. 1996). 
These cells had been found to be memory T lymphocytes expressing 
CD45RO and the integrin VLA-1 (Stemme, Holm et al. 1992) and later they 
showed that hypercholesterolemia is associated with a Th1/Th2 switch of 
the autoimmune response in ApoE-/- mice (Zhou, Paulsson et al. 1998) and 
that Th1 cells produced IFN-γ in the plaques, potentially stimulating 
macrophages. They showed that oxidized LDL (oxLDL) could drive this 
activation (Stemme, Faber et al. 1995). Subsequently, they studied the T 
lymphocyte receptor (TCR) gene expression in ApoE-/- lesions and found 
that there was a strongly skewed pattern of the CDR3 region, indicating 
oligoclonal expansion of T lymphocytes, suggesting the occurrence of 
antigen-driven T-cell proliferation in atherosclerosis (Paulsson, Zhou et al. 
2000). Hansson also described that a protective immune response 
counteracts the pathological process of atherosclerosis, as mediated by the 
anti-inflammatory cytokine TGF-β (Hansson, Ulfgren et al. 2002; Hansson 
and Robertson 2004). Mallat and co-workers were also interested in T 
lymphocytes and described the role of the anti-inflammatory cytokine IL-10 
in protection against atherosclerosis. They showed that IL-10 deficiency in 
C57BL/6 mice fed an atherogenic cholate containing diet promoted early 
lesion formation, characterized by abundant influx of inflammatory cells, 
mainly activated T lymphocytes and increased production of cytokines 
(Mallat, Besnard et al. 1999).  
1.4.2.3 Inflammation and plaque stability 
 
Peter Libby came from a background in Eugene Braunwald’s laboratory, 
where they were interested in how to limit infarct size, but Libby soon 
realized how important it was to look at the plaque characteristics and its 
inflammatory aetiology rather than just physical properties. Libby cultured 
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endothelial cells and SMCs and discovered that the vascular wall cells could 
produce pro-inflammatory mediators, tying together cardiovascular medicine 
with modern cell and molecular biology (Libby 1995). Later his group 
showed that inflammatory mediators could compromise the fibrous cap by 
stimulating macrophages that can produce collagen-degrading enzymes, 
disrupting the collagen-rich fibrous cap (Galis, Sukhova et al. 1995). 
Simultaneously, he showed that such degradation would also inhibit SMCs 
from synthesizing new collagen, fuelling the damage imposed by 
macrophages (Libby, Sukhova et al. 1995). 
1.4.3 Vulnerable plaque (TCFA)  
 
Pathology studies by Stary and co-workers have led to the categorisation of 
the human plaques into lesion types listed from type I (least severe) to type 
VI (most severe) (Stary, Chandler et al. 1995).  In general, lesion type I until 
type III are categorised as reversible, and lesion types IV to type VI are 
considered irreversible with a more extensive lipid core, described as the 
atheroma (type IV) and fibrous cap (type Va) or surface defects with 
thrombus and hematoma-haemorrhage (type VI) (Stary, Chandler et al. 
1995). The cellular and molecular composition of the atherosclerotic plaque, 
rather than its size, is the main determinant of adverse clinical outcomes 
such as myocardial infarction (MI) and stroke. Inflammation and matrix 
degradation at the fibrous cap site is thought to be the major mechanism 
underlying plaque rupture and subsequent thrombosis (Hansson 2005). The 
seminal work of London-based pathologist Michael Davies indicated that 
plaques that have recently caused acute cardiovascular events are 
characterised by an increased numbers of macrophages, and reduced 
numbers of smooth muscle cells, and a plaque morphology with a large lipid 
core and a thin plaque cap (Davies and Thomas 1984; Davies 1996)  as 
shown in Figure 1.3.  
 
 














Figure 1.3 – Mediators of plaque rupture. 
Plaques presenting with a high degree of infiltration of macrophages, a large lipid core, low 
smooth muscle cell content and a thin cap have a high risk of rupture, described here as 
danger. Figure adopted from (Davies 1996) 
 
Independent studies by Davies and Falk have also highlighted plaque 
rupture as the most frequent pathological substrate for the development of 
coronary thrombosis in acute MI (Falk 1983; Davies, Bland et al. 1989). 
However other pathological substrates have been described such as plaque 
erosion or the calcified nodule (Loscalzo 2005). More recently, Virmani, 
Burke et al refined the definition, by describing that the plaque must contain 
a fibrous cap less than 65 µm thick, infiltrated by macrophages (Virmani, 
Burke et al. 2002; Burke, Farb et al. 1997). Collectively, these studies led to 
the definition of “vulnerable” or “high-risk” atherosclerotic plaque named by 
Virmani “thin cap fibroatheroma” described as a plaque with a large 
lipidic/necrotic core covered by a thin fibrous cap and with abundant 
inflammatory infiltrates (Burke, Farb et al. 1997; Virmani, Burke et al. 2002; 
Mauriello, Sangiorgi et al. 2010), shown in Figure 1.4. Thus, plaque 
















Figure 1.4 – Vulnerable plaque. 
Schematic representation of the morphological features of a rupture-prone 
vulnerable plaque. Characteristic features include an attenuated fibrous cap, 
measuring <65 μm in thickness. The necrotic core underlying the cap forms 25% or 
more of the plaque area. The infiltration of macrophages is an important component 
of the composition of the necrotic core. During plaque growth, neointimal 
neovascularization and intraplaque haemorrhage are observed. Figure adopted from 
(Narula, Garg et al. 2008). 
 
1.5 Role of the immune system and macrophages 
1.5.1 Innate sensing 
 
The innate branch is able to detect molecular signals, such as endogenous 
damage patterns and exogenous pathogen associated molecular patterns 
(DAMPS and PAMPS, respectively). These molecules possess motifs, 
which are recognised by Toll-like and Nod-like receptors (TLRs and NLRs, 
respectively). These receptors can activate downstream signalling events 
leading to the activation of pro-inflammatory transcription factors, such as 
NF-κB and production of pro-inflammatory mediators, such as TNF-α, IL-1β, 
and IFN-γ. This will activate cells of the innate and the adaptive immune 
system leading either to a clearance of the infection or persistence of 
inflammation. If for any reason the initial innate response fails to protect the 
host from danger, the cells of the innate immune system remain essential 
for secondary immunity, as they are the drivers of the adaptive immune 
response. Activation of the adaptive immune system occurs when the 
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microorganisms are able to break the barrier of the innate system (Murphy, 
Travers et al. 2012). 
The innate immune system responds primarily to microorganisms such as 
bacteria, fungi and viruses and is the first response against infection. It can 
fully clear the pathogen without activating the adaptive immune system.  
The first barrier of defence against invading pathogens is the epidermis and 
mucosal membranes. In addition to forming a physical barrier, the 
epithelium also eliminates microorganisms by the production of anti-
microbial peptides (Murphy, Travers et al. 2012). The innate immune 
system is composed of the cells and cellular signalling pathways that 
comprise a non-specific detection and activation for the defence against 
pathogens. This includes the monocyte-macrophage, dendritic cells, natural 
killer cells and other myeloid cells such as granulocytes, neutrophils and 
basophils. During infection and inflammation, neutrophils are early 
responders to the sites of pathogen invasion (e.g. the blood or extravascular 
tissue), where they rapidly eliminate the organism, coated with antibodies 
and complement (Murphy, Travers et al. 2012). Within a few hours, the 
neutrophils die and thus do not re-enter the circulation. Monocytes are the 
innate immune system's other arm of circulating early responders, as they 
rapidly fight off the invading microorganisms. However, unlike neutrophils 
that are usually short lived, monocytes may develop into dendritic cells or 
macrophages and become resident in the tissues. 
The innate system is able to activate the adaptive immune system, which 
works by means of B lymphocyte-mediated antibody production and  
T lymphocyte-mediated cellular responses from CD8 cytotoxic T 
lymphocytes and CD4 helper T lymphocytes (Murphy, Travers et al. 2012). 
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1.5.2 Macrophages – A bridge between the innate and adaptive 
immune system 
Macrophages are innate immune cells, forming part of the myeloid branch 
of leukocytes (Murphy, Travers et al. 2012). Their role is important as first 
responders to tissue injury, host invasion, allowing for the initiation of the 
immune response through phagocytosis, antigen presentation and innate 
sensing through pattern recognition and scavenger receptor sensing of 
foreign or damaged particles (Gordon 2003). The primary function of 
macrophages in tissues is to regulate homeostasis. They do this through 
multiple cell membrane receptors for detection and through production of 
secreted proteins. They recognise dead cells, and engulf abnormal and 
senescent cells (Gordon 2003). As such, they serve as sensors for foreign 
materials, including PAMPs from invading microorganisms, DAMPs and 
other immunogens. Their adaptive function complements these innate 
immune functions, where they regulate T and B lymphocyte responses, 
partially via their subordinates, the myeloid DCs. Macrophages take up and 
present antigens in absence of DCs and release cytokines, such as IL-1,  
IL-6, IL-10, IL-12, IL-18 and TNF-α stimulating other immune cells in the 
tissue (Gordon 2003). Thus, via cytokines, macrophages are able to either 
promote or dampen inflammation, through positive or negative feedback. 
Growth and differentiation of macrophages is firmly controlled by distinct 
growth factors e.g. MCSF, GMCSF, or cytokines e.g. IL-4, IL-13, or IFN-γ 
and TLR ligands (e.g. LPS), leading to either M2 or M1 polarisation 
(Martinez, Helming et al. 2009; Gordon and Martinez 2010). As we 
understand more about macrophage polarisation, targeting of specific 
subsets may become easier to modulate disease outcome.  
Macrophage (incl. microglial) activity has been shown as regulated by 
inhibitory receptors. These can be sub-grouped into three main categories: 
the immunoglobulin superfamily (IgSF), the Siglecs and the C-type lectin 
family. The IgSF embodies inhibitory receptors such as the CD200 receptor 
(CD200R) that signals upon interaction with the CD200 ligand (Hoek, Ruuls 
et al. 2000) resulting in the inhibition of TNF, IL-5, IL-6 (Jenmalm, 
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Cherwinski et al. 2006; Zhang, Cherwinski et al. 2004). Its role will be 
described in more detail later. Other inhibitory receptors in the IgSF found 
on monocytes/macrophages and numerous other immune cells include the 
leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), also known 
as CD305 (Meyaard 2008). It functions as a defence mechanism in self-
recognition, as the expression of CD305 is thought to prevent lysis of self-
recognised cells (Meyaard 2008). LAIR1 binds to collagen and controls the 
activation in extracellular matrix, as reviewed in (Bryceson, March et al. 
2006).  There are too many other inhibitory receptors to be mentioned here, 
however, a comprehensive list can be found in the review by (Steevels and 
Meyaard 2011). 
1.5.3 Macrophage differentiation, polarisation and activation 
 
Macrophages are plastic and capable of modifying their behaviour upon 
micro-environmental cues. Signals derived from T lymphocytes or pathogen 
associated molecular patterns are potent regulators of macrophage 
behaviour. A paradigm of macrophage polarisation has recently been 
defined on the basis of parallels to Th1/Th2 lymphocyte polarisation 
(Martinez, Gordon et al. 2006). When exposed to bacterial motifs (e.g. LPS) 
and IFN-γ, macrophages undergo a type of priming that mirrors Th1 
lymphocyte polarisation, also called classic ‘activation’ (or M1 polarisation). 
M1-type macrophages are characterised by the production of pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF-α (Martinez, Gordon et 
al. 2006). Alternative (or M2) macrophage polarisation was first identified 
upon exposure to IL-4, reviewed by (Gordon and Martinez 2010). 
Subgrouping of macrophages has become further multifarious by grouping 
alternatively activated M2 macrophages into subgroups M2a, M2b and M2c. 
The M2a are polarised after exposure to cytokines IL-4 and IL-13, M2b 
upon exposure to immune complexes in combination with IL-1β or LPS, and 
M2c after exposure to IL-10, TGFβ or glucocorticoids (Martinez, Sica et al. 
2008). M2 macrophages are phenotypically characterised by exhibiting the 
expression of several markers, including the mannose receptor (CD206) 
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(Gordon 2003). Interestingly, the interplay between the M1 and M2 
phenotypes based on cytokine signals may be described as cross-
regulatory. IL-4 and IFN-γ cross-regulate each other in such a way that 
when IFN-γ levels are low, IL-4 is produced and when IFN-γ levels are high, 
IL-4 production is inhibited. This inhibition of IL-4 is mediated by inhibition of 
suppressor of cytokine signalling 1 (SOCS1) via activation of signal 
transducer and activator of transcription 1 (STAT1) (Hu and Ivashkiv 2009). 
The induction with IL-4 stimulates the activation of PPAR-gamma and is 
also activated by oxLDL and fatty acids, leading to the positive expression 
of mannose receptor CD206, IL-10 production and scavenger receptor  
up-regulation (Shalhoub, Falck-Hansen et al. 2011) as shown below in 
Figure 1.5. 
 
Figure 1.5 – PPAR-γ regulates transcription in alternatively activated macrophages. 
Peroxisome proliferator-activated receptor- γ (PPAR-γ) is a ligand-activated nuclear 
receptor with potent anti-inflammatory properties that modulates the immune inflammatory 
response. It has been observed in human atherosclerotic lesions and is involved in 
macrophage cholesterol homeostasis, cellular differentiation, lipid storage, insulin 
modulation, macrophage lipid homeostasis and anti-inflammatory activities. Molecules such 
as oxidised low density lipoprotein or fatty acids may stimulate inflammatory mediators 
such as HODE (9- and 13- hydroxyoctadecadienoic acid) generated via the 12,15 
lipoxygenase pathway. These are ligands for PPAR-γ. IL-4 is a cytokine that can stimulate 
PPAR-γ. PPAR-γ activation is also associated with the expression of M2 macrophage 
markers such as the mannose receptor (MR) also known as CD206. Figure published in 
(Shalhoub, Falck-Hansen et al. 2011). 
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The M1 and M2 paradigm is still often considered an oversimplification and 
some authors have suggested that there may be as many macrophage 
subtypes as there exist external stimuli (Mosser and Zhang 2008). The 
studies of Hamilton and co-workers proposed the possibility that also growth 
factors involved in myeloid cell differentiation could delegate macrophage 
behaviour. According to this model, differentiation with MCSF would lead to 
the generation of macrophages that share features and gene expression 
with M2 macrophages. Exposure to GMCSF, instead, would lead to a pro-
inflammatory macrophage that may share characteristics of M1 
macrophages (Fleetwood, Lawrence et al. 2007). During in vitro polarisation 
studies using human macrophages, Waldo and co-workers examined 
macrophages matured with either MCSF or GMCSF and found that these 
subsets exhibited differential expression of pro-inflammatory and anti-
inflammatory genes in addition to cholesterol homeostasis. They found that 
GMCSF macrophages demonstrated a ten-fold increased gene expression 
of PPAR-γ (Waldo, Li et al. 2008). M1 macrophages are phenotypically 
characterised by their up-regulation of markers such as the enzyme 
inducible nitric oxide synthase (iNOS). It must also be noted that other 
signals during the differentiation step, such as retinoic acid and lipoproteins 
may also have a substantial impact on the phenotype of the mature 
macrophage (Gordon and Martinez 2010).  
 
Once monocytes are recruited to the sub-endothelial space via chemotactic 
signals and adhesion molecules, they are exposed to a complex 
microenvironment rich in chemokines, cytokines, growth factors as well as 
modified LDL (Chia 1998; Hansson 2005). Resident vascular cells, such as 
SMCs and ECs, secrete MCSF, leading to the differentiation of monocytes 
into macrophages (Figure 1.2) (Clinton, Underwood et al. 1992).  
Macrophage polarisation may also have a role in the formation and outcome 
of atherosclerotic lesions (Bouhlel, Derudas et al. 2007; Khallou-Laschet, 
Varthaman et al. 2010). Interestingly, M2 macrophages accumulate first in 
murine atherosclerosis, while lesion progression correlates with 
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predominance of M1 over M2 macrophages (Khallou-Laschet, Varthaman et 
al. 2010). Both IFN-γ and TLR4 – the LPS receptor – are implicated in M1 
polarisation (Goerdt and Orfanos 1999) and their genetic deletion reduces 
atherosclerosis development (Gupta, Pablo et al. 1997; Michelsen, Wong et 
al. 2004). In an investigation from Waldo et al. studying human 
atherosclerotic plaques, the predominant macrophages present in the 
plaque were of the CD68+CD14+ phenotype (also the phenotype achieved 
using MCSF in vitro) (Waldo, Li et al. 2008). 
 
Lipids are also known to affect macrophage activation patterns. Indeed, 
more recent studies have suggested the existence of a new phenotype, the 
so-called Mox macrophage that is generated in response to atherogenic 
phospholipids via nuclear factor erythroid 2-like 2 (NRF2) (Kadl, Meher et al. 
2010). These cells represent approximately 30% of all macrophages in the 
murine advanced atherosclerotic lesion. (Kadl, Meher et al. 2010). The 
same study identified M2 macrophages as a considerable fraction (~20%) 
of total macrophages in the plaque (Kadl, Meher et al. 2010). Due to 
macrophage heterogeneity, phenotype abundance in the plaque could 
affect the surface marker expression relating to specific subsets.  
 
1.5.4 Macrophage plasticity: The rainbow spectrum. 
 
Although three main macrophage subsets have been described, there is 
evidence that macrophages are adaptive to a microenvironment and 
possess an ability to switch their transcriptional and protein production 
programmes dependent on the microenvironment. Krausgruber et al 
described the ability of human macrophages to switch from 'classically 
activated' M1 macrophages matured with GMCSF to 'alternatively activated' 
M2 macrophages matured with MCSF, and vice versa, using the interferon 
regulatory factor 5 (IRF5) transcription factor (Krausgruber, Blazek et al. 
2011). Mosser and Edwards reviewed in 2008 the full spectrum of 
macrophage activation (Mosser and Edwards 2008). They presented that 
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the biochemistry and function of M2 macrophages is widely variable and the 
classification of the two subcategories is not representative of the entire 
spectrum.  Therefore they proposed that a more informative foundation for 
macrophage classification based on the fundamental macrophage functions 
involved in homeostasis should be employed. Such functions include wound 
healing, host defence and immune regulation (Mosser and Edwards 2008).   
 
 
Figure 1.6 – Macrophage polarisation and plasticity. 
Macrophages have classically been described as M1 and M2. Shown here are the 
expression patterns of how these two phenotypes differ substantially with respect to the 
expression of macrophage-associated genes. More recently, Kadl et al have described a 
new subset of macrophages termed the MOX macrophages. These are induced by an 
environment rich in structurally defined oxidation products such as oxidised 1-palmitoyl-2-
arachidonoyl-sn-3-phosphorylcholine (oxPAPC) and can be induced from an M1 or M2 
phenotype. Acronym explanations can be found in the list of abbreviations.  
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1.5.5 TLRs are potent activators of macrophages and other  
myeloid cells 
Toll-like receptors (TLRs) are specific sensors of molecular patterns and are 
expressed on myeloid cells such as macrophages, monocytes and dendritic 
cells. Together with the IL-1 receptors, they form a superfamily, known as 
the IL-1 receptor/TLR superfamily, and all have a TIR domain, reviewed by 
(Falck-Hansen, Kassiteridi et al. 2013). TLRs are type I transmembrane 
proteins possessing ectodomains with leucine-rich repeats that permit the 
recognition of PAMPS and DAMPS and the TIR domain, which is essential 
for the following downstream signalling cascade, reviewed by (Kawai and 
Akira 2010; Falck-Hansen, Kassiteridi et al. 2013). Until now, 12 TLRs have 
been identified in mice and 10 in humans, with TLR1-9 conserved in both 
species, with some differences in signalling functionality. Gene knockout 
studies in mice have shown that the various receptors have distinct patterns 
of recognition. The class of molecules recognised by the TLRs includes 
nucleic acids, lipoproteins, lipids, and proteins from a variety of 
microorganisms including viruses, bacteria, fungi and parasites, reviewed 
by (Kawai and Akira 2010; Falck-Hansen, Kassiteridi et al. 2013). Even if 
the function of the receptors is to protect the host against infection, an 
unwanted activation by TLRs may occur in autoimmune and other chronic 
inflammatory disease states, reviewed by (Fischer and Ehlers 2008; Falck-
Hansen, Kassiteridi et al. 2013). Furthermore, TLRs may be grouped into 
two subgroups.  The first are the cell surface TLRs, a subgroup, which 
includes TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11. The endosomal 
subgroup is constituted by TLR3, TLR7, TLR8 and TLR9. The TLR-
mediated responses are mainly controlled by the MyD88-dependent 
pathway, used by all TLRs except TLR3, reviewed by (Falck-Hansen, 
Kassiteridi et al. 2013). 
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1.5.6 Macrophages in atherosclerosis 
 
The osteopetrotic mouse model was crossbred with the ApoE-/- mouse to 
conduct studies on macrophages during experimental atherosclerosis 
(Smith, Trogan et al. 1995). This model carries a mutation of the MCSF 
gene, which leads to a deficiency in functional MCSF production (Kodama, 
Nose et al. 1991). A growth factor, such as MCSF is necessary for 
monocytes to differentiate into macrophages (Gordon 2003). Smith et al fed 
these mice a low-fat chow diet and found that the double mutants exhibited 
significantly smaller proximal aortic lesions, at an earlier stage of disease, 
with fewer macrophages compared with their ApoE-/- littermates (Smith, 
Trogan et al. 1995). Another growth factor – GMCSF – is produced by 
SMCs and is able to mature monocytes during atherogenesis (Stojakovic, 
Krzesz et al. 2007). In a GMCSF study, mice were injected with doses of 10 
µg/kg GMCSF or GCSF daily for 5 days on alternating weeks for 8 weeks, 
totalling 20 doses, it was discovered that both GMCSF and GCSF treatment 
lead to increased atherosclerotic progression (Haghighat, Weiss et al. 2007).  
The LDLR-/- model was also employed to study GMCSF. Systemic injections 
with GMCSF greatly increased the intimal cell proliferation, whilst blocking 
GMCSF inhibited cell proliferation (Zhu, Chen et al. 2009).  
 
1.5.7 Monocyte subsets and their recruitment to atherosclerotic 
lesions 
 
In both mice and humans, monocytes constitute 5 to 10% of peripheral 
blood leukocytes (Mestas and Hughes 2004).  Monocytes can be divided 
into two main groups: classically activated or resident monocytes. The 
distinction between the two is based upon size, granularity and the 
differential expression of adhesion molecules and chemokine receptors. In 
mouse, the two subsets are represented equally in the blood and can be 
distinguished by their expression levels of CCR2, CX3CR1 and Ly6C 
(Fleming, O'HUigin et al. 1993; Strauss-Ayali, Conrad et al. 2007). The 
classical inflammatory monocytes are labelled as CCR2+ CX3CR1low Ly6Chi, 
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whereas the non-classical monocytes are labelled CCR2- CX3CR1hi Ly6Clow 
(Geissmann, Jung et al. 2003; Gautier, Jakubzick et al. 2009; Mosser and 
Edwards 2008). Monocytes are recruited into the lesions using a well-
defined set of selectins, integrins and adhesion molecules including ICAM-1 









Figure 1.7 – Monocyte adhesion and extravasation from the circulation. 
Monocytes exit the blood to sites of inflammation. Following the blood flow direction, 
monocytes are able to form a tight binding by adhering to selectins and integrins 
simultaneously, eventually allowing them to traverse the endothelium. Figure adopted from 
(Murphy, Travers et al. 2012). 
 
Monocytes undergo a process described as diapedesis, also known as 
transmigration, with facilitation from the endothelial cells. The endothelial 
cells express surface molecules both inducibly and constitutively, regulated 
by the transcription factor nuclear factor NF-κB. Monocytes then bind to the 
surface receptors on endothelial cells via specific cell surface 
corresponding-receptors allowing for rolling, adhesion and transmigration to 
occur. Rolling is thought to occur partially by interactions between EC-
expressed E-Selectin and leukocyte expressed E-Selectin ligand 1 (ESL-1). 
Firm adhesion is likely mediated through interaction by ICAM-1 and VCAM-
1 (expressed on ECs) binding to MAC-1 (expressed on leukocytes) (Cines, 
Pollak et al. 1998). When adherent, the monocytes are exposed to local 
chemotactic stimuli, including MCP-1 (macrophage chemoattractant protein 
1, also termed CCL2). Furthermore, recent studies have highlighted the 
chemotactic stimuli involved in the recruitment of monocytes. Combardière 
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et al used knockout mice with multiple gene defects such as CCL2, 
CX3CR1, and CCR5 and showed that the absence of these migration 
molecules nearly abrogated atherosclerosis in mice (Combadiere, Potteaux 
et al. 2008). Tacke et al (2007), showed that the chemokine receptors 
CCR2, CCR5 and CX3CR1 are differentially employed for migration of 
monocytes to plaques with CCR2 being important for the recruitment of the 
Ly6Chi subset (Tacke, Alvarez et al. 2007). Also, the work by Cheng, 
Tempel et al (2007) showed that the molecule fractalkine (which binds to 
CX3CR1) was necessary for plaque growth, and blocking fractalkine 
induced differences in plaque composition (Cheng, Tempel et al. 2007).  
Studies have shown that the numbers of monocytes (and macrophages) 
infiltrating the plaque (Davies, Richardson et al. 1993) and their location at 
plaque rupture-sensitive sites (e.g. the fibrous cap and erosion areas) (van 
der Wal, Becker et al. 1994; Virmani, Burke et al. 2003) may be associated 
with plaque vulnerability. These studies combined suggest that the 
presence of inflammatory innate immune cells, such as migratory 
monocytes is highly important for atherosclerosis development. 
 
1.6 T lymphocyte and B lymphocyte mediated immunity 
 
Many pathogens are resistant to the protective mechanisms of the innate 
branch of the immune system. Some viruses are able to mutate, change 
their outer antigen coat and hi-jack cell machinery for their own synthesis, 
ultimately failing to undergo clearance by the immune system (Murphy, 
Travers et al. 2012). Similar mechanisms are used by bacteria and 
parasites, especially when under attack from anti-microbial drugs (e.g. 
MRSA) (Deurenberg and Stobberingh 2008; Ender, McCallum et al. 2008) 
or attack from the immune system; e.g. malarial infection (Cunningham, 
Jarra et al. 2005). T lymphocytes are essential players in cell mediated 
immunity and are able to recognise foreign and host peptides presented on 
MHC I (to cytotoxic CD8+ T lymphocytes) and MHC II molecules (to CD4+ T 
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helper lymphocytes), which can be conditionally expressed on nearly all 
cells of the body, but predominantly occurs on antigen presenting cells 
(APCs) (Muhlethaler-Mottet, Otten et al. 1997). The recognition of antigens 
occurs through a wide variety of receptors by T lymphocyte receptors (TCR) 
recognising antigen peptides presented on MHC molecules by APCs 
(Jenkins 2003).  Furthermore, cytotoxic T lymphocytes can deactivate (by 
sending apoptotic kill signals) damaged or infected cells, helping to clear 
them from the circulatory system. T lymphocytes are matured in the thymus 
and then enter into the circulation. Naïve T lymphocytes are in constant 
circulation around the body’s lymph nodes, where they screen for infections 
presented as antigen peptides through MHC molecules on the surface of 
APCs, such as DCs (Ellen V Rothenberg 2003). Other professional APCs 
include macrophages and B lymphocytes. APCs are able to distinguish 
between extracellular and intracellular microorganisms, a trait which T 
lymphocytes do not possess (Murphy, Travers et al. 2012). Following, naïve 
T lymphocytes become activated during antigen recognition, accompanied 
by cytokine secretion, clonal expansion and differentiation into effector T 
lymphocytes.  Effector T lymphocytes can reside in peripheral lymph nodes 
where they are able to eliminate infected cells and activate B lymphocytes. 
They may also circulate to the infection site (Murphy, Travers et al. 2012).  
DCs produce the cytokine IL-12; this may turn naïve cells to activated CD4+ 
T helper lymphocytes. T helper lymphocytes may be grouped into subsets, 
such as TH1 and TH2 cells, the former being inflammatory by producing the 
cytokine IFN-γ, activating macrophages and B lymphocytes and the latter 
being immune-dampening, by producing cytokines such as anti-
inflammatory IL-10 and activation of antibody producing plasma cells 
(Murphy, Travers et al. 2012). TH2 lymphocytes are also characteristic of 
producing the signature cytokines IL-4, IL-5 and IL-13. This group of 
cytokines may induce the synthesis of extracellular matrix proteins, and 
induce wound-healing activities by macrophages in addition to promoting 
anti-microbial activity in macrophages (Murphy, Travers et al. 2012). IL-4 
also induces B lymphocytes to produce antibodies and IL-5 recruits 
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eosinophils. TH2 lymphocytes are also important for clearance of parasite 
infections and are involved in the development of allergies and asthma via 
production of IgE antibodies by plasma cells, activating mast cells– an 
important mediator for allergies as these cells produce histamine leading to 
hypersensitivity reactions.  
T regulatory cells (defined as CD4+CD25+FOXP3+ T lymphocytes, 
abbreviated Treg) are also important T-lymphocyte subsets and have lately 
regained attention in the field of immune regulation, as they may be 
important in suppressing inflammation (Murphy, Travers et al. 2012). T regs 
produce IL-10 (Maynard, Harrington et al. 2007), uptake T lymphocyte 
growth factor (IL-2) (Nelson 2004) and are induced by TGF-β (Fu, Zhang et 
al. 2004). More recently, the discovery of a new T helper cell subset, 
namely IL-17 producing TH3 cells that can recruit neutrophils has opened up 
the route for a deeper understanding of the interplay between the innate 
and adaptive immune response (Stockinger and Veldhoen 2007). Another 
subset, termed the T follicular helper cell (TFH) has been described as an 
important subset in regulating the differentiation of antibody-producing  
B lymphocyte plasma and memory cells (Crotty 2011). B lymphocytes are 
able to recognise proteins, lipids, carbohydrates and nucleic acids and 
produce antibodies (Murphy, Travers et al. 2012). The receptors for both B 
and T lymphocytes are generated in the somatic line during lymphocyte 
development then generated randomly during gene segment recombination. 
When the receptor encounters the antigen, the cell will undergo clonal 
expansion, leading to multiple copies of the cells that are able to recognise 
the same pathogen. These traits are not inherited by the next generation of 
cells, thus, it is different to the innate system, where detection receptors are 
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1.7 Activation of the immune system during atherosclerosis 
 
This life-long, chronic disease is thought to begin at early adolescence and 
persist until death (Loscalzo 2005). The lack of resolution of the 
inflammatory response in atherosclerosis is an example of chronic 
activation of the immune system and persistence of inflammation. It has in 
recent years become clearer how this activation occurs. Mechanisms of 
recognition by the innate immune system, such as TLR2-activation may 
lead to inflammation in atherosclerosis (Monaco, Gregan et al. 2009). In this 
study conducted by Monaco et al, the authors showed that blocking TLR2 
signalling in cell culture grown human atherosclerotic endarterectomies 
reduced inflammation output as measured by levels of IL-6, IL-8, MMP-1, 
MMP-3, MMP-9 and MCP-1 (Monaco, Gregan et al. 2009).  
Recognition of atherogenic particles is largely orchestrated by scavenger 
receptors. They are a group of receptors able to detect LDL modified by 
acetylation or oxidation. Their expression is strongly present on 
macrophages and atherosclerotic plaques as initially described by Brown 
and Goldstein in 1979 (Goldstein, Ho et al. 1979), albeit their regulation is 
strongly coupled with macrophage polarisation (Brocheriou, Maouche et al. 
2011; Shalhoub, Falck-Hansen et al. 2011). They can be grouped into three 
main categories, class A, class B and others. Class A scavenger receptors 
are sub-grouped into type 1  (SRA1) and type 2 (SRA2). They recognise 
acLDL and oxLDL (Greaves and Gordon 2009). In addition, Class B 
receptors are also able to detect unmodified LDL. The macrophage marker 
CD68 falls under the category of other scavenger receptors together with 
LOX-1, a lectin-like receptor, and mucin-like receptors (Greaves and 
Gordon 2009) 
The oxidised low-density lipoprotein (oxLDL) may be recognised by CD36 
and by TLR4 (with CD14 co-receptor) in combination with TLR6, generating 
a pro-inflammatory IL-1β and NF-κB response. In fact, data suggests that 
CD36, TLR4 and TLR6 form a macromolecular complex leading to 
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signalling activation upon recognition of oxLDL (Stewart, Stuart et al. 2010), 
reviewed in (Falck-Hansen, Kassiteridi et al. 2013). Other scavenger 
receptors have also been reported. The acetyl-LDL receptor detects 
modified lipoproteins on the surface of monocytes (Clinton, Underwood et al. 
1992). Other scavenger receptors have been identified, amongst them 
aforementioned CD36, discovered by Endeman in 1993 (Endemann, 
Stanton et al. 1993) and CD68, discovered by Ramprasad in 1995 
(Ramprasad, Fischer et al. 1995; Steinberg and Witztum 2010). Another 
member in this family is the haptoglobin-haemoglobin scavenger receptor 
CD163 (Mantovani, Sica et al. 2004).  These receptors aid macrophages to 
become lipid-laden foam cells (Hansson 2005). More recent studies have 
found that cholesterol crystals are sensed by the inflammasome 
components NALP3, CARD, ASC and CASPASE1 leading to IL-1β 
production (Duewell, Kono et al. 2010; Rajamaki, Lappalainen et al. 2010). 
This stimulation of the immune system may persist as long as the crystals 
are recognised by the activated cells of the immune system, promoting 
unresolved inflammation (Figure 1.8). 




Figure 1.8 – The interaction of innate signalling, through TLRs, and inflammasome 
signalling in the transcription and translation of the pro-inflammatory cytokine IL-1β. 
Detection of atherogenic cholesterol crystals may lead to inflammasome activation. 
Alternatively, pro-inflammatory patterns activate NF-κB activation followed by 
inflammasome activation. The eventual production of IL-1β leads to pro-inflammatory 
responses. For a complete explanation of acronyms, see the list of abbreviations.  
Figure published in (Shalhoub, Falck-Hansen et al. 2011). 
1.8 Cytokines in atherosclerosis 	  
Recruitment of blood leukocytes to the vessel wall occurs already in the 
initial stages of plaque formation (Libby, Sukhova et al. 1995). Two types of 
leukocytes accumulate in the plaque; lymphocytes and mononuclear 
phagocytes (Jonasson, Holm et al. 1986; Tsukada, Rosenfeld et al. 1986) 
and the production of cytokines, in particular inflammatory cytokines, 
regulates the expression of leukocyte adhesion molecules on the 
endothelium surface enabling the entry of inflammatory cells to the intimal 
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layer of the vessel wall (Bevilacqua, Pober et al. 1985; Gimbrone, 
Bevilacqua et al. 1990; Springer 1990; Bevilacqua, Butcher et al. 1991).  
The balance of growth-promoting and growth-arresting cytokines in the 
plaque microenvironment may affect the cells’ ability to proliferate. 
Macrophages are likely the main source of cytokines in the plaque (Tedgui 
and Mallat 2006). Due to space constrictions, I will focus on the main 
findings concerning cytokines in atherosclerosis. The first cytokine of 
importance is TNF-α, which has been characterised as a “master-regulator” 
cytokine in previous inflammatory contexts (Feldmann and Maini 2003). 
Studies using experimental mouse models of atherosclerosis employing the 
use of ApoE-/- mice crossbred with TNF-α-/- mice found that aortic sinus 
lesions were reduced in double knockouts (Ohta, Wada et al. 2005). TNF-α 
(or IFN-γ) is also able to enhance the level of ICAM expression on cultured 
endothelial cells (Dustin, Rothlein et al. 1986). Furthermore, IL-1 a cytokine 
involved in the activation of the inflammasome by cholesterol crystals 
(Duewell, Kono et al. 2010; Rajamaki, Lappalainen et al. 2010) has been 
characterised for its role in atherosclerosis. IL-1 increased the total 
cholesterol levels by ~50%, but decreased lesion sizes by 50-70% (Elhage, 
Maret et al. 1998; Devlin, Kuriakose et al. 2002; Merhi-Soussi, Kwak et al. 
2005). Studies in human endothelial cells have shown that both IL-1 and 
TNF-α can induce IL-1 mRNA expression (Libby, Ordovas et al. 1986; 
Warner, Auger et al. 1987). The proliferation of SMCs can augment upon 
exposure to IL-1 (Warner, Auger et al. 1987).  TNF-α and IL-1 production 
may work in autocrine loops and both are able to regulate chemokine 
production, such as MCP-1 (CCL2) – a macrophage chemoattractant 
(Rollins, Yoshimura et al. 1990; Wang, Sica et al. 1991). These two 
cytokines can also increase the production of the macrophage growth factor 
MCSF (Rajavashisth, Andalibi et al. 1990; Clinton, Underwood et al. 1992; 
Rosenfeld, Yla-Herttuala et al. 1992), important for plaque progression and 
growth. Alongside these functions, IL-1 may induce the production of matrix 
metalloproteinase 1 (MMP-1), an interstitial collagenase involved in collagen 
catabolism (Yanagi, Sasaguri et al. 1991; Southgate, Davies et al. 1992; 
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Galis, Muszynski et al. 1994). A deficiency in T-cell growth factor, more 
recently described as IL-2, has not shown any particular effects. IL-2 has 
been recognised as an important growth factor for Tregs (which express a 
high level of the IL-2 receptor, CD25) (Nelson 2004) and Tregs may play a 
role in controlling plaque inflammation (Mallat, Gojova et al. 2003). IL-6 is a 
cytokine produced by SMCs and it can enhance fatty lesion development in 
mice (Huber, Sakkinen et al. 1999). In addition, it responds to a pro-
atherogenic environment, as shown in mouse studies with IL-6 treatment. In 
ApoE-/- mice, fatty streak formation was increased by 2-fold when treated 
with IL-6. However, it is described having a dual role in atherosclerosis as it 
is also regarded as anti-inflammatory. In two independent studies 
measuring atherosclerosis development in 1 year-old IL-6-/-ApoE-/- mice, it 
was reported that the animals demonstrated enhanced plaque formation 
compared to ApoE-/- controls (Elhage, Clamens et al. 2001; Schieffer, Selle 
et al. 2004)  
IFN-γ is a well-established inflammatory cytokine that may be able to up-
regulate the expression of adhesion factors, however, it is also a cytokine 
that can inhibit cell growth, for instance – it was shown to limit SMC 
proliferation (Hansson, Jonasson et al. 1988; Hansson, Hellstrand et al. 
1989; Warner, Friedman et al. 1989). IFN-γ could play a role in 
atherosclerotic lipid accumulation, by allowing lipids to gather in lesions 
through the inhibition of the triglycerides degrading enzyme macrophage 
lipoprotein lipase (LPL), through reduction in LPL synthesis (Jonasson, 
Hansson et al. 1990). In addition, IFN-γ has been found to down-regulate 
the enzyme cholesterol 27-hydroxylase, an enzyme that normally promotes 
the removal of lipids from the arterial wall, considered a protective 
mechanism against atherosclerosis (Reiss, Awadallah et al. 2001). TGF-β 
on the other hand, is a suppressive cytokine, which can limit smooth muscle 
cell proliferation (Owens, Rabinovitch et al. 1981; Gibbons, Pratt et al. 1992).  
The cytokine IL-10 has been described as an important anti-inflammatory 
cytokine, inhibiting TH1 lymphocytes, promoting proliferation and 
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differentiation of Tregs. IL-10 is produced by macrophages, B lymphocytes, 
TH2 lymphocytes, Tregs and mast cells targeting T & B lymphocytes as well 
as macrophages. Mallat et al investigated the role of IL-10 in 
atherosclerosis by studying IL-10-/- mice. They showed that C57BL/6 mice 
deficient in IL-10, fed an atherogenic diet exhibited a 3-fold increase in lipid 
accumulation with a 30-fold higher susceptibility to atherosclerosis in 
comparison to WT (IL-10+/+) mice. These mice had significantly higher 
infiltration of T lymphocytes, abundant IFN-γ expression, paired with 
decreased collagen content (Mallat, Besnard et al. 1999).  
The cytokine IL-12 belongs to the gp130 family (von der Thusen, Kuiper et 
al. 2003) and is produced by TH1 lymphocytes, monocytes, DCs and 
macrophages, where monocytes could be the main source (D'Andrea, 
Rengaraju et al. 1992). IL-12 targets NK cells and T helper lymphocytes, 
leading to increased IFN-γ production, increased cytotoxic activity and TH1 
differentiation (Hsieh, Macatonia et al. 1993). IL-12 is closely related to  
IL-23, with which it shares the IL-12p40 subunit and with IL-27, which 
signals through an IL-12 p40-related and IL-12p35-related protein (von der 
Thusen, Kuiper et al. 2003). Uyemura et al studied the expression of  
IL-12p70 and IL-12p40 mRNA in atherosclerotic lesions and observed an 
up-regulation of IL-12 production by monocytes after adding highly oxidised 
LDL (Uyemura, Demer et al. 1996). Lee et al followed-up these findings by 
injecting recombinant IL-12 into ApoE-/- mice and observed an accelerated 
progression of atherosclerosis (Lee, Yen et al. 1999). Blockade of IL-12 by 
vaccination of LDLR-/- mice led to a significant reduction in atherogenesis 
(68.5%; p<0.01) compared to control mice without any changes in serum 
cholesterol levels (Hauer, Uyttenhove et al. 2005). Furthermore, in a clinical 
context, raised levels of IL-12 have been associated with a risk of acute 
myocardial infarction (Zhou, Shi et al. 2001).  
In summary, cytokines are able to regulate inflammatory immune responses 
during atherosclerosis and work as a bridge between the innate and 
adaptive immune branches.  
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1.9 Immunotherapy for treating atherosclerosis 
 
In the treatment of autoimmune diseases, several approaches have been 
conducted in the field of biologics and anti-cytokine therapy. Biologics thus 
far have included cytokine receptor antagonists, anti-cytokine monoclonal 
antibodies, and fusion molecules composed of soluble cytokine receptors 
mixed with human fusion protein constructs or polyethylene glycol (Tedgui 
and Mallat 2006). Humanisation of monoclonal antibodies (HuMab) for 
better compatibility with the human organism has been a heavy focus in the 
biotechnology industry and at present most of the monoclonal antibodies 
are humanised (ECSPP 2008). Perhaps one of the most well known 
biologic immunotherapies is the anti-cytokine treatment of autoimmune 
rheumatoid arthritis with Infliximab/Remicade®, and later Etanercept™  
TNF-α inhibitors (Brennan, Chantry et al. 1989) reviewed in (Olsen and 
Stein 2004). Conversely, the use of recombinant cytokines for the treatment 
of autoimmune disease has yielded mixed results, such as with IL-10 
(Asadullah, Sterry et al. 2003).  Treatment with recombinant cytokines has 
also been used for boosting the immune response against viral hepatitis, 
with the use of interferon alpha (IFN-α) as a standardised therapy for 
Hepatitis C (Shepherd, Brodin et al. 2004).  
 
Because atherosclerosis has in recent years been described as a chronic 
inflammatory disease, either a blockage of pro-inflammatory pathways or a 
stimulation of anti-inflammatory pathways might lead to disease reduction or 
abrogation of plaques. Because of the increasing availability of biologics as 
a treatment modality, exploring new drug targets for atherosclerosis in this 
field could complement or even replace the use of NSAIDs and cholesterol-
lowering statin drugs, such as Atorvastatin (Lipitor), Simvastatin (Zocor) or 
Rosuvastatin (Ridker 2003).  
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An immunoregulatory pathway that has been explored successfully in a 
mouse model of arthritis is the CD200R-CD200 signalling pathway. In a pre-
clinical treatment trial with the biologic agent CD200-Fc fusion protein, the 
treated animals exhibited a markedly decreased expression of messenger 
RNA for the cytokines TNF-α, IL-1β, IL-10 and matrix metalloproteinase 13 
in the joint to the same extent as administration of TNFR-Fc (Simelyte, 
Criado et al. 2008). Thus far, this biologic has not been tested for the 
treatment of atherosclerosis and could prove to be useful in reducing the 
expression of inflammatory mediators. Expression of this receptor is largely 
restricted to the myeloid lineage cells (Gorczynski, Chen et al. 2004) such 
as the macrophage-monocytes, a cell for atherosclerosis, reviewed in 
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1.9.1 CD200R1/CD200 is a powerful regulatory signal for myeloid cells 
 
The CD200R1 glycoprotein is one of a family of four CD200R cell surface 
receptors. The other glycoproteins CD200R2, CD200R3, and CD200R4 
have less known functions in inflammation (Gorczynski, Chen et al. 2004). 
Thus, CD200R1 is the most well characterised, and has mainly been 
observed on the surface of myeloid cells such as macrophages, monocytes, 
mast cells, neutrophils, dendritic cells (DCs) and also CD4+ T helper cells 
(Copland, Calder et al. 2007; Barclay, Clark et al. 1986).  
 
 
Figure 1.9 – CD200R1/CD200 interaction provides an inhibitory signal. 
Macrophages and other myeloid cells carrying the surface receptor CD200R may 
interact with cells of the endothelium (or T lymphocytes) which carry the ligand that 
stimulates the receptor to down-regulate pro-inflammatory cytokine production. 
 
Interestingly, CD200R is differentially expressed in macrophages with 
different localization. Alveolar macrophages had unusually high basal 
expression of CD200R relative to that of non-mucosal splenic macrophages, 
lung interstitial monocytes and macrophages and peritoneal macrophages 
(Snelgrove, Goulding et al. 2008). Furthermore, in a study comparing mRNA 
expression of CD200R between species, tissues and cell types, it was 
found that the abundance of the receptor was highest in unstimulated 
macrophages, mast cells, followed by TH2 lymphocytes and dendritic cells 
(Wright, Cherwinski et al. 2003). Tissues such as lymph nodes, bone 
marrow, spleen, thymus (in mouse), lung, liver and kidneys exhibited a high 
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expression of the receptor. (Wright, Cherwinski et al. 2003). CD200R binds 
the ligand CD200 (Figure 1.10), which is expressed by SMCs, endothelial 
cells (ECs), certain peripheral T lymphocytes, neurons of the central 
nervous system, granulose of degenerating corpora lutea, placental 
trophoblasts and other parenchymal cell types, e.g. airway epithelium, 














Figure 1.10 – Binding structure of CD200 receptor with CD200 ligand. 
The complex shows CD200 in green and CD200R in orange. Beta strands of each 
Ig-like domain are labelled A-G. Observed NAG moieties are shown as pink sticks 
and potential N-linked glycosylation sites are represented by pink spheres. 
Disulphide bonds are represented as yellow sticks. Figure adopted from (Hatherley, 
Lea et al. 2013). 
 
 
Interestingly, a recent study described a soluble form of CD200; termed 
sCD200 (Wong, Brenneman et al. 2012), rendering that there could be 
various locations for CD200/CD200R1 interaction. 
 
CD200 acts by delivering an inhibitory signal on myeloid cells, and its role in 
dampening myeloid cell activation has been proven in different inflammatory 
diseases (Feuer 2007). The inhibition occurs via phosphorylation of its 
cytoplasmic NPXY motif that recruits DOK-1 and DOK-2, which 
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subsequently inhibits the Ras/Mitogen-activated protein kinase pathways 
(Jenmalm, Cherwinski et al. 2006; Zhang, Cherwinski et al. 2004). Mirshahi 
and Brown later showed that DOK-2 is significant in CD200R signalling, 
rather than its counterpart DOK-1 (Mihrshahi and Brown 2010). Mice 
lacking CD200 have more macrophage activity, measured by the release of 
cytokines such as TNF and IL-6 (Snelgrove, Goulding et al. 2008). CD200-/- 
mice also display delayed resolution of inflammation and enhanced 
sensitivity to influenza infection leading towards death (Snelgrove, Goulding 
et al. 2008). The administration of agonists that bind CD200R prevent 
influenza virus-related inflammatory lung disease and collagen induced 
arthritis (CIA) (Simelyte, Criado et al. 2008; Snelgrove, Goulding et al. 2008).  
In parallel, using a LA-4 epithelial cell line that constitutively expressed 
CD200, co-cultured together with macrophages ± IFN-γ, they observed that 
the macrophages only produced inflammatory cytokines at low levels when 
incubated with the epithelial cells and IFN-γ compared to controls, 
suggesting a role for CD200 in dampening cytokine production. Interestingly, 
during the peak of inflammation of influenza infection, the expression of 
CD200 on endothelial and epithelial cells was lower (Snelgrove, Goulding et 
al. 2008). This could be due to the pro-inflammatory environment having an 
effect on the expression of CD200. In a murine model of autoimmune 
uveoretinitis, mice lacking the CD200 gene had increased numbers of 
macrophages infiltrating the retina (Copland, Calder et al. 2007).  
 
CD200 knock out studies by Hoek et al (2000) have also demonstrated that 
splenocyte populations expressing macrophages and granulocytes are 
nearly doubled in numbers in the CD200-/- mouse compared to the CD200+/+ 
mouse. They showed that during experimental autoimmune 
encephalomyelitis (EAE), a murine model for the human disease multiple 
sclerosis, CD200-/- mice exhibited higher numbers of iNOS expressing 
inflammatory macrophages (Hoek, Ruuls et al. 2000). Also, using the 
collagen induced arthritis (CIA) mouse model for rheumatoid arthritis, they 
injected collagen into CD200-/- mice, showing that disease resulted already 
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after 20 days with a cumulative incidence of over 50% (Hoek, Ruuls et al. 
2000). Thus, CD200R appears to be critical for macrophage homeostasis 
and limitation of inflammatory amplitude and duration. More recently, 
Mukhopadhyay and colleagues observed that infection with the bacterium 
Neisseria Meningitidis induced CD200 expression and down-regulated 
CD200R expression. Using a variety of gene knockout models such as 
CD200-/-, c-Rel-/- and MyD88-/- mice, they showed that this mechanism 
occurred in a TLR4 and MyD88 dependent manner, where signalling from 
TLRs was dependent on the NF-κB member cRel (Mukhopadhyay, 
Pluddemann et al. 2010). Finally, CD200/CD200R signalling has been 
observed in viral infections. In a study by Foster-Cuevas, they showed that 
the K14 viral homologue mimics the CD200 down-modulatory signal to 
myeloid cells (Foster-Cuevas, Wright et al. 2004) a possible mechanism of 
viral immune evasion.  
As an important note on CD200R detection, Professor Neil Barclays’ group in 
Oxford recently described the cross-reactivity of the CD200R antibody  
(OX-110 clone) with CD200RLc (Akkaya, Aknin et al. 2013). Although 
CD200RLc exhibits low expression, the nomenclature for the OX-110 
antibody readouts used throughout this thesis, are labelled CD200R, rather 
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1.9.2 CD200-Fc fusion protein 
 
The glycoprotein receptor CD200R1 binds to the ligand CD200 expressed 
on endothelium, and is able to regulate cell activity. CD200 has been 
described as being secreted, but not released from the cell membrane. 
Therefore signalling is thought to occur only during direct cell-cell contact. 
To simulate this signal artificially, a synthetic biologic fusion protein has 
been developed. The recombinant CD200 extracellular domain was 
connected to an external IgG1-Fc portion, creating the CD200-Fc fusion 
protein. The IgG1 portion was mutated in the CH2 domain to prevent binding 
to Fc receptors (Hatherley, Cherwinski et al. 2005). 
 
Figure 1.11 – CD200-Fc fusion protein. 
The CD200-Fc fusion protein was generated by joining two extracellular portions of 
the CD200 protein (portion I + portion II) with the C-terminal polyhistidine-tagged 
Fc region of IgG1 at the C-terminus.  
 
Previous studies have tested CD200-Fc to treat inflammatory disease 
(Simelyte, E et al. Arthritis Rheum 2008; (Liu, Bando et al. 2010). During 
experimental arthritis, CD200-Fc dose-dependently reduced the clinical and 
histological severity of established CIA with a similar level of efficacy as 
when using TNFR-Ig (Simelyte, Criado et al. 2008). 
 





Atherosclerosis is a chronic, lifelong multifactorial inflammatory-driven 
disease that develops progressively. Currently, treatment modalities are 
insufficient to combat this disease and targeting inflammatory pathways, 
such as those mediated by macrophages could prove beneficial either on 




Based on the background detailed in this introduction chapter, the aims with 
this thesis are: 
1) To understand the patterns of expression of CD200R in  
           macrophages, a key cell type in atherosclerosis and how its    
           expression varies in the context of polarisation.  
 
2) To verify the expression patterns of CD200R in native and shear  
           stress-mediated atherosclerosis  
 
3) To test the effect of the provision of CD200 by administering a  
           CD200-Fc fusion protein in the context of shear stress-mediated  
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Reagents used for experimental work are listed in this section. 
 
2.1.1 Antibodies 
Antibodies for immunohistochemistry (IHC) and fluorescence activated cell 
sorting (FACS) are listed in tables 2.1 and 2.2 below. 
 
Specificity Species Application Dilution Clone Isotype Source 
CD200R FITC Rat FACS 1:100 OX-110 IgG2a AbD Serotec 
CD200R Rat IHC 1:200 OX-110 IgG2a AbD Serotec 
CD11b PE Rat FACS 1:100 M1/70 IgG2b, k eBioscience 
CD115 APC Rat FACS 1:100 AFS98 IgG2a, k eBioscience 
Ly6C PE-Cy7 Rat FACS 1:100 AL-21 IgM, k BD Pharmingen 
I-A/I-E PE-Cy7 Rat FACS 1:400 M5/114.15.2 IgG2b, k BioLegend 
CD68 Rat IHC 1:200 FA-11 IgG2a AbD Serotec 
Ly6G AF488 Rat FACS 1:100 RB6-8C5 IgG2b, k eBioscience 
CD11b PerCP Rat FACS 1:100 M1/70 IgG2b, k BioLegend 
Ly6C AF647 Rat FACS 1:100 HK1.4 IgG2c, k BioLegend 
CD16/32 Rat FACS 1:100 2.4G2 IgG2b, k BD Pharmingen 
IgG2a FITC Rat FACS 1:100 N/A - AbD Serotec 
IgG2a Rat IHC 1:200 LO-MG2a-7 - AbD Serotec 
IgG2b, k PE Rat FACS 1:100 eB149/10H5 - eBioscience 
IgG2a, k APC Rat FACS 1:100 eBR2a - eBioscience 
IgM, k PE-Cy7 Rat FACS 1:100 R4-22 - BD Pharmingen 
IgG2b, k PE-Cy7 Rat FACS 1:400 RTK 4530 - BioLegend 
IgG2b, k PerCP Rat FACS 1:100 RTK 4530 - BioLegend 
Table 2.1 – Primary anti-mouse antibodies used for IHC and FACS. 
Primary antibodies were purchased from AbD Serotec (Abingdon, UK), BD Pharmingen (Oxford, 
UK), BioLegend (CA, USA), eBioscience (CA, USA) and stored at +4°C. 	  	  





Table 2.2 – Secondary anti-rat antibodies used for IHC. 
A secondary rabbit anti-rat antibody was purchased from Vector Labs (CA, USA) and stored 
at +4 °C.  
 
2.1.2 Cytokines and growth factors 	  
Cytokine Application Concentration Source 
IL-4 Cell culture  50 ng/ml PeproTech  
IL-13 Cell culture 50 ng/ml PeproTech  
IFN-γ Cell culture 100 ng/ml PeproTech  
MCSF Cell culture 100 ng/ml PeproTech  
GMCSF Cell culture 10 ng/ml PeproTech  
Table 2.3 – Murine recombinant cytokines and growth factors. 
All reagents were purchased from PeproTech EC Ltd (London, UK) and stored at -20°C.  
2.1.3 TLR ligands 
 
Receptor Ligand Description Concentration Source 
TLR2/6 FSL-1 Synthetic diacylated 
lipoprotein 
100 ng/ml Invivogen  
TLR3 POLY(I:C) Synthetic dsRNA 1 μg/ml Invivogen 
TLR4 LPS Lipopolysaccharide from  
E. coli 
100 ng/ml Invivogen 
TLR7 R848 Resiquimod 1 μg/ml Invivogen 
Table 2.4 – TLR ligands for cell culture. 
All TLR ligands were purchased from Invivogen (CA, USA) and stored at -20°C. 
 
2.1.4 Oxidised LDL  
Receptor Ligand Description Concentration Source 
CD36 oxLDL Human CuSO4 oxidised       
low density lipoprotein  
100 μg/ml Biomedical 
Technologies  
 
Table 2.5 – Oxidised LDL for cell culture. 
Human oxidised LDL was purchased from Biomedical Technologies (MA, USA) and stored at 
+4°C. 
Specificity Species Application Concentration Clone Isotype Source 
IgG 
Biotinylated 
Rabbit IHC 1:400 - IgG Vector 
Labs 
Chapter 2    Materials and Methods 
 
 48 
2.1.5 Reagents for cDNA synthesis 	  
Reagent    Volume Source 
500 ng RNA (in ddH20)  12 μl  RNA extraction kit  
        Qiagen (CA, USA) 
 
50 μM Oligo (dT) Primer  1 μl  Eurofins (Kraainem, BE) 
  
M-MLV RT 5X Buffer  5 μl  Promega  (WI, USA) 
dNTPs (10 mM)   1 μl  Promega (WI, USA) 
RNase Inhibitor(RNasin® Plus)  1 μl  Promega (WI, USA) 
M-MLV-RT RNase   0.5 μl  Promega (WI, USA) 
Ultrapure ddH2O   4.5 μl  Life Technologies (CA, USA) 
 
2.1.6 Reagents for Q-PCR 
 
Mix 1 (Corbett mix for 72 well rotor in strip tubes) 
Reagent    Volume Source 
Taqman Primer Probe  0.5 μl  Life Technologies (CA, USA) 
 
Platinum PCR SuperMix  5 μl  Life Technologies (CA, USA) 
 
Ultrapure ddH2O   1.5 μl  Life Technologies (CA, USA) 
 
cDNA     3 μl  In-house  
 
Mix 2 (ABI mix for MicroAmp® 384-well plate) 
Reagent    Volume Source 
Taqman Primer Probe  0.3 μl  Life Technologies (CA, USA) 
 
Taqman Master Mix   3 μl  Life Technologies (CA, USA) 
 
ddH2O    0.3 μl  Life Technologies (CA, USA) 
 
cDNA     2.4 μl  In-house 
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2.1.7 Primers for Q-PCR 	  
Name Assay ID Location Species Source 
CD200R1 Mm00491164_m1 Chromosome 16 M. musculus ABI 
CD200 Mm00487740_m1 Chromosome 16 M. musculus ABI  
β-Actin Mm00607939_s1 Chromosome 5 M. musculus ABI  
Mrc1 
(CD206) 
Mm00485148_m1 Chromosome 2 M. musculus ABI  
NOS2 
(iNOS) Mm00440502_m1 Chromosome 11 M. musculus ABI  
IFN-γ Mm01168134_m1 Chromosome 10 M. musculus ABI  
HMOX-1 
(HO-1) 
Mm00516005_m1 Chromosome 8 M. musculus ABI  
IL-10 Mm00439614_m1 Chromosome 1 M. musculus ABI  
IL-12p35 Mm00434165_m1 Chromosome 3 M. musculus ABI  
 
Table 2.6– List of TaqMan primers. 
Taqman primer probes conjugated to FAM dye were purchased from ABI, Life Technologies 
(CA, USA) for Q-PCR amplification. All primer probes were stored in the dark at -20°C.  
All reactions were normalised to β-actin as housekeeping gene. 	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2.1.8 Histology solutions 
2.1.8.1 Immunohistochemistry 
 
Reagent   Conc.   Source 
Hydrogen Peroxide  0.3% in PBS  Sigma Aldrich (MO, USA) 
Rabbit Serum  10% in PBS  Abcam (Cambridge, UK) 
EtOH    100% in ddH2O VWR (Lutterworth, UK) 
EtOH    70% in ddH2O VWR (Lutterworth, UK) 
PBS    1X   BD Biosciences (Oxford, UK) 
Haematoxylin  1X (filtered)  Leica (Peterborough, UK) 
DAB solution   1X   Vector Labs (CA, USA) 
ABC kit   1X   Vector Labs (CA, USA) 
Avidin/Biotin Blocking Kit 1X   Vector Labs (CA, USA) 
PFA in PBS   4%   VWR (Lutterworth, UK) 
Histomount    1X   National Diagnostics (Hessle, UK) 
 
2.1.8.2 Elastin van Gieson  
 
All reagents were from the Sigma-Aldrich EVG kit (HT25A). 
 
Ferric Chloride Solution 
i. Haematoxylin Solution   = 216 ml 
ii. Ferric Chloride Solution   = 33 ml  
iii. Iodine Solution    = 87 ml 
iv. Deionised water (in-house)  = 54 ml  
Total Volume      = 390 ml 
 
Working Ferric Chloride Solution 
i. Ferric Chloride Solution  = 29 ml 
ii. Deionised Water   = 361 ml 
 Total Volume     = 390 ml 
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Other Solutions (Total Volume: 390 ml) 
Reagent    Conc.  Source   
EtOH     95%  VWR (Lutterworth, UK) 
Van Gieson Solution  1X  Sigma-Aldrich (MO, USA) 
EtOH     100%  VWR (Lutterworth, UK) 
Xylene     1X  Genta Medical (York, UK) 
PFA in PBS    4%  VWR (Lutterworth, UK) 
Histomount    1X  National Diagnostics  
        (Hessle, UK)  	  
2.1.8.3 Picrosirius Red  
 
Reagent     Conc. Source 
Haematoxylin Stain Solution  1X Sigma-Aldrich (MO, USA) 
 
Distilled H20      – In-house 
 
Staining Solution A    1X Polysciences, Inc. (PA, USA) 
(Phosphomolybdic Acid Hydrate in H2O) 
 
F3BA Solution B (Picric Acid)  1X Polysciences, Inc. (PA, USA) 
(Direct Red 80 + 2,4,6,-Trinitrophenol in H2O) 
 
0.01N Hydrochloride Acid Solution C 1X Polysciences, Inc. (PA, USA) 
(HCl in in H2O) 
 
Histomount     1X National Diagnostics  
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2.1.8.4 Oil Red O in Dextrin Staining Solution (Churukian method) 
 
Reagent   Conc.  Source 
Haematoxylin  1X  Sigma-Aldrich (MO, USA) 
Isopropanol   60%  VWR (Lutterworth, UK) 
Paraformaldehyde  4%  Sigma-Aldrich (MO, USA) 
Kaiser’s Glycerin Gelatine 1X  Merck Millipore (Darmstadt, GE) 
 
Oil Red O Solution  
Oil Red O   0.9 g  Sigma-Aldrich (MO, USA)  
Absolute Isopropanol 180 ml VWR International (Lutterworth, UK) 
 
Dextrin Solution 
Dextrin (Corn-derived) 1.2 g  Sigma-Aldrich (MO, USA) 
Distilled water  120 ml In-house 
 
Filtered Working Solution 
Oil Red O solution  180 ml   
Dextrin solution  120 ml   
 
2.1.9 Cell culture media and solutions  
 
Reagent      Source 
Dulbecco’s Modified Eagle Medium (DMEM) Lonza (Verviers, Belgium) 
Foetal Bovine Serum (FBS; South America) Life Technologies (CA, USA) 
Penicillin/Streptomycin (100X)   PAA Laboratories GmbH  
        (Pasching, Austria) 
2-Mercaptoethanol (50mM)   Life Technologies (CA, USA) 
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2.1.10 PBMC isolation reagents 
 
Reagent     Conc.  Source 
 
Sodium citrate tribasic (4% w/v)  1:10  Sigma-Aldrich, Inc.  
         (MO, USA) 
 
Histopaque Density Gradient Media  1:1  Sigma-Aldrich, Inc. 
         (MO, USA) 
 
Hank’s Basic Salt Solution (HBSS)          5:1  PAA Laboratories GmbH 
   (Pasching, Austria) 
 
2.1.11 FACS staining reagents 
 
Reagent     Conc.        Source 
 
PBS w/sodium azide (0.1%)  1X        BD Biosciences  
               (Oxford, UK) 
          
PBS w/FBS (1%), sodium azide (0.1%) 1X        BD Biosciences 
               (Oxford, UK) 
 
CellFIX     1X        BD Biosciences  
               (Oxford, UK) 
 
Red blood cell lysing buffer  1:5        Sigma-Aldrich, Inc.  
               (MO, USA) 
 
Trypan Blue solution   1:1        Sigma-Aldrich, Inc. 
               (MO, USA) 
 
 	  	  	  	  	  	  	  	  





Biologics supplied from Biogen Idec Inc./Trillium Therapeutics Inc. were used 
for treatment of ApoE-/- animals and are listed in the table below. 
 
Reagent Stock Suspension Final Dosing Source 
muCD200-agly 
muIgG 
6.0 mg/ml 20mM citrate 
100 mM NaCl 

















Biogen Idec & 
Trillium 
Therapeutics 
Vehicle control Powder 20 mM citrate 







Table 2.7 – Biologics and controls used for the fusion protein experiment. 
Reagents were received from Biogen Idec Inc. (Cambridge, MA, USA). The muCD200-agly 
muIgG was modified from its original version manufactured by Trillium Therapeutics Inc. 
(Toronto, Canada). The MOPC-21 is an IgG1 control to assess for non-specific effects from 
the fusion protein. Both reagents were diluted to a final concentration of 1 mg/ml. Vehicle 
control solution was generated in-house from NaCl and tri-Sodium citrate dihydrate powder 
(VWR International, Lutterworth, UK) into water for injection (Life Technologies, CA, USA) to 
control for the 20mM citrate, 100 mM NaCl solution suspending the muCD200-agly muIgG.   	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2.2 Methods 	  
Methods used for experimental work are described in this section. 
 
2.2.1 ApoE-/- mouse as a model for atherosclerosis 	  
Apolipoprotein E (ApoE) is a class of apolipoprotein involved in the receptor-
mediated removal of VLDL and chylomicron remnants (Zhang, Reddick et al. 
1992). The absence of ApoE induces the accumulation of cholesterol-rich 
remnants that are atherogenic (Plump, Smith et al. 1992; Zhang, Reddick et 
al. 1992). The ApoE deficient mouse model was generated for research in 
atherogenesis, as this model spontaneously develops hypercholesterolemia 
even when placed on a low-fat chow diet (Zhang, Reddick et al. 1992; Plump, 
Smith et al. 1992). 
2.2.2 Cell culture model 	  
Male C57BL/6 mice purchased from Jackson Laboratories and housed at the 
Biological Services Unit of the Kennedy Institute of Rheumatology were 
sacrificed at ages 8-15 weeks and femurs and tibias were collected post-
mortem. Cells were flushed using a 26 gauge blunt needle tip syringe 
containing serum-free high glucose (4,5 g/l) DMEM (PAA, Pasching, Austria) 
and centrifuged at 1500 rpm for 5 min at room temperature (20°C). Cell 
pellets were re-suspended in 1 ml red blood cell lysis buffer (Sigma, St Louis, 
MO) for 5 min. Cells were subsequently washed twice and then suspended in 
1 ml complete DMEM (with 10% FCS (GIBCO® Invitrogen, CA, USA), 0.5% 
2-mercaptoethanol (2-ME), 1% L-glutamine, 1% penicillin/streptavidin). Cells 
harvested from several sex-matched mice of the same genotype and 
background were pooled immediately after isolation and counted using the 
Neubauer chamber in a 1:1 dilution with Trypan blue stain. The cells were re-
suspended at a cell density of approximately 0.6 x 106 cells/ml in Petri dishes 
(90 mm diameter, 14.2 mm height) supplemented with 100 ng/ml MCSF 
(PeproTech Ltd, London, UK) for 7 days at 37°C, with 5% CO2. At day 7, the 
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medium was removed and cells were washed with 10 ml serum-free DMEM, 
removing non-adherent cells. Furthermore, 5 ml serum-free DMEM was 
added so that cells could be harvested using a cell scraper. Cells were 
pooled and counted, then re-plated with complete DMEM into 6-well cell 
culture dishes using 1x106 cells/ml. Cells were allowed to adhere over-night. 
The next day, the medium was replaced with a complete DMEM solution 
containing either single cytokine or LPS (Invivogen, CA, USA) stimuli (IL-4 
alone, IL-13 alone, IFN-ɣ alone, LPS alone) or double cytokine and LPS 
stimuli (IL-4 together with IL-13; IFN-ɣ together with LPS) or oxidised LDL 
(oxLDL) (Biomedical Technologies, MA, USA) for 2, 6 and 18 hours.   
	  	  	  	  	  	  	  	  	  	  
	  
Figure 2.1 – Schematic illustration of cell culture model for mRNA and protein studies. 
WT bone marrow was flushed from male C57BL/6 mice. Cells were lysed, counted and 
plated with either MCSF or GMCSF. After 7 days, cells were re-plated into 6 well plates for 
cytokine and TLR ligand stimulations in a time course, as appropriate.  
 
2.2.3 Cell harvest 	  
The reaction was terminated by removing the medium and replacing it with 
350 μl RLT (+2-Mercaptoethanol) buffer to lyse the adherent cells. The RLT 
lysate was frozen in eppendorf tubes at -20°C until all the time points had 
been collected.   
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2.2.4 Characterisation of mRNA expression in vivo  	  
Female ApoE deficient mice on a C57BL/6 background were purchased from 
Jackson Laboratories and bred at the Biological Services Unit of the Kennedy 
Institute of Rheumatology. C57BL/6 mice were purchased from Jackson 
Laboratories. All mice were fed a chow diet and sacrificed at 8, 12-15, and 35 
weeks of age. Spleens, aortas and lymph nodes were harvested into RNA 
later and frozen down before extraction of RNA using the Qiagen kit. The 
proceeding cDNA synthesis was executed as described below. Quantitative 
PCR was performed to study gene expression.   
 
2.2.5 Isolation and quantification of RNA 	  
The Qiagen RNA isolation kit was used for RNA extraction according to the 
manufacturer instructions. RLT samples (350 μl) were defrosted, then 
thoroughly mixed, added to the QIA-shredder columns and spun for  
2 minutes at 12 000 rpm, 4°C. The supernatant was pipetted out and into a 
collection tube. An equal volume of 70% ethanol was added to the solution. 
The solution was thoroughly mixed and was transferred into the RNeasy spin 
column and spun at 12 000 rpm for 30 seconds. The flow-through was 
discarded and 700 μl of RW1 buffer was added to the spin column, then spun 
at 12 000 rpm for 30 seconds, the flow-through was discarded and 500 μl 
RPE buffer was added and the spin column was spun for 30 seconds. This 
was repeated once. After removing the flow through, columns were spun for 
2 min to remove any remains of RPE buffer. Finally, 30 μl of RNase free H20 
was added to the column and the solution was spun from the column into an 
eppendorf tube before freezing. The NanoDrop 1000 spectrophotometer 
(ThermoFisher Scientific, MA, USA) was used to assess the quantity and 
quality of RNA isolated from tissues and cell culture samples. After 
calibration with nuclease free H20, an amount of 2 μl RNA was added to the 
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2.2.6 Synthesis of cDNA 	  
RNA quantity was normalized to 500 ng for a single sample of tissue or cell 
culture extract. The total solution of RNA was diluted into 12 μl H20, then 1 μl 
Oligo(dT) was added to the suspension, totalling a volume of 13 μl. Samples 
were set onto the PCR machine for 10 min at 70°C, then taken out and a mix 
containing MMLV-RT RNase (0.5 μl) and RNase Inhibitor (1 μl), MMLV RT 
5x buffer (5 μl), dNTPs (10 mM, 1 μl) and ddH20 (4.5 μl) was added to each 
sample after the reaction cooled to 4 °C. The PCR programme cycle is listed 
below in table 2.8: 
 
 
Step Time Temperature 
Denaturation 10 min 70°C 
Primer annealing 60 min 40°C 
Primer extension 15 min 70°C 
Hold Continuous 4°C 
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2.2.7 Quantitative polymerase chain reaction 	  
In mix 1 the PCR Platinum® SuperMix at a volume of 5 μl was added 
together with 3 μl of cDNA, 0.5 μl of TaqMan primer and 1.5 μl ddH20 into  
0.1 ml PCR strip tubes w/cap for qPCR cycling on the Corbett Rotor-Gene 
6000 PCR machine (Corbett Life Science, Sydney, Australia) with a 
programme listed in Table 2.9. Alternatively, in mix 2, the TaqMan master 
mix at a volume of 3 μl was added together with 2.4 μl of cDNA, 0.3 μl 
TaqMan primer and 0.3 μl ddH20 into MicroAmp® 384 well-plates for qPCR 
cycling on the ABI 7000TM Fast Real-Time PCR System, (Applied Biosystems, 
WI, USA) as listed in table 2.10. Programmes for both mixtures are listed 
below. 
 
2.2.7.1 Corbett Rotor-Gene 6000 Machine 	  
Step Time Temperature 
1. Amp Erase UNG activation 2 min 50°C 
2. Denaturation 3min 95°C 
3. Cycling (40x)   
4. Melting 15 sec 95°C 
5. Annealing/Extension 1 min 60°C 
Table 2.9 – Q-PCR cycling programme for the Corbett Rotor Gene 6000. 	  
 
2.2.7.2 ABI 7900HT Machine 	  
Step Time Temperature 
1. Amp Erase UNG activation 2 min 50°C 
2. Denaturation 10 min 95°C 
3. Cycling (40x)   
4. Melting 15 sec 95°C 
5. Annealing/Extension 1 min 60°C 
Table 2.10 – Q-PCR cycling programme for the ABI 7900HT. 	   	  	  	  	  
 




2.2.8 Q-PCR analysis  	  
	  
Figure 2.2 – Amplification of the genes of interest iNOS, CD206, HO-1 and CD200R1 in 
WT macrophages on the ABI 7900HT Fast Real-Time PCR System. 
Macrophage cell culture derived cDNA samples were run on the ABI7900 HT machine in 
384-well plates. CT values were registered based on the threshold set on the logarithmic plot 
using SDS software. Shown is one representative plot of a total of three experiments 
performed with the displayed gene of interest. All genes were normalized to β-actin. 
iNOS CD206 
CD200R1 HO-1 





Figure 2.3 – Amplification of the genes of interest TNF-α, IL-12p35 and IL-10 in WT 
macrophages on the ABI 7900HT Fast Real-Time PCR System. 
Macrophage cell culture derived cDNA samples were run on the ABI7900 HT machine in 
384-well plates. CT values were registered based on the threshold set on the logarithmic plot 
using SDS software. Shown is one representative plot of a total of three experiments 
performed with the displayed gene of interest. All genes were normalized to β-actin. 
IL-12p35 IL-10 
TNF-­‐α 
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2.2.8.1 Delta delta CT analysis 
 
Threshold was set using the housekeeping gene primer curve. The same 
threshold was applied to the gene of interest curve. Threshold cycle (CT) 
values were determined at the cycle where fluorescence enters the 
exponential phase. Triplicate CT values were exported to MS Excel on a 
template for determining fold-change. The template averaged the           
MEAN ±SEM of CT value triplicates for the housekeeping gene (endogenous 
control) and the gene of interest. Expression of the gene of interest can be 
normalised in relation to the endogenous control and hence minimises any 
pipetting error and sample size. The ∆CT values were thus calculated based 
on the relative fluorescence of the gene of interest relative to the endogenous 
control. More precisely, the change in CT values of the sample (∆CT, 
sample) was calculated by an equation (∆CT, gene of interest – ∆CT, 
endogenous control), which normalises the data. The expression levels are 
plotted against a control (e.g. WT week 8 tissue), to yield the ∆∆CT value by 
(∆CT, Sample – ∆CT, control). Relative expression (fold-change) is 
determined by 2-∆∆CT.  
 
2.2.9 Statistical analysis 
 
All qPCR data are presented as mean fold change ± SEM. Statistical tests 
were chosen as appropriate for each individual qPCR reaction depending on 
the size of the datasets and experimental design. All statistical tests were 
performed on ∆CT values. Sample ∆CT values were assessed for 
significance using either a repeated measures ANOVA followed by Dunnett’s 
post-test (n=3), a Bonferroni’s multiple comparison post-test or by a two-
tailed t-test to account for individual changes, as appropriate. ApoE-/- and WT 
tissue samples were tested for mRNA expression using a two-tailed t-test as 
appropriate (variable sample size). Histology staining percentages were 
assessed by the ANOVA test followed by Bonferroni’s multiple comparison-
test, or a two-tailed t-test, as appropriate.  
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2.3 Thin cap fibroatheroma engineering 	  
Recently, Professor Krams’ group has shown the impact of shear stress 
modification on inflammatory cell recruitment and chemokine expression in 
atherosclerosis (Cheng, Tempel et al. 2007). By inserting a biomechanical 
shear stress modifying cuff around the carotid artery of hyperlipidaemic 
ApoE-/- mice, the group observed that after 9 weeks, regions of low shear 
stress (LSS) are associated with plaques of a “vulnerable” phenotype 
(enhanced macrophage content and activation) characterised by a higher 
lipid content (15.8±0.9%), thin layers of smooth muscle cells and collagen in 
the cap of the lesion, while the oscillatory shear stress (OSS) region is 
associated with a “stable” plaque phenotype characterised by a lower lipid 
content (10.2±0.5%) and uniform distribution of smooth muscle cells and 
collagen in the intima (Cheng, Tempel et al. 2006). In addition, MMP activity 
was increased by one third in the lowered shear stress region and 
inflammatory adhesion molecules VCAM-1 and ICAM-1 were up-regulated by 
3-fold in the lowered shear stress region. The expression of CRP was 
increased by 3-fold in the lowered shear stress region and 2-fold in the 
oscillatory shear stress region in comparison to controls (Cheng, Tempel et al. 
2006). Furthermore, the expression of VEGF was increased 5-fold and the 
cytokine IL-6 was increased by 14-fold in the lowered shear stress region. 
Moreover, outward vascular remodelling, a phenomena that is regarded as a 
prototypical feature of vulnerable plaques, was more enhanced in the 
lowered shear stress region (Cheng, Tempel et al. 2006). The results 
indicated that low shear stress regions induced the development of lesions 
with a vulnerable phenotype. This model uniquely reproduces human-like 
disease (with thin cap fibroatheroma) in the mouse (Cheng, Tempel et al. 
2006).  
Given the essential role that blood flow plays in TCFA formation, this model 
will be employed to evaluate the role of macrophage polarisation and 
CD200R in atherosclerosis and plaque formation. 
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2.3.1 Surgical shear stress modifying perivascular cuff model 
 
ApoE-/- female mice on a C57BL/6 background were placed on a high fat diet 
for 8 weeks at 16 weeks of age. After 2 weeks the mice were anaesthetised 
with a 4% isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane), air 
and oxygen mixture and maintained at 2% isoflurane during the procedure. 
After weighing, a sagittal anterior neck incision was made to access the 
anterior cervical triangles. Connective tissues and salivary glands were 
moved aside to expose the mediastinum and access either the left or right 
common carotid artery. A perivascular cuff was tied around one of the 
common carotid arteries with ligature. Following wound closure the mice 
recovered in a chamber at 28°C. The wounds, weight and behaviour of the 
mice were monitored for 10 days post-surgery as an indication of their health. 
For surgical experiments, death rates were around 2% spanning three years.  
 
For CD200-Fc biologics experiments, mice were placed on a high fat diet for 
2 weeks before surgery and sustained the cuff placement for 9 weeks 
thereafter. The placement of this cuff created patterns of high, low and 
oscillatory shear stress as previously described (Cheng, Tempel et al. 2006). 
Mice were euthanized by pentobarbital overdose. Senior Research 
Technician M.E.G., in compliance with Home Office Regulations, performed 































Figure 2.4 – Perivascular shear stress modifying cuff. 
The 250µm in diameter perivascular cuff was placed onto the main carotid artery inducing 
regions of LSS (low shear stress), HSS (high shear stress) and OSS (oscillatory shear 
stress). Figure adapted from (Cheng, Tempel et al. 2006). 
 
 
2.3.2 High fat diet composition 
 
ApoE-/- mice were placed on a western high fat diet containing 15% cocoa 
butter, 10% maize starch, 20% casein, 40.5% sucrose, 5.95% cellulose and 
other vitamins and minerals (for desired composition) and 0.25% cholesterol 
to aid the induction of atherosclerosis (Lillico Biotechnology, Surrey, UK).  
 
2.3.3 Cryosectioning of tissues 
 
Murine carotid arteries were snap frozen in OCT medium and stored at -80°C. 
The frozen sections were fixed vertically with OCT medium on the sectioning 
plate of the cryostat. For perivascular cuff treated carotid arteries, 5 μm 
sections were obtained throughout the whole artery. For corresponding 
contralateral arteries, 60 x 5 μm sections were collected at 30 μm intervals. 
Consecutive sections were utilised for different stains along the entire artery. 
All sections were sliced on a Leica CM1900 UV Cryostat. 
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2.3.4 Elastin van Gieson method 
Sections every 30 μm for the whole length of the main carotid artery were air-
dried for 30 min and fixed in 4% PFA (Paraformaldehyde) in PBS for 10 min. 
Subsequently, the sections were stained in the elastin stain solution 
(containing 72 ml haematoxylin solution, 11 ml ferric chloride solution, 29 ml 
iodine solution and 18 ml deionised water) for 10 min. Slides were briefly 
rinsed in deionised water, before differentiating them in working ferric 
chloride solution (containing 9.75 ml ferric chloride solution and 120.25 ml 
deionised water) for 1 min.  The slides were briefly rinsed in tap water, and 
then rinsed in 95% ethanol before staining in van Gieson solution for 30 
seconds. Slides were next rinsed and kept in 95% ethanol for 5 min, then 
transferred into 100% ethanol for another 5 min, then transferred into xylene 
for 5 min. Slides were allowed to air dry for 30 min before clarion mounting 
medium was added to the visible sections, cover slides were gently placed 
on top of the slides (avoiding air bubbles) and left overnight to dry before 
imaging. Images for quantification were acquired with a 10x lens on a 
Olympus BH2 research microscope using a Jenoptik Progres CF scan digital 
camera. Imaging was performed on 10 sections per slide. Intima/Media ratios 
were calculated as described below.  
2.3.5 Intima/media ratios 	  
The intima/media ratio was calculated based on quantifications of 
photomicrographs depicting areas stained with Elastin van Gieson solution 
using ProgRes® CapturePro (v.2.5) image acquisition software (Jenoptik 
Laser, Optik Systeme GmbH, Jena, Germany). The scale was set at  
100 μm = 184 pixels for consistency. The quantification measured the 
external, internal elastic laminas and lumen. The area of the media was 
determined by subtracting the area of the internal elastic lamina from the 
external elastic lamina. The area of the intima was calculated by subtracting 
the area of the lumen from the area of the internal elastic lamina. The lesion 
size was then determined by dividing the area of the intima over the area of 
the media. The mean intima/media ratio value for 10 sections on each slide 
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was determined (set as y-values) and plotted against the spatial distribution 
axis in micrometres (set as x-values).  
2.3.6 Oil Red O (Churukian method) 
 
The Oil Red O method stains for lipids and triglycerides. It contains Solvent 
Red 27 and Sudan Red, a fat-soluble dye for lipids and lipoprotein staining; 
and diazo dye (used for staining neutral triglycerides). Slides were first air 
dried, then fixed in 4% PFA, then washed in distilled H20, rinsed in 
isopropanol 1 min. Thereafter, slides were submerged in Oil Red O solution 
15 min, then washed gently, while agitating. Counterstain was applied using 
filtered haematoxylin for 40 seconds. Slides were rinsed in water until the 
water was clear. Slides were air-dried and mounted using Kaiser’s glyceryl 
gel. Solutions were made up in-house using reagents as listed in the 
materials section. 
2.3.7 Picrosirius red  
 
The Picrosirius Red method is used for staining of collagen type III and I. The 
stain quantifies the amount of collagen in a given area of tissues and binds to 
collagen fibrils of different diameter. Thus, it can be used to distinguish 
collagen type III (green birefringence) from collagen type I (orange/yellow). 
The method involves a 4-step approach and was done with the Picrosirius 
Red Kit (Polysciences, Inc., PA, USA). First, all the cryosections were air 
dried and fixed in PFA (4%) for 10 min. The slides were then washed in 
distilled water for 5 min. Subsequently, slides were stained with haematoxylin 
for 8 min, then rinsed in distilled water 5 min. Slides were placed in solution A 
for 2 min, rinsed in distilled water for 5 min, placed in solution B for 60 
minutes, then solution C for 2 min. At the final step, slides were treated briefly 
with 70% EtOH for 45 seconds, then dehydrated, cleared and mounted. All 
images were acquired using a polarised light filter under a dark background. 
Quantifications were performed with Clemex Vision (Clemex Technologies 
Inc, Québec, Canada), where the percentage area of collagen type I was 
selected for, as described by the manufacturer (Polysciences Inc., PA, USA).	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2.3.8 Immunohistochemistry 	  
Adjacent sections every 30 μm for the length of the main carotid artery were 
used for immunostaining. The section outer borders were drawn with an 
ImmEdge hydrophobic barrier pen (Vector Laboratories, CA, USA), then air-
dried for 30 minutes and fixed in acetone for 5 min on ice, then washed in 
PBS for 5 min. Slides were air-dried for 30 seconds, then washed in PBS for 
2 x 4 min. Slides were blocked with 10% heat-inactivated serum in PBS of 
the species from the secondary antibody for 60 min, then washed in PBS for 
5 min. Slides were blocked with avidin solution (Vector Laboratories, CA, 
USA) for 15 min at room temperature, washed in PBS 5 min, then blocked 
with biotin solution for 15 min at room temperature and washed in PBS for 5 
min. Slides were then added the primary antibody at the appropriate 
concentration in PBS for 45 min and washed in PBS 5 min. Slides were then 
incubated with the secondary biotinylated antibody for 40 min (1:400 dilution 
into PBS) and washed in PBS for 5 min. Slides were inactivated for 
endogenous peroxidase by incubation for 15 min with 0.3% hydrogen 
peroxide in PBS, then washed for 5 min in PBS. Slides were incubated with 
Vector’s ABC-Elite Standard Kit for Peroxidase solution A (1 μl solution A - 
avidin/100 μl PBS) mixed with solution B (1 μl solution B – biotin 
peroxidase/100 μl PBS) for 40 min. This solution was made up 30 min before 
usage. Slides were washed with PBS for 5 min, then incubated with 3,3’-
Diaminobenzidine (DAB) solution (Vector Laboratories, CA, USA) for 3 min, 
then washed in PBS for 5 min. Slides were counterstained with haematoxylin 
for 30 sec, then washed in water. Finally, slides were dehydrated for 1 min in 
70% ethanol, and 1 min in 100% ethanol and air-dried before Histomount 
medium was added to the visible sections. Cover slides were gently placed 
on top of the slides (avoiding air bubbles) and left overnight to dry before 
imaging. All staining steps were either done in solution (as for haematoxylin) 
or in a moist chamber at room temperature and at a volume of 50 μl/section.  
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2.3.9 Clemex image analysis 	  
Images for quantification were obtained from stained tissue sections using an 
Olympus BH2 microscope (Olympus Corporation, Japan), with a Jenoptik 
digital camera linked to ProgRes® CapturePro (v.2.5) image acquisition 
software (Jenoptik Laser, Optik Systeme GmbH, Jena, Germany) using a 10x 
lens. Alternatively, images were captured with a 20x lens on an Olympus 
BX51 microscope coupled to a DP71 camera (Olympus, Japan). Image 
analysis was performed using Clemex Vision software (v.5.0, Clemex 
Technologies Inc., Québec, Canada). Clemex calculations are based upon 
bitplane-highlighted regions of the image, calculated as a percentage of user-
drawn lesion area. Data was gathered using a user-defined automated image 
analysis template from visual basic into MS-Excel. 
2.3.10 3-D histology 
 
Carotid arteries were excised and prepared for histology. Embedded arteries 
were sectioned between two physiological landmarks, the aortic arch and 
carotid bifurcation, at 5 μm intervals in sets of 6 slides. Sections proximal to 
the cuffed-region are then stained for various markers, making the interval 
distance between sections within sets of a particular stain 30 μm. Images of 
the stained sections are acquired, which are imported into Clemex where a 
threshold is applied to identify the location and area of stained pixels. In 
addition, the centroid and area of the vessel lumen and wall is calculated for 
each section. Vectors can then be created from the histology section centroid 
to each region of stained pixels. Finally, the location of a fiduciary marker on 
each vessel section is acquired, which allows the reconstruction program to 
maintain the correct orientation of each section relative to the others. This 
information is then imported into a custom MATLAB program to construct a 
3-D histology map. Briefly, this program takes a 3-D carotid artery geometry, 
reconstructed from intravascular ultrasound images acquired in a living rabbit 
(this geometry is computationally scaled down to the dimensions of a mouse 
carotid artery), and breaks the lumen and outer-wall contours into a user 
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defined number of circumferential and radial sections that combine to make 
elements. These elements are equally sized and spaced around the 
circumference. Aligning the centroid of the histology section with the 
corresponding in vivo vessel section (determined based on the histology 
sectioning intervals and IVUS pullback speed, respectively), the ratio of the in 
vivo vessel wall area to histology section wall area can be used to scale the 
aforementioned stain vectors to map them from the histology section to the in 
vivo section. The result is a 3-D histology stain map superimposed onto the 
in vivo geometry. Since this geometry is computationally broken into 
elements, the ratio of scaled stain area to element area is used to define a 
stain “intensity”. Thus, the 3-D histology map colour bar represents a 
normalised stain intensity, which goes from 0 (blue) to 1 (red), indicating the 
amount of stain present over the area of the vessel in that particular element. 
Blue means no stain was present and red means that the entire area of that 
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2.4 Principles of flow cytometry 
 
The first phase of flow cytometry involves the collection and staining of cells 
as described later in the methods chapter. The second phase is for gathering 
of cells (events) on a cytometer. Flow cytometry enables cell analysis of 
multivariate parameters. A simplified figure is illustrated in Figure 2.5 below. 
 
Figure 2.5 – FACS allows laser-assisted fluorescent phenotyping of cell populations. 
A laser excites the fluorochrome tagged to the monoclonal antibody attached to the cell. 
After excitation, the fluorochrome emits the light at another wavelength and the light is 
detected (this emission is called stokes shift). The PMT is used to amplify the signal, then 
analogue to digital converters convert the signal so the data can be acquired and analysed 
by the PC. Figure adapted freely from (Dako 2006). 
 
2.4.1 Stokes shift 
 
A photon of certain energy is emitted, and the excited fluorochrome is 
returned to its ground state. Due to separation of the energy during the 
excited state, the emission photon carries a lower energy (longer 
wavelength) than the excitation photon. This difference in energy is called the 
Stokes shift, and is essential for the sensitivity of fluorescence, by allowing 
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2.4.2 Spectral overlap and compensation 	  
Although the bandpass is supposed to filter out a high amount of the overlap, 
there is still some interfering overlap (Figure 2.6). Overlapping emission 
spectra can be corrected for by compensation. By tweaking the raw data, it is 
possible to subtract and correct this spillover. In the present example the total 
area measured in the bandpass of FITC would be: area (a) + (b); the area 
measured in the bandpass of PE would be: area (c) + (d), which illustrates 
the total area measured. This includes the area the two have measured in 
common. As this area would interfere with the results, it is removed, 
meaning: the actual area looked at for FITC would be only area (a) and the 
respective measurement for PE would be only area (c) alone.  
 
Figure 2.6 – Spectral overlap and compensation. 
The figure shows an example of the two different fluorochromes FITC (a) and PE (c), which 
interfere with one another (b, d) due to overlapping emission spectra. Figure adapted freely 
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2.4.3 Principles of flow cytometry analysis 	  
On the plot, cells will at first be positioned at different places according to 
their respective size and granularity (Figure 2.7). 
 
Figure 2.7 – Live gate: Forward scatter vs. side scatter profiling. 
The physical properties of a cell can be measured using forward (size) vs. side scatter 
(granularity) parameters on a flow cytometer live gate. 
 
Forward scatter measures cells size and side scatter measures granularity. 
For example, granulocytes are more granular than lymphocytes and 
macrophages are larger than lymphocytes. The cell lineage and the 
physiological environment a cell has been exposed to will determine its 
granularity and size. This will determine signal intensity. As seen on the plot 
above, larger cells are shifted towards the upper limits on the forward scatter 
parameter (A & B populations) and more granular cells are shifted towards 
the upper section of the side scatter parameter (C & A populations), whereas 
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2.5 FACS staining of cells 	  
2.5.1 PBMC isolation 
 
Whole blood was pooled from 2-3 mice into one sample and isolated on a 
Histopaque separation gradient (buffy coat). The mononuclear cell buffy coat 
was gently in contact with the pipette. The layer with cells was isolated from 
the tube then stained using the FACS staining protocol.  
2.5.2 Splenocytes and bone marrow cell isolation 	  
Cells were extracted from their respective tissues using mechanical shear 
(spleen) or syringe perfusion (bone marrow) followed by filtration before RBC 
lysis buffer treatment for 5 min (with 1:1 ratio of lysis buffer : cell medium).  
Cells were thereafter washed in FACS buffer and spun at 12,000 rpm for 5 
min at 4 °C. Cells were counted and suspended for staining with monoclonal 
antibodies using monocyte specific cell surface markers. 
2.5.3 Macrophage harvest 	  
Bone marrow cells matured in vitro with MCSF or GCSF were stimulated with 
cytokine cocktails for 36 hours, then scraped off gently, counted and 
suspended for staining with monoclonal antibodies using macrophage 
specific cell surface markers. 
2.5.4 Monoclonal antibody staining 	  
Cells were counted and seeded in 96 well plates, with volume-adjusted 
numbers. The cells were first blocked on ice with 1:100 Fc block 
(CD16/CD32) for 5 min. Subsequently, fluorochrome labelled mononuclear 
antibody cocktails, single stains or antibody-free FACS buffer were added to 
the appropriate wells for 30 min on ice (under light-free conditions). Cells 
were centrifuged at 12,000 rpm at 4ºC for 5 min, washed twice in FACS 
buffer and fixed in BD CellFIX for 15 min, then washed and re-suspended 
before acquisition on a flow cytometer. 
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2.5.5 Cell acquisition 	  
The BD LSR II flow cytometry machine at the FACS facilities of the Kennedy 
Institute of Rheumatology was used for the acquisition of cells from mouse 
blood, spleen, bone marrow and cell cultures. Voltage parameters of forward 
scatter (FSC), side scatter (SSC), and compensation for individual 
fluorochrome channels were standardised before acquiring all cells on the 
same day.  
2.5.6 Cell analysis 
 
FlowJo Software (Tree Star Inc., OR, USA) was used for the analysis and 
gating of cell populations. Cells were analysed for combinations of the 
markers CD11b, CD115, Ly6C and CD200R to account for monocyte subsets. 
Alternatively, cells were analysed for the expression of CD11b, I-A/I-E and 
CD200R in cell cultures to study the effect of in vitro stimuli on macrophages. 
2.5.7 Gating of monocytes 
 	  
All cells were selected from the live cell gate on the FSC vs. SSC plot. Live 
cells were gated for the co-expression of CD11b+ and CD115+ markers. 
Back-gating to live gate revealed the correct FSC vs. SSC was selected with 
these markers. Subsequently, subpopulations of monocytes expressing 
variable levels of Ly6C were selected.  
2.5.8 Gating of bone marrow-derived macrophages 
 
After maturation of murine bone marrow cells with 100 ng/ml MCSF or 10 
ng/ml GMCSF for 7 days, cells were re-plated and stimulated with cytokines 
oxLDL, and/or LPS for 36 hours. Cells were isolated into FACS tubes and 
stained using fluorochrome-tagged monoclonal antibodies, as previously 
described.  Gating using forward vs. side scatter, live cell populations were 
selected and subsequently subpopulations of interest (Figure 2.8).  
Where applicable, the CD11b+ marker was used to look at individual stimuli 
affecting the expression of CD200R together with MHCII.	  


















Figure 2.8 – Live gating strategy for MCSF/GMCSF matured BM cells. 
A total of 50,000 bone marrow matured cells were collected on a FACS BD LSRII machine 
within 24 hours of staining the cells. Data was analysed using TreeStar FlowJo v.X.10.0.7. 
(A) Identical live gating was applied to all MCSF matured bone marrow under various stimuli 
and allowed to detect macrophages, in accordance with previous reports, shown in the 
FASCS gating by Francke et al, Figure 5B (Francke, Herold et al. 2011).   
(B) The CD200R FITC-positive gate was drawn based on an isotype control in the live-gated 
sub-population and revealed the total expression of CD200R at the steady state. The same 
gate was applied for all other stimuli in each experiment. (C) Total live cells matured with 
GMCSF were selected for analysis using the same gate as cells matured with MCSF.  
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2.5.9 Pilot study for isolation and staining of monocytes 
 (HKU protocol) 	  
The University of Hong Kong operated with a different protocol from our lab. 
Murine splenocytes were collected from 20-26 week old ApoE-/- or WT mice 
in serum free RPMI (Sigma, St Louis, MO). Splenocytes were homogenised 
by mechanical shear and filtered with PBS, then washed twice in PBS by 
centrifugation (at 1500 rpm, 4 °C for 5 min). The supernatant was discarded 
and cells were subsequently lysed with 1 ml 1x ACK lysis buffer  
after mixing thoroughly (Lonza Walkersville Inc., Walkersville, MD, USA).  
The reaction was ended with the addition of 5 ml PBS and cells were 
centrifuged (as above). Flow cytometry tubes received 50 μl PBS each and 
the respective antibody was added to the tube (Ly6C Alexa 647 (BioLegend, 
San Diego, CA, USA) in APC channel, Abs/Em maxima at 650/665 nm, 
diluted 1:125) and vortexed. A quantity of 1/10 of the total splenocytes was 
added into each FACS tube and vortexed. Fluorochrome-labelled antibodies 
were incubated with the cells for 20 min, 4 °C. Tubes were washed twice in 
PBS, supernatant discarded, tubes were vortexed and fixing buffer (4% PFA 
in PBS) was added. The fixation step was applied for 10-20 min, 4 °C. Tubes 
were washed with PBS (1x, 800 μl), supernatant was discarded and 100 μl 
PBS was added. Samples were stored at 4 ºC, in dark until acquisition on a 
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3.1 Introduction 	  
Generation of animal models that can produce atherosclerotic plaques have 
been developed over the years (Daugherty 2002). Classically, the rabbit has 
been widely used for studies on atherosclerotic plaques (Yanni 2004). 
However, the limitations with the approach are that genetically engineered 
rabbits are not available. For relative ease of use, the mouse model has 
become the most characterised model in cardiovascular studies. Mice are 
naturally resistant to atherosclerosis, due to partitioning of the majority of 
cholesterol into the anti-atherogenic HDL type of lipoproteins (Hughes and 
Hekimi 2009), and have a lipoprotein status very different from humans (Shih, 
Welch et al. 1995; Rader and Pure 2000). Only genetic modifications in 
lipoprotein metabolism renders them susceptible to hypercholesterolemia-
induced atherosclerosis (Rader and Pure 2000).  
The ApoE protein is a VLDL apolipoprotein and is responsible in part for 
removing cholesterol from the bloodstream (Curtiss 2000). Jan Breslow 
demonstrated an association between the function of the ApoE gene and 
cardiovascular disease in humans while working at Harvard in 1982 (Breslow, 
Zannis et al. 1982) which later contributed to the generation of the 
hypercholesterolaemic ApoE-/- mouse model by Nobuyo Maeda and 
colleagues at UNC, Chapel Hill in 1992 (Piedrahita, Zhang et al. 1992; Zhang, 
Reddick et al. 1992). This development revolutionised the field by allowing for 
the detection of atherosclerotic lesion development as early as 10-15 weeks 
of age even when mice are fed on a chow diet (Nakashima, Plump et al. 
1994) and cholesterol levels are up to five times higher than normal (e.g. 434 
mg/dl versus 86 mg/dl, respectively) (Zhang, Reddick et al. 1992). 
Atherosclerotic lesions occur at predilection sites, such as those of low shear 
(LSS) and oscillatory shear stress (OSS), typical of side branches, inner 
curvatures or bifurcations (DeBakey, Lawrie et al. 1985). A traditional 
approach to the study of haemodynamic stress in atherosclerosis is the 
characterisation of the lesions generated at the inner curvatures of the aortic 
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arch compared to external arch (Cybulsky, Iiyama et al. 2001; Dansky, 
Barlow et al. 2001; Sukhova, Zhang et al. 2003; VanderLaan, Reardon et al. 
2004). However, the hemodynamic shear stress in the aortic arch is very 
complex as described by Feintuch et al., based on mathematical models, 
MRI and ultrasound of the same region (Feintuch, Ruengsakulrach et al. 
2007) and does not permit the dissection of the effect of single hemodynamic 
states on atherogenesis. 
In order to circumvent these limitations of previous models, a perivascular 
shear stress altering cast for the ApoE-/- mouse was invented (Cheng, 
Tempel et al. 2006). The funnel-shaped device, placed around the carotid 
artery supplying blood to the brain, creates two distinct types of shear stress 
in the same artery, adjacent to each other. LSS is generated proximally to the 
device while OSS is generated distally. The application of LSS and OSS 
leads, to two rather diverse lesions: LSS is associated with higher lipid 
content, lower collagen and smooth muscle cells; OSS is characterised by 
lower lipid content, higher collagen content and increased smooth muscle cell 
content (Cheng, Tempel et al. 2006). These lesions are reminiscent of the 
thin cap fibroatheroma and stable plaques in humans, respectively, and they 
are so far one of the closest approximations of human pathology in a rodent 
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3.2 Shear stress-induced vasoconstriction generates 
lesions in low and oscillatory regions in carotid arteries 
 
No previous studies have explored the expression of CD200R during 
atherogenesis and the relationship between its expression and shear stress. 
By employing the surgical model developed by Cheng et al., it was possible 
to study protein expression of CD200R in the context of different types of 
shear stress. I studied the effect of the perivascular cuff on lesion size, by 
quantifying Elastin van Gieson stained lesions. Intima/media ratio (IMR) 
calculations were used to measure the atherosclerotic lesion size, as 
previously described (Bots, Hofman et al. 1997). Subsequently, I used 
immunohistochemistry to detect anti-CD68+ and anti-CD200R+ cells in OSS 
and LSS regions. I then plotted the results using in-house software 
developed by collaborators at Bioengineering at Imperial College for 
displaying the localisation in 3-D of the developed lesions and cellular 
infiltrates. As a comparison, I measured the gene expression of CD200R1, 
CD200, iNOS, CD206 and IFN-γ in aortas, spleens and lymph nodes (LNs) in 
atherosclerosis and age-matched WT C57BL/6 mice.   
Cheng et al described the size of the lesions in the upstream region to be 
larger than downstream regions, with close to no IMR in the high shear stress 
region at week nine (Cheng, Tempel et al. 2006). To replicate these findings, 
mice were killed at week six. This different time-point was chosen because 
previous experience from the Kennedy Institute provided evidence for earlier 
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Figure 3.1  – Immunohistochemistry staining of ApoE-/- carotid artery sections with 
macrophage markers after 6 weeks of shear stress alteration. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 
2 weeks, underwent surgical intervention and were culled for collection of carotid arterial 
tissue, snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced 
using a Leica CM1900 cryostat beginning from the lower main carotid artery towards the 
upper bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C. 
Shown here are representative photomicrographs for the upstream (LSS), and downstream 
lesion (OSS) stained with Anti-mouse iNOS (Polyclonal Rabbit IgG, Abcam), CD206 
(Polyclonal Rat IgG2a, AbD Serotec), HO-1 (Polyclonal Rabbit IgG, Abcam) and IRF-5 
(Polyclonal Rabbit IgG, Abcam). All antibodies were diluted 1:200 in PBS for staining. An 
isotype control for each marker revealed no unspecific staining was captured. Figure 
courtesy of Anusha Seneviratne, Kennedy Institute of Rheumatology. Scale bar = 100μm. 
Data is representative of one single experiment. 
 
 
After placement of the perivascular shear stress altering cuff for 6 weeks, in 
ApoE-/- mice on a high fat diet, the LSS lesion was eccentric (Figure 3.2) as 
described by Cheng (Cheng, Tempel et al. 2006). In the midstream HSS 
region, no lesion was present while in the downstream OSS region, a rather 
concentric lesion surrounding the entire vessel was present, in accordance 
with previous findings (Cheng, Tempel et al. 2006).	  










Figure 3.2  – Elastin van Gieson staining of shear-modified plaques after six weeks of 
vasoconstriction in ApoE-/- carotid arteries. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 
2 weeks, underwent surgical intervention and were culled for collection of carotid arterial 
tissue, snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced 
using a Leica CM1900 cryostat beginning from the lower main carotid artery towards the 
upper bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C then 
stained with Elastin van Gieson for each mouse. Shown here are representative 
photomicrographs for the upstream (LSS), midstream (HSS) and downstream lesion (OSS), 
Scale bar 1 unit = 200μm. Images representative of one single experiment. 
 	  
Geometric areas of lesions were quantified from sequential images starting 
from the beginning of the artery (heart end) towards the bifurcation in 
direction to the brain. This was done in order to describe the lesions formed 
by perivascular cuff placements. Plotting of the IMR quantifications yielded 
an overview of how the lesion was distributed across the artery (Figure 3.3). 
IMR with values ranging from 0.6 to 2.3 was observed in the upstream LSS 
region. In the downstream OSS segment, a distinct second peak was found, 
with lesion sizes ranging from IMR 0.6 to 2.2, with average of 1. These data 
show that the perivascular effect had generated two lesions subject to shear 
stress against the vessel wall. There were no statistical differences in IMR 
values between the LSS and OSS region (p=ns). These findings are in 
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contrast to studies by Cheng et al, where no changes in lesion size were 
observed between the two sites at six weeks, but significant differences 
between sites were observed at nine weeks (Cheng, Tempel et al. 2006). 
This could mean that in order to see a full change in the IMR between the 
two regions, mice should have generated lesions for a further 3 more weeks, 
in order for a larger lesion to grow in the LSS region.  
 
 
Figure 3.3 – Perivascular cuff placed ApoE-/- mice exhibit lesion development at the 
LSS and OSS regions in the carotid artery 6 weeks after cuff placement. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 2 
weeks, underwent surgical intervention and were culled for collection of carotid arterial tissue, 
snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced using a 
Leica CM1900 cryostat beginning from the lower main carotid artery towards the upper 
bifurcation. Sections for Elastin van Gieson were collected every 30 µm onto slides then 
frozen at -20°C. After staining, slides were imaged and the intima/media area ratio for each 
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Atherosclerosis development is highly associated with macrophage influx 
through migrating monocytes, as reviewed by (Woollard and Geissmann 
2010). The presence of macrophages in plaques can be destructive through 
production of pro-inflammatory cytokines and plaque structure-degrading 
enzymes, such as MMPs, reviewed by (Newby 2008). In order to study the 
plaque content of macrophages, the pan-macrophage marker CD68 content 
was determined by immunohistochemistry staining. The photomicrographs 
depict the regions of LSS and OSS stained with the pan macrophage marker 
CD68 or macrosialin (brown) (Figure 3.4). CD68 was highly expressed in 
both upstream (LSS) and downstream (OSS) regions of the carotid artery, in 
keeping with previous literature. 
 	  
Figure 3.4 – Atherosclerotic lesions contain the macrophage marker CD68.  
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 2 
weeks, underwent surgical intervention and were culled for collection of carotid arterial tissue, 
snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced using a 
Leica CM1900 cryostat beginning from the lower main carotid artery towards the upper 
bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C. Each 
section was 5 µm downstream from the previous stain with EVG. An isotype control revealed 
no unspecific staining was captured. Shown here are representative photomicrographs of 
sections from the CD68+ lesions at the upstream (LSS, low shear stress) and downstream 
(OSS, oscillatory shear stress) regions. These sections were imaged with a 20x lens on an 
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The presence of CD68+ staining was quantified from the photomicrographs 
using Clemex Vision software and characterised the expression patterns of 
CD68 across the five ApoE-/- mouse carotids. 
Figure 3.5 – Atherosclerotic lesions contain the macrophage marker CD68. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 
2 weeks, underwent surgical intervention and were culled for collection of carotid arterial 
tissue, snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced 
using a Leica CM1900 cryostat beginning from the lower main carotid artery towards the 
upper bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C. 
Each section was 5 µm downstream from the previous stain with EVG. The HSS area 
between LSS and OSS was not stained, as there were no lesions present. Lesions were 
stained for CD68, imaged and quantified for percentage CD68 content using Clemex Image 
Analysis software. Percentages were plotted according to spatial location in the carotid 
artery for each section (N=5). Data is representative of one single experiment. 
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The initial experiment in Figure 3.2 and Figure 3.3 showed there was no 
statistical difference in the lesion size between regions.  
ApoE-/- carotid lesions stained for CD68 did not exhibit significant difference 
in CD68+ cells in the LSS versus the OSS region (Figure 3.6). Both regions 
had an abundance of >25% CD68 in the lesions. This finding was consistent 
with the finings by Cheng et al. after nine weeks (Cheng, Tempel et al. 2006; 
Cheng, Tempel et al. 2007).	  
	  	  
Figure 3.6 – Plot of the average percentages for atherosclerotic lesions containing 
the macrophage marker CD68 in LSS and OSS regions. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 
2 weeks, underwent surgical intervention and were culled for collection of carotid arterial 
tissue, snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced 
using a Leica CM1900 cryostat beginning from the lower main carotid artery towards the 
upper bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C. 
Each section was 5 µm downstream from the previous stain with EVG. The HSS area 
between LSS and OSS was not stained, as there were no lesions present. Lesions were 
stained for CD68, imaged and quantified for percentage CD68 content using Clemex Image 
Analysis software. Percentages for the two regions were averaged for each individual mouse, 
and plotted together according to spatial location in the carotid artery. Unpaired two-tailed t-
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3.3 Atherosclerotic lesions exhibit CD200 receptor expression 
 
The myeloid receptor CD200R has never before been studied in the context 
of atherosclerosis. Based on in vitro studies, CD200R is known to be 
regulated by macrophage polarisation (Koning, van Eijk et al. 2010). After 
validating the perivascular cuff model in our lab, I proceeded to study the 
expression of CD200R in shear stress modified plaques. CD200R was 
evaluated in parallel sections with immunohistochemistry every 30 μm across 
the whole length of the carotid artery following the previous stain (CD68). The 
photomicrographs depict representative images from the regions upstream 
(LSS) and downstream (OSS) stained with CD200R (Figure 3.7).  
 
Figure 3.7 – Atherosclerotic lesions contain the CD200 receptor. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 2 
weeks, underwent surgical intervention and were culled for collection of carotid arterial tissue, 
snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced using a 
Leica CM1900 cryostat beginning from the lower main carotid artery towards the upper 
bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C. Each 
section was 5 µm downstream from the previous stain with CD68. An isotype control 
revealed no unspecific staining was captured. Shown here are representative 
photomicrographs of sections from the CD200R+ lesions at the upstream (LSS, low shear 
stress) and downstream (OSS, oscillatory shear stress) regions. These sections were 
imaged with a 20x lens on an Olympus BX51 microscope coupled to a DP71 camera 
(Olympus, Japan). Images representative of one single experiment. 
 	  
LSS Region	   OSS Region	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Quantification of CD200R expression as percentage immunopositive plaque 
area did not reveal statistically significant differences in CD200R expression 
in vascular segments subjected to LSS and OSS. (Figure 3.8; Figure 3.9) 
 
 
Figure 3.8 – Atherosclerotic lesions contain the CD200 receptor. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 
2 weeks, underwent surgical intervention and were culled for collection of carotid arterial 
tissue, snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced 
using a Leica CM1900 cryostat beginning from the lower main carotid artery towards the 
upper bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C. 
Each section was 5 µm downstream from the previous stain with CD68. The HSS area 
between LSS and OSS was not stained, as there were no lesions present. Lesions were 
stained for CD200R, imaged and quantified for percentage CD200R content using Clemex 
Image Analysis software. Percentages were plotted according to spatial location in the 
carotid artery for each section (N=5). Data is representative of one single experiment. 
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Figure 3.9 – Average percentages of CD200 receptor staining in lesion for the LSS 
and OSS regions. 
Five female ApoE-/- mice on a C57BL/6 background were kept on a high fat western diet for 
2 weeks, underwent surgical intervention and were culled for collection of carotid arterial 
tissue, snap frozen into OCT media and stored at -80°C after 6 weeks. Tissues were sliced 
using a Leica CM1900 cryostat beginning from the lower main carotid artery towards the 
upper bifurcation. Sections were collected every 30 µm onto slides then frozen at -20°C. 
Each section was 5 µm downstream from the previous stain with CD68. The HSS area 
between LSS and OSS was not stained, as there were no lesions present. Lesions were 
stained for CD200R, imaged and quantified for percentage CD200R content using Clemex 
Image Analysis software. Percentages for the two regions were averaged for each individual 
mouse, and plotted together according to spatial location in the carotid artery. Statistical 
analysis was performed using an unpaired two-tailed t-test (N=5; ns=non-significant). Data is 
representative of one single experiment.	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3.4 3-D display of atherosclerotic lesions reveals CD68 and 
CD200R content 
  
Three-dimensional (3-D) model reconstructions are in development for a 
range of clinical applications to ensure more sophisticated accurate diagnosis 
with applications in fields such as cardiology or wound healing care (Ronald 
Daniel 2011) (Dvir and Kornowski 2010). Computational 3-D models of the 
rabbit aorta have been generated previously and have revealed the 
distribution of lipids on the interior of the blood vessel, providing a new 3-D 
visualization methodology for assessing histology in blood vessels and 
plaques revealing spatial localisation, complementing classical histology 
readouts (Segers, Helderman et al. 2007). 
The localisation of cellular and inflammatory atherosclerotic plaque features 
has not yet been studied using 3-D histology in the mouse model. The 
presentation of immunohistological markers with 3-D histology imaging 
allows for a spatial overview of the distribution of plaque components. This 
may be used for longitudinal studies to assess how the plaque content 
evolves over time. Secondly, it may also be utilised to assess the distribution 
of a treatment target in the plaque and compare regions representative with 
high risk of rupture with regions of lower risk. The approach involved analysis 
of photomicrographs with a new template in Clemex software, generating an 
excel file for each single image. Each single file contained information about 
the location of each individual staining point in the lesions and its intensity. 
These positive staining points in were stacked and re-plotted using MATLAB 
software for 3-D display.  
The 3-D histology images (Figure 3.10) were created to show the distribution 
in the different plaques. They show how the distribution occurs in the low wall 
shear stress region and the oscillatory wall shear stress region. The staining 
of the representative mouse is generated from the CD68+ staining (Figure 
3.4) and CD200R+ staining (Figure 3.7), thus aiding the display in a 
horizontal, vertical and depth profile (Figure 3.10).  
























Figure 3.10 – Perivascular cuffed ApoE-/- mouse carotid arteries were sectioned, 
stained, imaged, quantified and computationally re-constructed in 3-D using MATLAB.  
Stained and imaged CD68+ and CD200R+ immunopositive photomicrographs were 
quantified using Clemex vision to detect x, y, z coordinates and % positive area in the 
lesions. Numerical data was re-plotted using an in-house developed programming package 
in MATLAB software to generate tubed vessel and open conformation plots of carotids 
displaying the stained area. Intensity is measured with colour bar, which goes from 0 (blue) 
to 1 (red). This scale indicates the amount of stain present over the area of the vessel of 
either CD200R or CD68. Colours in between blue and red mean partial staining. Images are 
representative of one mouse carotid artery undergone perivascular shear stress modification 
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3.5 The gene expression of CD200R and its cognate ligand 
CD200 are reduced during atherogenesis 	  
The kinetics of CD200R1 and CD200 expression during atherogenesis is 
unknown. In order to determine their temporal changes, the in vivo 
expression of CD200R1 mRNA and related genes in the spleen, aorta and 
lymphoid organs of WT mice compared with diseased ApoE-/- mice was 
assessed at three different time points 8, 12 and 35 weeks of age using      
Q-PCR (Figure 3.11; Figure 3.12). The small sizes of carotid lesions did not 
allow this analysis due to low RNA yields, and fresh frozen aortas were used 
for this analysis.  
Previous studies have shown that CD200R1 levels are increased during M2 
polarisation (Koning, van Eijk et al. 2010). Moreover, previous reports that 
studied CD206-/- (MR-/-) mice, found that during absence of CD206, immune 
responses were Th1 biased (Paveley, Aynsley et al. 2011), a similar effect 
has been registered in CD200-/- mice (Hoek, Ruuls et al. 2000).  
The expression of CD200R1 and CD200 were determined together with the 
expression levels of macrophage polarisation markers to assess whether 
there was an association between polarisation and CD200R1 expression.  
At early stages of atherogenesis (8 and 12 weeks), CD200R1 was not 
statistically different in ApoE-/- and WT mice in spleen, aorta and lymph 
nodes  (p=ns; Figure 3.11A; Figure 3.11B; Figure 3.11C). A significant 3-
fold increase of CD200R1 expression was observed in the spleen of WT 
mice, even in the absence of disease (p<0.05). This increase in CD200R1 
was not apparent in spleens derived from 35-week-old ApoE-/-, which had 
significantly lower levels of CD200R1 compared to WT (p<0.05)  
(Figure 3.11A). The same reduction was observed with the M2 polarisation 
marker CD206 in the spleen (p<0.05) (Figure 3.11D) and lymph nodes 
(Figure 3.11C). No significant changes were observed in CD200R1 
expression in the aorta and lymph nodes (Figure 3.11E). Also, the 
expression of CD200 increased in WT mice with age in the aorta (p<0.05), 
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although CD200 levels did not differ between WT and ApoE-/- mice (p=ns; 
Figure 3.11G).  
I then quantified the expression of M1 polarisation markers and stimuli in the 
same organs. IFN-γ was not differentially expressed in the spleen of ApoE-/- 
mice compared to WT, while changes were observed in the aorta (at 8 
weeks; p<0.05), (Figure 3.12). In the lymph nodes, IFN-γ expression 
increased with age but not with disease status (Figure 3.12C). The M1 
marker iNOS was increased in the spleen at the early stage of disease 
(p<0.05; Figure 3.12D), but was markedly reduced at later stages of disease 
(p<0.01; Figure 3.12D) while no marked changes were observed in other 
organs (Figure 3.12F). In summary, CD200R1 was significantly reduced in 
the spleen of aged ApoE-/- mice compared to WT, a pattern mirrored by the 
macrophage polarisation markers CD206 and iNOS, suggesting that 
CD200R1 levels may be regulated by ageing and the development of 
atherosclerosis disease and is maybe related to macrophage polarisation. It 
must also be noted that the changes in mRNA level expression may be a 














Figure 3.11 – CD200R1, CD2000 and CD206 gene expression in ApoE-/- mice 
are reduced in the spleen at late stages during experimental atherosclerosis 
disease. 
ApoE-/- or WT mice were fed a chow diet for 8, 12 or 35 weeks. Tissues from the 
spleen, aorta, and lymph nodes (LN) were collected on time of sacrifice and snap-
frozen in liquid nitrogen. Tissues were grinded with mechanical shear, RNA was 
extracted and cDNA synthesized. Samples of cDNA were run on a Corbett qPCR 
machine with Taqman primers. CD200R1 gene expression was reduced in the 
spleen (p<0.05). The trend is followed by the M2 marker CD206 (p<0.05) Unpaired 
t-test, (n=3); p<0.05=*, p<0.01=**, p<0.001=***. Data for CD200R1 and CD200 
mRNA is representative of two independent experiments. Data for CD206 mRNA is 















 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
Figure 3.12 – WT vs. ApoE-/- mice and the gene expression of iNOS and IFN-γ. 
ApoE-/- or WT mice were fed a chow diet for 8, 12 or 35 weeks. Tissues from the 
aorta, and lymph nodes (LN) were collected on time of sacrifice and snap-frozen in 
liquid nitrogen. Tissues were grinded by mechanical shear, RNA extracted and 
cDNA synthesized. The cDNA samples were run on a Corbett qPCR machine with 
Taqman primers. The IFN-γ gene expression increased at 8 weeks whilst iNOS 
remained unchanged in aortas. Simultaneously, IFN-γ increased in lymph nodes 
and appeared to increase during disease and iNOS displayed a trend of increase 
after 12 weeks of disease in lymph nodes. In the spleen, iNOS increased early but 
was reduced in late disease in ApoE-/- mice. Unpaired t-test (n=3), p<0.05=*, 
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3.6 Discussion 	  
In this chapter I showed that both LSS and OSS induce CD200R expression 
in atherosclerotic lesions. I further established that CD200R expression 
levels are reduced during atherosclerosis disease. The finding is in 
accordance with other studies in the literature demonstrating that during 
chronic inflammation, the CD200R pathway is downregulated. This chapter 
shows for the first time that this occurs in atherosclerosis.  
The expression of macrophage marker CD68 has previously been used to 
quantify murine macrophages in tissues (Scholtes, Johnson et al. 2012;	   da 
Silva and Gordon 1999). Abundance of CD68 expression correlated with 
previous studies (Cheng, Tempel et al. 2006), where macrophage content 
was unchanged between LSS and OSS regions, with average expression 
ranging around 25-30% (Figure 3.6). Content of CD200R expression in the 
carotid arteries was lower than for CD68 expression, with the expression 
ranging 12-18% (Figure 3.9). Based on these findings, it appears that not all 
macrophages in the plaque expressed CD200R. This finding was suggestive 
that CD200R is heterogeneously expressed, with low levels in 
atherosclerosis. The reduced expression of CD200R observed was 
characteristic of other chronic inflammatory diseases, such as Alzheimer’s 
disease (Walker, Dalsing-Hernandez et al. 2009). Findings reported by 
Mukhopadhyay et al. also showed that the receptor is decreased upon 
exposure to pro-inflammatory signals (Mukhopadhyay, Pluddemann et al. 
2010).  
Recent developments in imaging have enabled the study of regions in the 
vasculature containing plaque components (Segers, Helderman et al. 2007). 
In-house developed software packages enabled the plotting of 
immunochemical antigens present in the distinct plaque regions. Shown in 
Figure 3.10 are the closed and open 3-D conformations of CD68 and 
CD200R revealing the abundance of CD68+ macrophages and 
correspondingly low expression of CD200R. The advantage of this technique 
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is that it allows for a visual display of parallel sections of the atherosclerotic 
plaque, complementing 2-D histology. However, vascular 3-D histology only 
enabled examination of expression in plaques. With atherosclerosis being a 
systemic disease (Lahoz and Mostaza 2007) (Heras and Chamorro 2000) it 
was natural to study the expression of CD200R and related markers in other 
tissues, including lymphoid tissue.  
Gene transcript studies comparing WT to ApoE-/- animals revealed significant 
changes in CD200R1 expression in the spleens occurring during vascular 
ageing as well as atherogenesis, while no significant changes in CD200R1 
mRNA were observed in the aorta and lymph nodes (Figure 3.11). My data 
suggests that CD200R1 might be an endogenous modulator of vascular 
disease during ageing. The decrease in CD200R1 was associated with a 
decrease of macrophage polarisation markers CD206 and iNOS in the 
spleens, leaving uncertain whether its levels can be modulated solely by 
macrophage polarisation patterns. In Chapter 4, I will investigate the in vitro 
stimuli that modulate CD200R1 expression on macrophages.  
In summary, this Chapter demonstrates the first in vivo evidence CD200R 
expression during atherosclerosis and shows that shear stress modulated 
plaques were developed after 6 weeks. Macrophages localised to both LSS 
lesions and OSS lesions and	   CD200R expression was low, both in shear 
stress modulated plaques and secondary lymphoid organs, as shown by IHC, 
3-D histology and mRNA transcript levels during disease progression. 
In conclusion, the lowered expression of the inhibitory CD200R during 
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4.1 Introduction 	  
Macrophages play a critical role in host defence and inflammation. These 
phagocytic cells polarise towards either M1 (classically activated) or M2 
subsets (alternatively activated) with distinct physiological functions in the 
organism (Mantovani, Sozzani et al. 2002). Classical M1 macrophages 
express high levels of iNOS and form part of the Th1 response; they are 
involved in tissue destruction, and production of reactive oxygen species 
(ROS) that can be highly toxic for microorganisms and neighbouring tissue 
(Lusis 2000; Nathan and Ding 2010; Sica and Mantovani 2012).  
M2 macrophages express CD206 and are involved in Th2 responses; 
including immune regulation, angiogenesis and tissue remodelling. Additionally, 
M2 macrophages up-regulate scavenger receptors such as CD36, involved in 
the detection of oxidised lipoproteins (Lusis 2000; Sica and Mantovani 2012).  
A key feature of immune resolution is the ability of an inflammatory immune 
response to retract after clearing a pathogen or other foreign organism, 
allowing the tissue/organism to return to homeostasis. During atherosclerosis, 
inflammation is chronic and can persist an entire lifetime (Ross 1999). A key 
feature of inflammatory disease chronicity is failure to resolve inflammation. In 
cardiovascular comorbidities, such as type II diabetes and the metabolic 
syndrome, the chronic inflammation persists (Akash, Rehman et al. 2013; 
Cruz, Sousa et al. 2013). Similarly, up-regulation of inflammatory cytokines, 
such as TNF-α has been found in certain autoimmune diseases (Kodama, 
Davis et al. 2005). During chronic inflammation, the immune system fails to 
induce catabasis, a feature characterised by production of wound-healing and 
anti-inflammatory soluble factors, including TGF-β (Grainger, Kemp et al. 
1994; Singh and Ramji 2006), IL-10 (Ogawa, Duru et al. 2008) and resolvins 
(Marcheselli, Hong et al. 2003; Bannenberg, Chiang et al. 2005). Recent work 
has demonstrated that CD200R is expressed on alternatively activated M2 
macrophages (Koning, van Eijk et al. 2010). On the other end of the spectrum, 
macrophage polarisation towards M1 via TLR4 stimulation resulted in the 
reduction of CD200R expression (Mukhopadhyay, Pluddemann et al. 2010). 
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However a comprehensive study on the effect of macrophage polarisation and 
activation of CD200R levels has not been carried out. Understanding the 
signals affecting macrophage regulation and inflammation in the context of the 
regulatory CD200R pathway could help explain the heterogeneity of its 
expression during atherosclerosis disease (Chapter 3). Thus, I investigated 
the effect of pro-inflammatory (M1), anti-inflammatory (M2) signals as well as 
pro-atherogenic stimuli (oxLDL) and pattern recognition receptor activation 
pathways on CD200R expression in vitro.  
 
In view of the recent literature I hypothesised that CD200R is reduced by pro-
inflammatory signals other than LPS, such as IFN-γ. To test the hypothesis, I 
used bone marrow-derived macrophages (BMDM). Cells underwent 
maturation with MCSF for 7 days and subsequent polarisation for 2, 6 and 18 
hours with cytokines or oxLDL according to established protocols (Manzanero 
2012). The optimal concentrations of IFN-γ, LPS, IL-4 and IL-13 were 
established based on previous studies (Ip, Wong et al. 2006; Zhang, Kim et al. 
2010) and validated in-house. The expression levels of typical markers of 
polarisation, cytokine production and CD200R1 were assessed. 
 
 
4.2 Polarisation signals modulate CD200R1 expression 
 
Pro-inflammatory signals in the macrophage environment can dictate a tissue 
destructive response such as the production of reactive oxygen species (ROS) 
and nitric oxide (NO) (Murray and Wynn 2011). The synthesis of NO comes 
from the catalytic reaction mediated by the enzyme inducible nitric oxide 
synthase (iNOS) using L-arginine as a substrate. M1 polarisation has been 
reported to generate high levels of iNOS (Gordon 2003). M2 macrophages 
express higher levels of the C-type lectin mannose receptor CD206 than their 
baseline counterparts, defining CD206 as an M2 marker (Gordon 2003). 
Concomitantly, CD206 was found down regulated by IFN-γ at the transcription 
level in murine macrophages (Harris, Super et al. 1992). Kadl et al studied the 
activation of macrophage genes in atherosclerosis in association with oxidised 
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phospholipids, namely the oxidised phospholipid1-palmitoyl-2-arachidonoyl-
sn-3-phosphorylcholine (oxPAPC), which up-regulated the expression of 
heme-oxygenase 1 (HO-1) and nuclear factor erythroid-derived 2-like 2 
(NRF2) genes, and down-regulated M1 and M2-related genes (Kadl, Meher et 
al. 2010). This macrophage was coined the Mox subset (Kadl, Meher et al. 
2010). The M4 macrophage is another emerging subset and stems from 
transcriptomics data in the laboratory of Klaus Ley at La Jolla Institute for 
Allergy and Immunology where this novel macrophage subset was found to 
transcribe high levels of the chemokine CXCL4 (Gleissner, Shaked et al. 2010).  
Thus, I assessed iNOS, TNF-α and IL-12p35 (M1), CD206 (M2) and HO-1 
(Mox) in matured and polarised BMDM. As expected, the M1 marker iNOS 
was increased after polarisation with IFN-γ or IFN-γ and LPS together  
(Figure 4.1). The levels of iNOS were increased from baseline untreated with 
a fold change of 3108 ± 376 when treating the cells with IFN-γ alone (p<0.001) 
or 54,319 ± 16,534 when treating together with LPS (p<0.001; Figure 4.1). 
Accordingly, TNF-α was significantly increased after M1 polarisation  
(Figure 4.2). IFN-γ treatment induced a significant up-regulation of TNF-α 
mRNA transcript of 23.86± 2.82 when treated individually (p<0.001) or 
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Figure 4.1 – Macrophage polarisation with M1 signals induces iNOS expression. 
Levels of iNOS mRNA transcripts after 6 hours stimulation with IFN-γ (100ng/ml) or IFN-γ 
together with LPS (100 ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. 
Progenitor cells were used after 7 days of maturation with MCSF (100ng/ml) at a density of 
10^6 cells/ml. After stimulation, total RNA was extracted, cDNA was synthesised and mRNA 
transcript measured with Real-Time PCR (triplicates). Data are expressed as means ±	  SEM. 
N=3; ANOVA with Dunnett’s post-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data 
is representative of three independent experiments. 
 
Figure 4.2 – Macrophage polarisation with M1 signals induces TNF-α expression. 
Levels of TNF-α mRNA transcripts after 6 hours stimulation with IFN-γ (100ng/ml) or IFN-γ 
together with LPS (100 ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. 
Progenitor cells were used after 7 days of maturation with MCSF (100ng/ml) at a density of 
10^6 cells/ml. After stimulation, total RNA was extracted, cDNA was synthesised and mRNA 
transcript measured with Real-Time PCR (triplicates). Data are expressed as means ±	  SEM. 
N=3; ANOVA with Dunnett’s post-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data 
is representative of three independent experiments. 
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Furthermore, IL-12p35, a cytokine mainly produced by antigen presenting cells 
that can dictate pro-inflammatory Th1 polarisation (Murphy, Travers et al. 
2012) was induced following exposure to M1 polarisation cytokines together 
with LPS (Figure 4.3). When treating macrophages with IFN-γ there was no 
increase from baseline (p=ns), however, interestingly upon adding IFN-γ 
together with LPS, a strong increase from baseline was found (p<0.001). As 
expected, the addition of LPS induced an overall stronger M1 polarisation than 
IFN-γ by itself (Figure 4.1, Figure 4.2, Figure 4.3).  
HO-1 is a ubiquitously expressed enzyme that catalyses the degradation of 
heme, leading to the production of iron, biliverdin and carbon monoxide 
(Kikuchi, Yoshida et al. 2005). HO-1 is activated upon the response to stress 
signals, such as hypoxia, certain cytokines and heavy metals (Motterlini, 
Foresti et al. 2000). The interest in HO-1 came because of the novel 
association of HO-1 expression in macrophages upon exposure to oxidised 
phospholipids usually contained within oxLDL (Kadl, Meher et al. 2010).  
M1 macrophage polarisation resulted in a reduction in HO-1 expression 
(Figure 4.4). The reduction from baseline suggests that M1 polarisation 
reduces HO-1 expression after IFN-γ treatment (p<0.01) or upon treatment 
with IFN-γ together with LPS (p<0.001), as seen in Figure 4.4. The further 
reduction of HO-1 observed when polarising with IFN-γ together with LPS 
(Figure 4.4) mirrors the same pattern of additive effect when treating together 
with LPS as happens with increased pro-inflammatory gene expression of 
iNOS (Figure 4.1), TNF-α  (Figure 4.2) and IL-12p35 (Figure 4.3).  
M2 polarisation generated by treating macrophages with IL-4 together with IL-
13 also resulted in decreased expression of HO-1 (Figure 4.5), similar to M1 
polarisation (Figure 4.4).  
As previously published by Kadl et al, stimulation of macrophages with oxLDL 
induced an increased fold change of HO-1 (p<0.05; Figure 4.6), confirming 
previous studies that the expression of HO-1 might define a distinct 
macrophage programming pattern of macrophages in atherosclerosis.  
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Figure 4.3 – Macrophage polarisation with M1 signals induces IL-12p35 expression. 
Levels of IL-12p35 mRNA transcripts after 6 hours stimulation with IFN-γ (100ng/ml) or IFN-γ 
together with LPS (100 ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. 
Progenitor cells were used after 7 days of maturation with MCSF (100ng/ml) at a density of 
10^6 cells/ml. After stimulation, total RNA was extracted, cDNA was synthesised and mRNA 
transcript measured with Real-Time PCR (triplicates). Data are expressed as means ± SEM. 
N=3; ANOVA with Dunnett’s post-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data 
is representative of three independent experiments. 
Figure 4.4 – Macrophage polarisastion with M1 signals reduces HO-1 expression. 
Levels of HO-1 mRNA transcripts after 6 hours stimulation with IFN-γ (100ng/ml) or IFN-γ 
together with LPS (100ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. 
Progenitor cells were used after 7 days of maturation with MCSF (100 ng/ml) at a density of 
10^6 cells/ml. After stimulation, total RNA was extracted, cDNA was synthesised and mRNA 
transcript measured with Real-Time PCR (triplicates). Data are expressed as means ± SEM. 
N=3; ANOVA with Dunnett’s post-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data 
is representative of three independent experiments.  
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Figure 4.5 – Macrophage polarisation with M2 signals reduces HO-1 expression. 
Levels of HO-1 mRNA transcripts after 6 hours stimulation with IL-4 (50 ng/ml) together with 
IL-13 (50 ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. Progenitor cells 
were used after 7 days of maturation with MCSF (100 ng/ml) at a density of 10^6 cells/ml. 
After stimulation, total RNA was extracted, cDNA was synthesised and mRNA transcript 
measured with Real-Time PCR (triplicates). Data are expressed as means ± SEM. N=3; 
Unpaired t-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data is representative of 












Figure 4.6 – Macrophage polarisation with Mox signals induces HO-1 expression. 
Levels of HO-1 mRNA transcripts after 6 hours stimulation with oxLDL (100 μg/ml). Bone 
marrow was isolated from WT C57BL/6 male mice. Progenitor cells were used after 7 days of 
maturation with MCSF (100 ng/ml) at a density of 10^6 cells/ml. After stimulation, total RNA 
was extracted, cDNA was synthesised and mRNA transcript measured with Real-Time PCR 
(triplicates). Data are expressed as means ±SEM. N=3; Unpaired t-test on dCT values, p<0.05 
=*, p<0.01=**, p<0.001=***. Data is representative of three independent experiments.  
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4.2.1 The expression of CD200R1 is strongly reduced during M1 
polarisation 
 
It was previously shown that CD206 gene expression became reduced with 
IFN-γ treatment (Harris, Super et al. 1992). Therefore, it was natural to verify 
whether using the current polarisation protocol had resulted in a similar 
reduction. When treating macrophages with IFN-γ together with LPS, the 
mRNA for CD206 was significantly reduced (p<0.01; Figure 4.7). This 
suggested that polarisation towards M1 had worked and reduced the M2 gene-
level expression.  
After verifying that I had the right experimental conditions, I set out to study the 
expression of CD200R1 upon macrophage polarisation. Upon M1 polarisation, 
CD200R1 expression was significantly reduced (p<0.01; Figure 4.8). In 
particular, IFN-γ by itself reduced CD200R1 after 6 hours polarisation  
(Figure 4.9) at the lower dose of 25 ng/ml (p<0.001), as well as higher dose of 
100 ng/ml (p<0.001) and remained reduced after 18 hours (p<0.001). Two 
hours stimulation with 25 or 100 ng/ml IFN-γ was not enough time to observe 
a reduction in CD200R1 expression from untreated baseline control (p=ns). 
Stimulation with LPS induced a reduction in CD200R1 gene expression as 
early as 2 hours at 25 ng/ml (p<0.05) and higher dose of 100 ng/ml (p<0.01). 
The CD200R1 reduction induced by LPS was sustained at 6 hours with 25 
ng/ml (p<0.001) and 100 ng/ml (p<0.01). The reduction continued at 18 hours 
with LPS at 25 ng/ml (p<0.05) and 100 ng/ml (p<0.05). Combined stimulation 
of IFN-γ with LPS reduced CD200R1 expression after 6 hours (p<0.001) and 
18 hours (p<0.001) but not after 2 hours (p=ns) (Figure 4.9).  
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Figure 4.7 – Macrophage polarisation with M1 signals reduces CD206 expression. 
Levels of CD206 mRNA transcripts after 6 hours stimulation with IFN (100 ng/ml) and LPS 
(100 ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. Progenitor cells were 
matured with MCSF (100 ng/ml) for 7 days at a density of 10^6 cells/ml. After stimulation, total 
RNA was extracted, cDNA was synthesised and mRNA transcript measured with Real-Time 
PCR (in triplicates). Data are expressed as means ± SEM. N=3; Unpaired t-test on dCT values, 
p<0.05 =*, p<0.01=**, p<0.001=***. Data is representative of three independent experiments. 
Figure 4.8 – Macrophage polarisation with M1 signals reduces CD200R1 expression. 
Levels of CD200R1 mRNA transcripts after 6 hours stimulation with IFN-γ together with LPS 
(100ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. Progenitor cells were 
used after 7 days of maturation with MCSF (100 ng/ml) at a density of 10^6 cells/ml. After 
stimulation, total RNA was extracted, cDNA was synthesised and mRNA transcript measured 
with Real-Time PCR (triplicates). Data are expressed as means ± SEM. N=3; Unpaired t-test 




















































Figure 4.9 – CD200R1 reduction by M1 polarisation is time-dependent and can be 
mediated by IFN-γ alone. 
Levels of CD200R1 mRNA transcripts after 2, 6 and 18 hours stimulation with IFN-γ or LPS 
(25 or 100 ng/ml) by themselves or together (100 ng/ml each). Bone marrow was isolated from 
WT C57BL/6 male mice. Progenitor cells were used after 7 days of maturation with MCSF 
(100 ng/ml) at a density of 10^6 cells/ml. After stimulation, total RNA was extracted, cDNA 
was synthesised and mRNA transcript measured with Real-Time PCR (triplicates). Data are 
normalised to untreated control (fold change=1) and expressed as means ± SEM. N=3; 
ANOVA with Dunnett’s post-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data is 










































































































Chapter 4   Results II 
 110 
4.2.2 CD200R1 is increased during M2 polarisation 	  
The M2 marker CD206 was significantly increased after M2 polarisation 
(p<0.001; Figure 4.10) suggesting that my M2 polarisation had worked in 
accordance with previous findings (Porcheray, Viaud et al. 2005; Harris, Super 
et al. 1992).  
In accordance, CD200R1 was significantly increased (P<0.01; Figure 4.11), 
suggesting that CD200R1 followed the expression pattern of CD206  
(Figure 4.10). IL-4 and IL-13 bind to the same receptor IL4R, leading to the 
alternative activation of macrophages (Van Dyken and Locksley 2013). To 
dissect if the contribution of CD200R1 increase was derived from IL-4 or IL-13 
stimulation, the two cytokines were separated and macrophages were 
stimulated with either IL-4 or IL-13 individually (Figure 4.12). IL-4 contribution 
to the expression of CD200R1 alone (p<0.05) was stronger than IL-13 alone 







Chapter 4   Results II 
 111 
 
Figure 4.10 – Macrophage polarisation with M2 signals induces CD206 expression. 
Levels of CD206 mRNA transcripts after 6 hours stimulation with IL-4 (50 ng/ml) together with 
IL-13 (50 ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. Progenitor cells 
were used after 7 days of maturation with MCSF (100 ng/ml) at a density of 10^6 cells/ml. 
After stimulation, total RNA was extracted, cDNA was synthesised and mRNA transcript 
measured with Real-Time PCR (triplicates). Data are expressed as means ± SEM. N=3; 
Unpaired t-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data is representative of 









Figure 4.11 – Macrophage polarisation with M2 signals induces CD200R1 expression. 
Levels of CD200R1 mRNA transcripts after 6 hours stimulation with IFN-γ together with LPS 
(100ng/ml). Bone marrow was isolated from WT C57BL/6 male mice. Progenitor cells were 
used after 7 days of maturation with MCSF (100 ng/ml) at a density of 10^6 cells/ml. After 
stimulation, total RNA was extracted, cDNA was synthesised and mRNA transcript measured 
with Real-Time PCR (triplicates). Data are expressed as means ± SEM. N=3; Unpaired t-test 
on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data is representative of three 
independent experiments.  
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Figure 4.12 – Macrophage polarisation with IL-4 was the strongest inducer of CD200R1 
expression after 6 hours. 
Levels of CD200R1 mRNA transcripts after 2, 6 and 18 hours stimulation with IL-4 (50 ng/ml), 
IL-13 (50 ng/ml) individually or together (50 ng/ml each). Bone marrow was isolated from WT 
C57BL/6 male mice. Progenitor cells were used after 7 days of maturation with MCSF (100 
ng/ml) at a density of 10^6 cells/ml. After stimulation, total RNA was extracted, cDNA was 
synthesised and mRNA transcript measured with Real-Time PCR (triplicates). Data are 
normalised to untreated control (fold change=1) and expressed as means ± SEM. N=3; 
ANOVA with Dunnett’s post-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. Data is 
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4.2.3 Treating macrophages with oxLDL did not affect CD200R gene 
expression 
Finally, oxLDL was studied on the grounds of its role in plaque initiation and 
growth in atherosclerosis (Stocker and Keaney 2004). No previous studies had 
assessed the effect of oxLDL on CD200R expression. The oxLDL was 
incubated with BMDM for 2, 6 and 18 hours at three dosages (10 μg/ml, 40 
μg/ml and 100 μg/ml). Stimulation of macrophages with oxLDL did not appear 
to induce any significant changes after either 2,6 or 18 hours stimulation with 
10 μg/ml, 40 μg/ml or 100 μg/ml (Figure 4.13; p=ns). This suggested that if 
there is heterogeneity of CD200R expression in atherosclerotic plaques it 
might not be derived from exposure to oxLDL. 
 
 
Figure 4.13 – Macrophage stimulation with oxLDL did not affect CD200R1 expression. 
Levels of CD200R1 mRNA transcripts after 2, 6 and 18 hours stimulation with oxLDL (10 
μg/ml, 40 μg/ml or 100 μg/ml). Bone marrow was isolated from WT C57BL/6 male mice. 
Progenitor cells were used after 7 days of maturation with MCSF (100 ng/ml) at a density of 
10^6 cells/ml. After stimulation, total RNA was extracted, cDNA was synthesised and mRNA 
transcript measured with Real-Time PCR (triplicates). Data are normalised to untreated control 
(fold change=1) and expressed as means ± SEM. N=3; ANOVA with Dunnett’s post-test on 
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4.2.4 Protein levels of CD200R were reduced upon M1 polarisation 
 
To confirm that the changes in gene expression of CD200R reflected in 
changes at the protein level, flow cytometry was employed to study BMDMs 
after treatment with polarisation signals. The 36 hours time-point was chosen 
based on initial pilot studies determining the minimum exposure time required 
for observing changes in CD200R protein expression (data not shown). In 
order to validate the in vitro system, I first verified activation of macrophages 
by studying the expression of MHC II and demonstrated that it was 
significantly increased on cells treated with IFN-γ alone (p<0.05) but not when 
treated with IFN-γ together with LPS (p=ns) (Figure 4.15). 
 
In this series of experiments (Figure 4.15) IFN-γ significantly reduced the 
number and percentage of BMDM expressing CD200R (p<0.05). The addition 
of LPS to IFN-γ did not achieve further reduction (p=ns). Importantly, no 
significant changes were seen in the expression of CD200R after stimulation 
with IL-4 and IL-13 or oxLDL, albeit a small increase in expression was 
observed. Furthermore, histogram analysis revealed that the increased 
activation of cells (MHCII+) stimulated with IFN-γ correlated with reduced 
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Figure 4.14 – CD200R protein levels after 36 hours polarization. 
Bone marrow-derived macrophages were matured from C57BL/6 WT male mice femurs and 
tibias using MCSF (100ng/ml) for 7 days. Cells were stimulated with IFN-γ alone (100 ng/ml) 
or IFN-γ together with LPS (100ng/ml), IL-4 with IL-13 (50 ng/ml each) or oxLDL (100 μg/ml). 
After 36 hours, cells were stained with anti-CD200R FITC monoclonal antibody for FACS 
reading. A live gate was drawn and FITC gates were set using an isotype control antibody.  
(A) Percentages (B) Cell numbers.  (C) Representative histograms of stimulated cells and 
isotype control. (D) Representative zebra plots. One-way ANOVA with Dunnett’s post-test 
(n=3-4); p<0.05=*; p<0.01=**; p<0.005=***; p<0.001=****; ns=non-significant. Data is 
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Figure 4.15 – IFN-γ significantly induced MHC II expression during polarisation. 
Bone marrow-derived macrophages were matured from C57BL/6 WT male mice femurs and 
tibias using MCSF (100ng/ml) for 7 days. Cells were stimulated with IFN-γ alone (100 ng/ml) 
or IFN-γ together with LPS (100ng/ml), IL-4 with IL-13 (50 ng/ml each) or oxLDL (100 μg/ml). 
After 36 hours, cells were stained with anti- I-A/I-E PerCP and CD11b PE monoclonal 
antibodies for FACS reading. Gates were set using isotype controls. (A) Representative zebra 
plots (B) Percentage cells. Statistics were performed with an ordinary ANOVA with Dunnett’s 
post-test (n=3-4); p<0.05=*; p<0.01=**; p<0.005=***; p<0.001=****. Data is representative of 
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4.2.5 IFN-γ inhibition correlated with the activation status of BMDMs 
 
Complementary to these findings, histogram analysis showed that the 
increased activation (MHCII+) of BMDMs stimulated with IFN-γ correlated with 
a reduced CD200R expression in total BMDMs (blue histogram, Figure 4.16B) 
as previously shown (Figure 4.14 and Figure 4.15). 
 
 
Figure 4.16 – MHC II expression was inversely associated with CD200R expression in 
IFN-γ polarised macrophages. 
Bone marrow-derived macrophages were matured from C57BL/6 WT male mice femurs and 
tibias using MCSF (100ng/ml) for 7 days. Cells were stimulated with IFN-γ alone (100 ng/ml) 
or IFN-γ together with LPS (100ng/ml), IL-4 with IL-13 (50 ng/ml each) or oxLDL (100 μg/ml).  
After 36 hours stimulation cells were stained with anti- I-A/I-E PerCP and CD11b PE 
monoclonal antibodies for FACS reading. A live gate was drawn and gates were set using 
isotype controls. (A) Representative zebra plots and (B) MHCII PerCP histograms (C) 
CD200R FITC histograms (n=4). Data is representative of four independent experiments.  
A B 
C 
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4.3 GMCSF maturation increased CD200R1 gene levels but 
not protein levels 
 
Macrophage polarisation with cytokines is one way to induce macrophage 
heterogeneity. Another step to induce macrophage heterogeneity is during the 
maturation phase with different growth factors. Growth factor maturation has 
been associated with macrophage phenotype (Lacey, Achuthan et al. 2012). 
Granulocyte Macrophage Colony Stimulating Factor (GMCSF) has previously 
been shown to induce a pro-inflammatory phenotype in macrophages 
(Krausgruber, Blazek et al. 2011). To assess if GMCSF maturation could alter 
CD200R1 expression, progenitor cells were harvested from WT C57BL/6 bone 
marrow and matured with either MCSF (100 ng/ml) or GMCSF (10 ng/ml) for 7 
days. Because of previous correlation between CD200R1 and CD206, I 
studied these two gene transcripts in the same system.  
Previous studies reported an increase in CD206 expression upon GMCSF 
maturation (Porcheray, Viaud et al. 2005). Interestingly, CD200R1 expression 
increased after maturing bone-marrow progenitor cells with GMCSF (p<0.05) 
compared to MCSF matured (Figure 4.17 B). The increase was consistent 
with the M2 marker CD206 (p<0.05; Figure 4.17 A).  
Although CD200R1 mRNA transcript was significantly up regulated (p<0.05 
Figure 4.17 B), no significant increase was observed in CD200R protein 
levels after GMCSF maturation compared to MCSF maturation  










Figure 4.17 – Macrophage maturation with GMCSF increases CD200R1 expression at 
the mRNA transcript level. 
Levels of (A) CD206 and (B) CD200R1 mRNA transcripts after 7 days maturation. Bone 
marrow was isolated from WT C57BL/6 male mice. Progenitor cells were matured with either 
MCSF (100 ng/ml) or GMCSF (10 ng/ml) at a density of 10^6 cells/ml. After stimulation, total 
RNA was extracted, cDNA was synthesised and mRNA transcript measured with Real-Time 
PCR (triplicates). Data are expressed as means ± SEM. (n=5); Unpaired t-test on dCT values, 



















































Figure 4.18 – Protein expression of C200R in macrophages matured with GMCSF was 
no higher than when maturing with MCSF. 
Bone marrow was isolated from C57BL/6 WT male mice. Cells were perfused from femurs and 
tibias, then lysed, counted and pooled. Progenitor cells were matured using MCSF (100ng/ml) 
or GMCSF (10ng/ml) at a density of 1x10^6 cells/ml on bacterial petri dishes for 7 days in full 
DMEM. At day 7, cells were detached, counted and seeded onto 6 well plates for 36 hours. 
Cells were detached and stained with monoclonal antibodies, washed and fixed and run on a 
BD LSR II flow cytometer. A live gate was drawn and FITC gates were set using an isotype 
control. Cells were counted and plotted using percentage positive cells. (A) Zebra plots of 
CD200R+ cells (B) Histogram displaying CD200R FITC+ stain MFI on cells after maturation 
with GMCSF, MCSF (and MCSF isotype staining) (C) Comparison of % CD200R+ cells with 
MCSF and GMCSF maturation. Unpaired t-test (n=4); p<0.05=*; p<0.01=**; p<0.005=***; 
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4.4 CD200R regulates pro-inflammatory signalling in macrophages 
 
Absence of CD200 signalling is associated with increased inflammation by 
iNOS and TNF-α production (Hoek, Ruuls et al. 2000;	  Gorczynski, Chen et al. 
2004). No previous findings had studied the HO-1 enzyme in the context of 
CD200R1. BMDMs from CD200R-/- or WT were matured for 7 days with MCSF 
and mRNA transcript examined with RT-PCR (Figure 4.19). During the 
absence of CD200R1 increased expression of TNF-α, iNOS and HO-1 was 
observed in MCSF matured BMDM, suggesting that the CD200R pathway 
regulated these genes.   
 
Figure 4.19 – CD200R regulates TNF-α, iNOS and HO-1 at baseline. 
Levels of mRNA transcripts after maturation. Bone marrow was isolated from CD200R+/+ (WT) 
and CD200R-/- (KO) C57BL/6 male mice. Progenitor cells were used after 7 days of maturation 
with MCSF (100 ng/ml) at a density of 10^6 cells/ml. After stimulation, total RNA was extracted, 
cDNA was synthesised and mRNA transcript of (A) IL-12p35, (B) IL-10, (C) CD206, (D) TNF-α, 
(E) iNOS and (F) HO-1was measured with Real-Time PCR (triplicates). Data are normalised to 
untreated control (fold change=1) and expressed as mean ± SEM. (n=3); Unpaired t-test on 































































































































Chapter 4   Results II 
 122 
4.5 TLR stimulation reduces CD200R1 expression via MyD88- 
dependent pattern recognition receptors 
 
TLRs have been widely described as pro-inflammatory and are crucial for 
clearing pathogens from the body by mounting an early innate-immune 
response (Akira and Takeda 2004). Stimulation of TLRs with synthetic or 
natural ligands induces a gene expression response specific for the stimulated 
pathway. For instance, stimulation of TLR3 and TLR4 activates IRF3 and IRF7 
(Doyle, Vaidya et al. 2002), whereas stimulation of TLR7 and TLR8 activate 
IRF5 and IRF7 (Schoenemeyer, Barnes et al. 2005).  
It is yet unknown whether CD200R1 expression is modulated through other 
TLR pathways already studied in atherosclerosis, such as TLR2/6, TLR3 and 
TLR7 (Monaco, Gregan et al. 2009) (Cole, Navin et al. 2011; Salagianni, 
Galani et al. 2012), and I set to explore it. First I assessed the effect of TLR 
ligand stimulation on inflammatory and macrophage polarisation genes:  
TNF-α, iNOS, IL-12p35, IL-10, HO-1, and CD206 whilst studying CD200R1 
expression.  
TLR2/6 stimulation increased the expression of TNF-α (p<0.001), iNOS 
(p<0.001), IL-12p35 (p<0.001), IL-10 (p<0.01) and HO-1 (p<0.01)  
while it decreased CD206 (p<0.05) and CD200R1 (p<0.01) (Figure 4.20B). 
Similarly, TLR7 stimulation induced an increased expression of TNF-α 
(p<0.001), iNOS (p<0.001), IL-12p35 (p<0.001), IL-10 (p<0.001), and HO-1 
(p<0.001) (Figure 4.20C). The expression of CD200R1 was significantly 
reduced (p<0.01), whereas the CD206 transcript exhibited no change from 
untreated baseline (p=ns) (Figure 4.20C). Stimulation of TLR3 with the 
agonist poly(I:C), induced an increased expression of TNF-α (p<0.001), iNOS 
(p<0.0001) and IL-10 (p<0.01) (Figure 4.20A). However, no increase was 
found in IL-12p35 (p=ns) or HO-1 expression (p=ns) and no decrease 
occurred for CD200R1 and CD206 (p=ns). In that respect, TLR3 stimulation 
differed from TLR2/6 and TLR7 gene expression.   






Figure 4.20 – TLR3, TLR2/6 and TLR7 gene expression after stimulation. 
Levels of mRNA transcripts after 6 hours stimulation with (A) POLY I: C (1 μg/ml), (B) FSL-1 
(100 ng/ml) and (C) R848 (1 μg/ml). Bone marrow was isolated from WT C57BL/6 male mice.  
Progenitor cells were used after 7 days of maturation with MCSF (100 ng/ml) at a density of 
10^6 cells/ml. After 6 hours stimulation, total RNA was extracted, cDNA was synthesised and 
mRNA transcript measured with Real-Time PCR (triplicates). Data are normalised to untreated 
control (fold change=1) and expressed as means ± SEM. (n=3); One-way ANOVA with 
Bonferroni’s multiple comparison post-test on dCT values, p<0.05 =*, p<0.01=**, p<0.001=***. 
Data is representative of three independent experiments. 
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Comparing the effect of CD200R1 expression of TLR3 stimulation with other 
TLRs revealed a pattern of reduced expression occurring only in MyD88-
dependent receptors, such as TLR2/6 (p<0.05), TLR4 (p<0.01) and TLR7 
(p<0.05) but not TLR3 (p=ns) (Figure 4.21). This lack of decrease of 




Figure 4.21 – CD200R1 transcript was decreased after TLR2/6, TLR4 and TLR7 
stimulation, but was not decreased upon TLR3 stimulation. 
Levels of mRNA transcripts after 6 hours stimulation with FSL-1 (100 ng/ml), poly(I:C) (1μg/ml), 
LPS (100ng/ml) and R848 (1 μg/ml). Bone marrow was isolated from WT C57BL/6 male mice. 
Progenitor cells were used after 7 days of maturation with MCSF (100 ng/ml) at a density of 
10^6 cells/ml. After stimulation, total RNA was extracted, cDNA was synthesised and mRNA 
transcript measured with Real-Time PCR (triplicates). Data are normalised to untreated control 
(fold change=1) and expressed as means ± SEM. (n=3); One-way ANOVA with Dunnett’s 
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4.6 Expression of CD200R on monocytes is heterogeneous 
  
When monocytes migrate to lesions they encounter micro-environmental cues 
and differentiate into macrophages, becoming tissue resident cells (Gordon 
and Taylor 2005). The expression of CD200R on monocytes was explored in 
vivo. I studied expression on peripheral blood, primary and secondary 
lymphoid organs, populations and sub-populations. I began with characterising 
the myeloid cell population, using the myeloid marker CD11b (MAC-1). The 
highest number of CD11b+ myeloid cells was observed in the bone marrow 
(Figure 4.22). 
Out of the CD11b+ myeloid cell population, 2-7% were positive for CD115 
(MCSF receptor). In the literature, CD11b+CD115+ cells have been described 
as monocytes in mice (Breslin, Strohacker et al. 2011). Most monocytes were 
found in the bone marrow, then spleen and blood (p<0.001; Figure 4.23). 
Bone marrow contained on average 7.23±0.42% CD11b+CD115+ cells. Spleen 
contained 1.42±0.21% and blood contained 4.39±0.52% CD11b+CD115+ cells. 
Average cell numbers in the bone marrow ranged 3,194,476 ± 243,349, in the 
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Figure 4.22 – CD11b+ myeloid cells are abundant in bone marrow followed by blood or 
spleen. 
WT C57BL/6 male mouse bone marrow and spleen tissues were isolated and lysed for FACS 
monoclonal antibody staining. Blood was layered on a density gradient and PBMCs were 
collected. Cells were counted and labelled. After fixation, cells were read in FACS buffer on a 
BD LSR II flow cytometer. Live gating was applied. (A) Gating for C11b vs. SSC on zebra plots, 
(B) Histogram displaying percentage of cells expressing CD11b and (C) Number of cells 
expressing CD11b in blood, bone marrow and spleen. One-way ANOVA with Bonferroni’s 
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Figure 4.23 – CD11b+CD115+ myeloid cells are abundant in bone marrow followed by 
blood or spleen. 
WT C57BL/6 male mouse bone marrow and spleen tissues were isolated and lysed for FACS 
monoclonal antibody staining. Blood was layered on a density gradient and PBMCs were 
collected. Cells were counted and labelled. After fixation, cells were read in FACS buffer on a 
BD LSR II flow cytometer. Live gating was applied. (A) Gating for C11b vs. CD115 on zebra 
plots, (B) Histogram displaying percentage of cells co-expressing CD11b and CD115, and (C) 
Number of cells co-expressing CD11b and CD115 in blood, bone marrow and spleen.  Data 
are presented as mean ± SEM. One-way ANOVA with Bonferroni’s post-test, (n=5); p<0.05 = 
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Expression of total CD200R was then assessed on live-gated cells. In 
absolute numbers, bone marrow and spleens contained an equal abundance 
of CD200R+ cells. Bone marrow CD200R+ cells averaged 657,712 ± 103,818. 
In spleen they averaged 679,352 ± 123,044 and in blood 150,897 ± 42,732, 
significantly reduced from bone marrow and spleen  (p<0.01). Percentage 
average values ranged from 1.45 ± 0.09 % in bone marrow, 1.66 ± 0.26 in 
spleen and 2.18 ± 0.48 in blood per mouse (Figure 4.24). 
 
A higher portion of CD11b+CD115+ cells were positive for CD200R, in 
comparison to the total cells. Between 5% and 20% of monocytes expressed 
CD200R (Figure 4.25). On average, CD200R expression on monocytes 
ranged in percentages from 3.11 ± 0.28% in bone marrow, 19.48 ± 5.1% in 
spleen to 23.53 ± 6.27% in blood (Figure 4.25). Average absolute numbers 
ranged from 101,349 ± 17,307 in bone marrow, 88,318 ± 33,329 in blood to 
31,382 ± 9430 in spleen, which contained a significantly lower number of 
CD11b+CD115+CD200R+ cells than bone marrow (Figure 4.25). 
 
Monocytes can be subcategorised into two main subsets and an intermediary 
subset (Gordon and Taylor 2005). Labelling of CD200R on blood monocyte 
subsets revealed that Ly6Chi subsets expressed an average CD200R+ 
geometric MFI of 824 ± 141. Ly6Cint subsets expressed on average 2888 ± 
882, whereas Ly6Clow subsets expressed on average 505 ± 62.1 levels of 
CD200R geometric MFI (Figure 4.26). Ly6Cint subset expression of CD200R 
was significantly higher compared with Ly6Chi and Ly6Clow subsets in the 
blood (Figure 4.26; p<0.001). 	  





Figure 4.24 – Total CD200R abundance is lowest in blood. 
WT C57BL/6 male mouse bone marrow and spleen tissues were isolated and lysed for FACS 
monoclonal antibody staining. Blood was layered on a density gradient and PBMCs were 
collected. Cells were counted and labelled. After fixation, cells were read in FACS buffer on a 
BD LSR II flow cytometer. Live gating was applied. (A) Gating for CD200R vs. SSC on zebra 
plots, (B) Histogram displaying percentage of cells expressing CD200R, and (C) Number of 
cells expressing CD200R in blood, bone marrow and spleen. Data are presented as mean ± 
SEM. One-way ANOVA with Bonferroni’s post-test, (n=5); p<0.05 = *; p<0.01=**; p<0.001=***. 
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Figure 4.25  – Monocytes in spleen express less CD200R than monocytes in blood or 
bone marrow. 
WT C57BL/6 male mouse bone marrow and spleen tissues were isolated and lysed for FACS 
monoclonal antibody staining. Blood was layered on a density gradient and PBMCs were 
collected. Cells were counted and labelled. After fixation, cells were read in FACS buffer on a 
BD LSR II flow cytometer. (A) Live cell gating and CD11b+CD115+CD200R+ subset gating 
was applied. (B) Percentage CD11b+CD115+CD200R+ cells, and (C) Number of 
CD11b+CD115+CD200R+ cells in blood, bone marrow and spleen. Data are presented as 
mean ± SEM. One-way ANOVA with Bonferroni’s post-test, (n=5); p<0.05 =*; p<0.01=**; 










Figure 4.26 – CD200R expression is higher in Ly6Cint blood monocytes.  
WT C57BL/6 male mouse blood was layered on a density gradient and PBMCs were collected. 
Cells were counted and antibody labelled. After fixation, cells were read in FACS buffer on a 
BD LSR II flow cytometer. (A) Live and subset gating was applied. (B) Representative 
histograms displaying CD200R+ MFI. (C) Geometric MFI expression of CD200R on 
CD11b+CD115+ monocyte subsets expressing different levels Ly6C: Ly6Chi, Ly6Cint and 
Ly6Clow. Data are presented as mean ± SEM. One-way ANOVA with Bonferroni’s post-test, 
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Monocyte heterogeneity could vary from the blood to secondary lymphoid 
organs and therefore subsets were studied for CD200R expression in the 
spleen. Average CD200R geometric MFI expression in Ly6Chi monocyte 
subsets ranged 1609 ± 395. Ly6Cint subset expression of CD200R ranged 
2193 ± 558; Ly6Clow expression of CD200R ranged 1625 ± 304 (Figure 4.27).  
No statistical changes were found amongst subsets in the spleen (p=ns). 
Bone marrow monocytes subsets were mainly positive for Ly6Chi and Ly6Cint 
expression (Figure 4.28A). A very small percentage of Ly6Clow monocytes 
were found in bone marrow compared to other subsets (Figure 4.28A). Thus, 
differences amongst subset abundance in bone marrow were more 
pronounced than in other tissues. Previous reports found that bone marrow 
mainly harbours Ly6Chi monocyte subsets that can be recruited to sites of 
injury (Lin, Castano et al. 2009). Expression of CD200R geometric MFI was 
highest in Ly6Clow monocyte subsets with 1051±43, followed by Ly6Cint, 
719±29 CD200R geometric MFI expression (p<0.001) and last by Ly6Clow 
subsets with 579±21.8 CD200R geometric MFI expression (further reduced 
from Ly6Cint; p<0.05) (Figure 4.28C). 	  





Figure 4.27  – Spleen monocyte subsets express CD200R at similar levels. 
WT C57BL/6 male mouse spleen tissues were isolated and lysed for FACS monoclonal 
antibody staining. Cells were counted and antibody labelled. After fixation, cells were read in 
FACS buffer on a BD LSR II flow cytometer. (A) Live and subset gating was applied. (B) 
Representative histograms displaying CD200R+ MFI. (C) Geometric MFI expression of 
CD200R on CD11b+CD115+ monocyte subsets expressing different levels Ly6C: Ly6Chi, 
Ly6Cint and Ly6Clow. Data are presented as mean ± SEM. One-way ANOVA with Bonferroni’s 
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Figure 4.28 –Bone marrow Ly6Clow monocytes express highest CD200R levels. 
 
WT C57BL/6 male mouse spleen tissues were isolated and lysed for FACS monoclonal 
antibody staining. Cells were counted and antibody labelled. After fixation, cells were read in 
FACS buffer on a BD LSR II flow cytometer. (A) Live and subset gating was applied. (B) 
Representative histograms displaying CD200R+ MFI. (C) Geometric MFI expression of 
CD200R on CD11b+CD115+ monocyte subsets expressing different levels Ly6C: Ly6Chi, 
Ly6Cint and Ly6Clow. Data are presented as mean ± SEM. One-way ANOVA with Bonferroni’s 
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In the interest to understand the effect of CD200R deficiency on Ly6C expression, 
total PBMCs were stained for the subset marker Ly6C. In view of the finding 
demonstrating higher MFI expression of CD200R on Ly6Cint in blood and Ly6Clow cells 
in bone marrow (Figure 4.26 and 4.28), the total percentage expression of Ly6C in 
CD200R-/- cells revealed an interesting pattern. The total percentage Ly6Chi 
expression was decreased in CD200R-/- cells and the total Ly6Clow expression was 
increased in the CD200R-/- cells compared to CD200R+/+ cells (Figure 4.29).  
As the expression of the marker Ly6C also occurs on CD8+ T cells and Ly6G+ 



























Figure 4.29 - Deficiency in CD200R favours Ly6Clow and reduces Ly6Chi expression in 
total PBMC. 
WT C57BL/6 male mouse PBMCs were isolated using histopaque density gradient separation. 
Cells were used for FACS monoclonal antibody staining. Cells were counted and antibody 
labelled. After fixation, cells were read in FACS buffer on a BD LSR II flow cytometer. (A) Total 
Ly6Chi % expression in CD200R+/+ and CD200R-/- PBMCs. (B) Total Ly6Chi expression 
calculated to cell numbers. (C) Total Ly6Clow expression in CD200R+/+ and CD200R-/- PBMCs. 
(D) Total Ly6Chi expression calculated to cell numbers. Data are presented as mean ± SEM. 
Unpaired t-test (N=4); p<0.05 =*; p<0.01=**; p<0.001=***. Data is representative of one single 
experiment. 
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4.7 Discussion 	  
In this chapter I studied the expression of CD200R on macrophage and 
monocyte subsets. I have shown that IFN-γ is a potent down-regulator of 
CD200R1 expression (Figure 4.8; Figure 4.9). IL-4 slightly increased 
CD200R1 gene expression (Figure 4.11; Figure 4.12), while IL-13 did not 
induce any significant increase at 6 hours (Figure 4.12). GMCSF also 
increased its gene expression (Figure 4.17) but failed to increase protein 
expression (Figure 4.18). No changes in CD200R expression were 
demonstrated upon incubation with oxLDL (Figure 4.13; Figure 4.14) 
suggesting that proper inflammatory rather than atherogenic stimuli are likely 
to regulate the expression of CD200R. TLR stimulation had a differential effect 
on CD200R1 expression depending on MyD88 signalling (Figure 4.20; Figure 
4.21). Finally I showed that CD200R is particularly enriched in Ly6Cint 
monocytes in the blood (Figure 4.23). 
When I started my studies, knowledge was limited with respect to the effect of 
polarising stimuli on CD200 and CD200R expression. During my PhD research, 
a few studies emerged that pointed in this direction. (Lyons, McQuillan et al. 
2009). Genetic deletion of IL-4 in mice removed CD200 expression. Thus, in 
their observations, Lyons et al. conclude that IL-4 induces CD200 expression 
and propose that IL-4 induces regulation of microglial activation via CD200 
(Lyons, Downer et al. 2007); (Lyons, McQuillan et al. 2009). A later study 
showed that CD200R expression correlates with Th2/M2 activation (Koning, 
van Eijk et al. 2010). 
My results showed that, while IL-4 increases gene expression, it does not 
reflect an abundant increase in CD200R protein expression in murine BMDM. 
This is in contrast with previous studies where human macrophages 
(differentiated from PBMC for three days with IL-4, IL-13 or MCSF, compared 
to untreated) were used (Koning, van Eijk et al. 2010). An alternative 
explanation is the fact that the few antibodies available for CD200R do not 
discriminate well between CD200R1 and homologous proteins like CD200RLc 
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(Akkaya 2010; Akkaya, Aknin et al. 2013). More selective antibodies might be 
needed to verify whether there is an increase in CD200R1, the only true 
inhibitory receptor (Wright, Cherwinski et al. 2003; Gorczynski, Chen et al. 
2004). Although protein levels were not significantly affected, the up-regulation 
of CD200R1 at the mRNA-level by M2 macrophage polarisation (i.e. dosing of 
IL-4 together with IL-13) lead to the investigation around the individual efficacy 
of IL-4 separated from IL-13. I found that IL-4 was the strongest stimulator of 
CD200R1. A possible explanation for this finding could be ligand-receptor 
binding kinetics. Even though IL-13 binds the IL-4 receptor (Zurawski, 
Chomarat et al. 1995), it has a higher affinity to the IL-13 type II receptor (IL-
13Ra2) than the type I receptor (IL-13R dimerised with IL-4R) (Murata, Obiri et 
al. 1998). The IL-13 type II receptor could be slowing down the kinetics of  
IL-13 binding to the type I receptor, where it has a weaker affinity, not allowing 
it to signal via IL-4R. In contrast, the cytokine IL-4 can bind directly and signal 
through the common IL-4Ra/common γ chain receptor (Mannon and Reinisch 
2012). A second option could be that IL-13 encounters a soluble version of  
IL-13Ra2 present in the cell culture media, reported to be cleaved in murine 
cells and inhibits the binding to IL-4Ra/common γ chain receptor (Kasaian, 
Raible et al. 2011). 
The most novel finding of my work is the potent role of IFN-γ in the down-
regulation of CD200R expression. The expression of CD200R was significantly 
reduced by IFN-γ both at the mRNA level (after 6 hours) and protein levels 
(after 36 hours). This down-regulation correlated with increased activation of 
macrophages as shown by increased expression of MHC II protein. Thus, 
CD200R1 appears to be strongly regulated by this type II interferon. The 
function of IFN-γ is evident in atherosclerosis, as shown by experiments 
conducted on ApoE-/- mice, treated with exogenous IFN-γ, whereby treated 
mice exhibited accelerated lesion development (Gupta, Pablo et al. 1997). 
IFN-γ has also been detected in human atherosclerotic plaques (Frostegard, 
Ulfgren et al. 1999). In later years IFN-γ has been described as a master 
regulator of atherosclerosis (McLaren and Ramji 2009) reflecting the central 
function of this cytokine. More in vivo studies will be needed to elucidate if e.g. 
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ApoE-/-IFN-γR-/- mice display increased expression of CD200R in 
atherosclerosis.   
Another observation from this chapter was the increase of CD200R1 transcript 
in GMCSF matured macrophages compared to MCSF matured macrophages 
(Figure 4.17B). GMCSF has been associated with M1 macrophage 
transcription in human macrophages (Krausgruber, Blazek et al. 2011). 
However, GMCSF is reported to be unable to increase pro-inflammatory 
cytokine release such as TNF-α, and rather primed cells to increase TNF-α 
after stimulation with IFN-γ and LPS (Heidenreich, Gong et al. 1989). Together, 
the findings suggest that GMCSF/MCSF maturation is quite different than 
polarisation with cytokines, and it induces different transcription profiles 
(Fleetwood, Dinh et al. 2009).  
I also showed that CD200R1 transcript was significantly reduced after 
stimulation of TLR2/6, TLR4 and TLR7, but not after TLR3 binding  
(Figure 4.21). This finding was in accordance with a previous study by 
Mukhopadhyay et al. (Mukhopadhyay, Pluddemann et al. 2010), where the 
authors demonstrated that N. Meningitides mediated reduction of CD200R 
expression was MyD88-dependent. In this study, treatment of MyD88-/- 
macrophages exhibited no reduction in CD200R levels, whereas the reduction 
in WT macrophages was prominent using the same conditions. TLR3 is the 
only MyD88-independent TLR and instead signals through TRIF (Matsumoto, 
Oshiumi et al. 2011). It could be a possible explanation for why CD200R1 is 
not decreased after Poly(I:C) treatment, but is decreased after FSL-1, LPS and 
R848 treatment (Figure 4.21).   
Another innovative finding of my work is the observation that CD200R 
regulated HO-1 expression (Figure 4.19). Transcription measurements of 
CD200R-/- macrophages also demonstrated that CD200R regulates the 
production of pro-inflammatory mediators. Macrophages deficient in CD200R 
displayed increased expression of TNF-α, iNOS and, importantly HO-1 
(Figure 4.19). Although previous studies have already shown that TNF-α 
(Gorczynski, Boudakov et al. 2008), and iNOS are regulated by the CD200 
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pathway (Hoek, Ruuls et al. 2000), no previous studies had demonstrated that 
HO-1 is regulated by CD200R. This is an interesting observation in the light of 
the study by Choi et al. where HO-1 expressing, CD206-positive macrophages 
protect against diabetes (Choi, Kashyap et al. 2010). Furthermore, another 
study on arteriosclerosis, where the authors used siRNA to silence HO-1 in 
DCs, resulting in increased MHC II expression, intimal hyperplasia and 
increased CD4+ T helper cell abundance (Cheng, Noorderloos et al. 2010) 
further suggests that HO-1 could play a protective role in inflammation. 
However, the effect of HO-1 in atherosclerosis is yet to be fully understood. 
HO-1 deletion reduces atherosclerosis development (Yet, Layne et al. 2003) 
and further studies are needed to fully clarify whether CD200R effects are 
carried out through HO-1 expression. 
In vivo expression of CD200R revealed expression heterogeneity. First, 
CD11b+ myeloid cells were assessed and found abundant in bone marrow, 
blood and spleen, in particular in bone marrow with 60% of all cells expressing 
the CD11b+ marker (Figure 4.22). Due to the abundance of myeloid cells, it 
was expected to find a high expression of CD200R in the bone marrow, 
compared with blood and spleen. The bone marrow revealed a high 
expression of CD200R, but so did the spleen (Figure 4.24). This was 
surprising, since the spleen only harboured a fraction of CD11b+ cells, 
contributing 5-10% of total cells (Figure 4.22). This could suggest that the 
spleen contained another subset of CD11b negative cells expressing CD200R. 
Moreover, monocytes, characterised as CD11b+CD115+, were highly abundant 
in the bone marrow (Figure 4.23). Monocytes emigrate from the bone marrow 
into circulation from where the cells enter secondary lymphoid organs or other 
tissues (Geissmann, Manz et al. 2010). Total expression of CD200R on 
monocytes was different than on total cells in terms of tissue distribution. 
Blood and bone marrow carried the highest abundance of CD200R on 
monocytes (Figure 4.25), whereas in total cells the highest abundance of 
CD200R was found in the bone marrow and spleen (Figure 4.24). This finding 
could imply that monocytes are differently regulated by CD200R in the spleen 
and blood than other cell types. Overall, the abundance of CD200R was higher 
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on monocytes (5-20% of monocytes) than total cells (1-2% of total)  
(Figures 4.25 and 4.24, respectively), suggesting that CD200R may be 
important for monocyte regulation. 
Monocytes are heterogeneous; however, it has not been clarified at what 
levels different subsets express CD200R in mice. I found that monocyte 
heterogeneity affected expression levels of CD200R, where blood harboured 
Ly6int that were higher in CD200R expression than Ly6Chi and Ly6Clow 
counterparts (Figure 4.26). Splenic monocyte subsets displayed no significant 
changes in CD200R MFI expression between groups (p=ns; Figure 4.27). 
This suggested the subsets could change their heterogeneity from the blood to 
spleen and vice-versa. In the bone marrow, the highest CD200R MFI 
expression was observed on Ly6Clow subsets, followed by Ly6Cint and Ly6Chi 
subsets (Figure 4.28). This variation in CD200R expression could be 
distributed in such a way that inflammatory Ly6Chi subsets are less inhibited 
(M1 macrophage-like) than Ly6Clow counterparts. This behaviour goes in 
accordance with the theories that migratory Ly6Chi monocytes are associated 
with M1 macrophages (Auffray, Fogg et al. 2007). In summary, this Chapter 
describes my main findings on the expression of CD200R on macrophages 
and monocyte subsets: 
1) Exposure to IFN-γ potently reduces the expression of CD200R1. 
2) TLR2/6, 4 and 7 decrease its expression while TLR3 has no effect. 
3) IL-4 slightly increases its expression. 
4) OxLDL does not modulate its expression. 
5) Ly6Cint monocytes are enriched with CD200R expression in the blood. 
These results in aggregate indicate that the precise inflammatory stimuli 
encountered in the environment by macrophages have a significant effect on 
the ability of macrophages to express CD200R and respond to CD200 leading 
to the resolution of inflammation. Further studies are necessary to understand 
the selective expression in Ly6C monocytes and its reflection on the 
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Effect of systemic treatment with CD200-Fc  
































Macrophages enter atherosclerotic lesions at the very beginning of plaque 
formation and remain a part of the disease through its development (Gordon 
2007; Tabas 2010). By uptake of oxidised lipids, macrophages generate 
foam cells, which become resident, necrotic and secondarily necrotic, 
forming necrotic, lipid cores in plaques (Tabas 2010). The first evidence that 
soluble factors could modulate host reactions was published by Menkin 
(Menkin 1944). Many groups investigated these soluble factors from the mid 
1940’s to the 1970’s, as reviewed by Oppenheim (Oppenheim 2001) until 
they became termed ‘monokines’ as proposed by Gery et al, a term for 
soluble pyrogenic factors produced by macrophages (Gery, Gershon et al. 
1971; Gery and Waksman 1972). The term ‘cytokine’ was subsequently 
launched by Cohen et al for describing the same soluble factors (Cohen, 
Bigazzi et al. 1974). Overproduction of pro-inflammatory cytokines is a 
hallmark of chronic inflammation and can be detrimental to the host by 
promoting disease progression (de Toledo 2006; Libby, Ridker et al. 2009; 
Scrivo, Vasile et al. 2011; Morrison 2012). Cytokines derived from myeloid 
cells, such as macrophages, can be detrimental for atherosclerosis (Libby 
2012; Moore and Tabas 2011). The down-modulation of excessive 
inflammation in myeloid cells can be mediated through CD200R1 agonism 
(Liu, Bando et al. 2010; Simelyte, Criado et al. 2008). I hypothesised that 
CD200-Fc agonism would reduce macrophage infiltration and lesion size 
and/or modify the morphological features of vulnerable plaques. Previous 
studies using a model of inflammatory arthritis generated positive results with 
CD200-Fc reduced severity and onset of disease (Simelyte, Criado et al. 
2008).  
In order to assess the effect of CD200-Fc on shear stress-induced plaques I 
set to (a) validate that the model generates normal shear-induced plaques 
after 9 weeks in our laboratory; (b) verify what morphological features were 
affected by treatment and (c) study a potential mechanism, by studying 
myeloid cell populations in bone marrow, blood and the spleen.  
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5.2 Mouse weights increased gradually during the  
high fat diet  
 
To ensure that ApoE-/- mice were maintaining or gaining their weight during 
the high fat diet period, mice were monitored for weight twice per week at the 
time of administration with fusion protein, IgG control and vehicle control. 
ApoE-/- mouse weights increased gradually during the exposure to a high fat 
diet, and no groups were losing weight yielding to any of the treatments in 
accordance with Home Office regulations (Figure 5.1). 
 
Figure 5.1 – Mouse weights were monitored for the course of the experiment. 
Four or five female ApoE-/- in each treatment group were placed on a high fat diet for 2 
weeks, then underwent perivascular cuff placement. The first dosage of CD200-Fc fusion 
protein, IgG, and vehicle controls were given to animals at the day of surgery and 
subsequently bi-weekly for the duration of 9 weeks treatment. Mouse weights first decreased 
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5.3 Effect of CD200-Fc on lesion size in shear stress-       
 induced atherosclerosis 	  
Mice were injected intra-peritoneum (i.p.) twice per week for nine weeks with 
CD200-Fc, IgG control or a sodium citrate vehicle treatment to control for 
unwanted effects from the drug’s suspension solution. The choice of an IgG 
control to test for unspecific activity by comparing with CD200-Fc treated 
animals was made on the basis of previous studies conducted at the 
Kennedy Institute of Rheumatology (Simelyte, Criado et al. 2008). ApoE-/- 
mice underwent perivascular shear stress altering cuff placement on the right 
carotid artery. Nine weeks after surgery, the carotid arteries and their sham-
operated contralaterals were snap frozen and submerged in OCT compound. 
Cryosections were taken every five micrometres starting from the heart 
towards the bifurcation. As expected, no lesion formation was observed in 
the intra cast HSS region. Also no significant differences were observed in 
lesion size (assessed as IMR) or length (assessed as distance from the 
upstream lesion free area to the end of the lesion towards the heart) between 
LSS and OSS regions in each treatment group (Figures 5.2, 5.3, 5.4), 
despite a statistical trend towards a higher lesion size in the OSS region 
compared to the LSS region (Vehicle group, p=0.06; unpaired t-test), (IgG 
control group, p=0.06; unpaired t-test), (CD200-Fc group, p=0.56; unpaired t-
test). No statistically significant changes in plaque size were found In the LSS 
or OSS region when comparing vehicle control, IgG control and CD200-Fc 
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Figure 5.2 – Vehicle treated ApoE-/- mice exhibit two distinct lesions. 
ApoE-/- females on a high fat diet underwent perivascular cuff placement surgery. For 9 
weeks after surgery, mice were injected i.p. with a vehicle solution volume equivalent to 
drug-dosed mice, twice per week. Carotid arteries were snap-frozen, sectioned and stained 
with elastic van Gieson solution as described in methods. Image areas were quantified using 
Image J software and intima/media ratios were obtained as described in methods. An 
unpaired, two-tailed t-test was performed to test for statistical significance (p=0.0643). Scale 
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Figure 5.3 –  IgG control antibody-treated ApoE-/- mice exhibit two separate lesions. 
ApoE-/- females on a high fat diet underwent perivascular cuff placement surgery. For 9 
weeks after surgery, mice were injected i.p. with 10 mg/kg IgG control antibody solution twice 
per week. Carotid arteries were snap-frozen, sectioned and stained with elastic van Gieson 
solution as described in methods. Image areas were quantified using Image J software and 
intima/media ratios were obtained as described in methods. An unpaired, two-tailed t-test 
was performed to test for statistical significance (p=0.0664). Scale bar 1 unit = 200μm, (N=4), 
Data is representative of one single experiment. 
 





































































































Figure 5.4 – CD200-Fc fusion protein-treated ApoE-/- mice exhibit two separate lesions. 
ApoE-/- females on a high fat diet underwent perivascular cuff placement surgery. For 9 
weeks after surgery, mice were injected i.p. with 10 mg/kg CD200-Fc protein solution twice 
per week. Carotid arteries were snap-frozen, sectioned and stained with elastic van Gieson 
solution as described in methods. Image areas were quantified using Image J software and 
intima/media ratios were obtained as described in methods. An unpaired, two-tailed t-test 
was performed to test for statistical significance (p=0.567). Scale bar 1 unit = 200 μm, (N=5). 
Data is representative of one single experiment. 

























































































































Figure 5.5 – Treated ApoE-/- mice did not exhibit changes in plaque size. 
ApoE-/- females on a high fat diet underwent perivascular cuff placement surgery. For 9 
weeks after surgery, mice were injected i.p. with a vehicle solution volume equivalent to 
drug-dosed mice, twice per week. Carotid arteries were snap-frozen, sectioned and stained 
with elastic van Gieson solution as described in methods. Image areas were quantified using 
Image J software and intima/media ratios were obtained as described in methods.  
(A) Dotplot of individual arteries in the LSS region. (B) Dotplot of individual arteries in the 
OSS region. An ANOVA was performed to test for statistical significance, however, no 
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5.4 Effect of CD200-FC on lesion composition 	  
Collagen plays an important role in tissue structural composition and function 
(Whittaker 2005). Previous studies have reported an association between 
plaque stability and collagen content (Cheng, Tempel et al. 2006). High 
collagen content is associated with stable plaques whereas low collagen 
levels have been found in ruptured plaques, as reported from the pathology 
studies of Renu Virmani (Virmani, Burke et al. 2003). In order to assess for 
the effects of CD200-Fc treatment on plaque collagen content, carotid 
sections were stained with the Picrosirius Red Method (Sweat, Puchtler et al. 
1964; Puchtler, Waldrop et al. 1973; Junqueira, Bignolas et al. 1979). 
Picrosirius Red staining binds specifically to collagen fibrils of different 
diameter and the method can be used to distinguish type I collagen from type 
III collagen under a polarized light filter. Type I collagen fibers display an 
orange/yellow birefringence and are formed by the thick fibers, collagen type 
III is a green birefringence and displays the thin fibers. All sections were 
stained according to the Polysciences Picrosirius Red Kit staining protocol.  
Quantification of photomicrographs revealed similar percentage collagen  
type I content in the LSS and OSS regions. The average percentages for LSS 
region vehicle control, IgG control and CD200-Fc treated samples were of 
6.49±0.36, 8.32±0.52 and 7.32±0.41, respectively (Figure 5.6A;  
Figure 5.6B).  In the OSS region, the average percentages for vehicle 
control, IgG control and CD200-Fc were 6.89±1.02, 8.07±1.47 and 
10.50±0.72, respectively (Figure 5.6C; Figure 5.6D). The average 
percentages of type I collagen revealed different figures from treatment 
groups in the LSS region, where values from vehicle to IgG control appeared 
to increase slightly, but changes were non-significant (ANOVA, p=ns). For 
the OSS region, an increasing trend of collagen type I content was displayed 
as follows: Vehicle control < IgG control < CD200-Fc. The changes, however, 
were non-significant (ANOVA; p=ns; Figure 5.6 C).  
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Figure 5.6 – Type I collagen in ApoE-/- mice after CD200-Fc treatment.  
ApoE-/- female mice at 17 weeks of age were placed on a high fat diet for 2 weeks then 
underwent perivascular cuff placement surgery. Mice were injected 10 mg/kg i.p. twice per 
week of CD200-Fc or IgG control. After 9 weeks, carotid arteries were snap-frozen, 
sectioned and stained with Picrosirius Red solution. (A) Average % collagen type I in the 
LSS region for treatment groups. (B) Representative photomicrographs under polarisation 
filter, orange/yellow is collagen type I. (C) Average % collagen type I in the OSS region for 
treatment groups. (D) Representative photomicrographs for OSS region under polarisation 
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Atherosclerosis develops when macrophages become lipid laden foam cells, 
generated from their ingestion of modified lipoproteins (Tabas 2010). Lipid 
accumulation inside the plaques form part of the necrotic lipid core, highly 
associated with ruptured plaques (Richardson, Davies et al. 1989). 
Lipid cores are also correlated with lower collagen content (thin-cap 
fibroatheroma) (Constantinides 1966), fewer functional smooth muscle cells 
(Kim, Klyachkin et al. 1994) and lipid-laden macrophages at the edge of the 
plaque (Aqel, Ball et al. 1984). Previous studies have reported a 10-16% 
content of lipids in murine carotid plaques (Cheng, Tempel et al. 2006). Thus, 
lipid content is an important feature of lesion composition. 
Oil Red O staining was used to detect lipid content in plaques. It contains 
Solvent Red 27 and Sudan Red, a fat-soluble dye for lipids and lipoprotein 
staining; and diazo dye (used for staining neutral triglycerides). Staining 
revealed the percentage of the plaque area positive for lipids. Vehicle control, 
IgG control and CD200-Fc treated animals’ carotids expressed a LSS region 
percentage lipid content of 26.34±4.37, 36.23±4.51 and 32.88±1.21, 
respectively (Figure 5.7A, Figure 5.7B; p=ns). In OSS region plaques, 
vehicle control, IgG control and CD200-Fc treated animals’ carotids 
expressed a percentage lipid content of 31.30±3.53, 30.60± 0.16 and 
35.63±1.87, respectively (Figure 5.7C, Figure 5.7D; p=ns). In summary, no 
changes were observed across treatment groups (Figure 5.7; p=ns). 
 
 
























Figure 5.7 – CD200-Fc treated ApoE-/- mice exhibit similar lipid content in LSS and 
OSS regions as IgG and vehicle control treated animals. 
ApoE-/- female mice at 17 weeks of age were placed on a high fat diet for 2 weeks then 
underwent perivascular cuff placement surgery. Mice were injected i.p. with 10 mg/kg twice 
per week of CD200-Fc or IgG control. After 9 weeks, carotid arteries were snap-frozen, 
sectioned and stained with Oil Red O solution. (A) Average % ORO in the LSS region for 
treatment groups. (B) Representative photomicrographs: red is lipid positive region.  
(C) Average % ORO in the OSS region for treatment groups. (D) Representative 
photomicrographs for OSS region Scale bar 1 unit= 200μm. N=4-5, (ANOVA, p=ns),  
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5.5 Analysis of macrophage content after CD200-FC  
treatment 
 
Macrophage foam cells form an important component of plaques  
(Tabas 2010). The myeloid receptor CD200R is expressed in the plaque, 
thus it was natural to measure the content of macrophages in plaque by 
staining for the scavenger receptor CD68 after treatment with CD200-Fc or 
controls.   
Percentage CD68+ macrophage LSS region lesions averaged in the range 
from 26.83±6.46 in CD200-Fc treated- to 28.8±4.32 in IgG control-treated 
animals, respectively, with no statistically significant changes (Figure 5.8A; 
Figure 5.8B; n=3-5, ANOVA, p=ns). The OSS region displayed a trend 
towards decreased content in the CD200-Fc treated plaques, with averages 
of IgG control treated animals displaying 32.1±7.2 percent CD68+ 
macrophage content (Figure 5.8C: Figure 5.8D). For CD200-Fc treated 
animals, average CD68+ macrophage plaque content in the OSS region was 
20.6±11.3 (Figure 5.8C; Figure 5.8D). This apparent change in average 
CD68 expression compared with IgG treated animals was not significant 
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Figure 5.8 – Percentage macrophage marker CD68 expression in female ApoE-/- mice 
after CD200-Fc treatment appears reduced in the OSS region. 
ApoE-/- female mice at 17 weeks of age were placed on a high fat diet for 2 weeks then 
underwent perivascular cuff placement surgery. Mice were injected i.p. with 10 mg/kg twice 
per week of CD200-Fc or IgG control. After 9 weeks, carotid arteries were snap-frozen, 
sectioned and stained with monoclonal anti-CD68 antibody. An isotype control was used to 
exclude non-specific staining. (A) Average % CD68 the LSS region for treatment groups.  
(B) Representative photomicrographs with CD68 (brown). (C) Average % CD68 in the OSS 
region for treatment groups. (D) Representative photomicrographs for OSS region. Scale bar 
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5.6 Hypercholesterolemia and monocytosis 
The study of lesions only represents part of the potential physiological impact 
of treatment, thus myeloid cell populations were studied by employing flow 
cytometry. During a short placement at the Faculty of Medicine of Hong Kong 
University, I conducted some preliminary pilot studies on ApoE-/- mice using 
FACS to assess for changes in myeloid markers during atherosclerosis. 
Previous studies have suggested an association between monocyte 
populations and cholesterol levels in ApoE-/- mice (Swirski, Libby et al. 2007). 
The spleen was also reported as a reservoir organ for monocytes (Swirski, 
Nahrendorf et al. 2009). In my pilot studies, I found that high expression of 
total Ly6C was up to three-fold increased during hypercholesterolemia, from 
5.24% in WT versus 14.10% in ApoE-/- splenocytes (Figure 5.9). The Ly6Chi 
cells that appeared during hypercholesterolemia also exhibited a higher side 
scatter profile, suggesting these cells were more granular. Higher granularity 
is also a typical trait of Ly6Chi cells (Lin, Castano et al. 2009). Expression of 
associated markers such as Ly6G was markedly increased during disease; in 
particular Ly6G and Ly6C double positive cells (Figure 5.10). There was an 
increase from 7.46% in WT to 9.03% in ApoE-/- spleens of Ly6GlowLy6int cells. 
An increase from 7.05% in WT to 11.2% in ApoE-/- was observed for 
Ly6ChiLy6Glow and finally an increase from 0.37% to 4.95% was apparent for 
Ly6ChiLy6Ghi cells (Figure 5.10). The total myeloid cell (MAC-1, CD11b+) 
population was also examined. A noticeable change occurred in the most 
granular cells, CD11b+SSChi cells representing 0.64% in WT, being 
completely shifted to 44.4% in ApoE-/- splenocytes (Figure 5.11).  Thus, 
based on the abundance of myeloid cell markers up-regulated during 
hypercholesterolemia, I hypothesized to encounter changes affecting myeloid 
cell populations after CD200-Fc agonist treatment. To assess whether 
CD200R1 agonism was resulting in changes in monocyte populations, cells 
treated with vehicle control, IgG control and CD200-Fc were FACS stained 
for combinations of the markers CD11b, CD115 and Ly6C in bone marrow, 
blood and spleen (Table 5.1; Table 5.2; Table 5.3).  
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Figure 5.9 – Pilot data suggested hypercholesterolemia increased inflammatory 
monocyte marker Ly6C. 
WT and ApoE-/- C57BL/6 mice were culled at age 20-25 weeks of age. Spleen tissues were 
isolated, lysed and stained for FACS using monoclonal antibodies as described in methods. 
Cells were counted with a neubauer chamber and cell numbers were volume-adjusted for 
labelling. After fixation with PFA, cells were read in FACS buffer on the flow cytometer. 
Compensation was done post-acquisition using BD Cell Quest. Gating was first applied on 
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Figure 5.10 – Pilot data suggested hypercholesterolemia increased subpopulations of 
Ly6ChiLy6Glow cells and Ly6ChiLy6Ghi cells in spleen. 
WT and ApoE-/- C57BL/6 mice were culled at age 20-25 weeks of age. Spleen tissues were 
isolated, lysed and stained for FACS using monoclonal antibodies as described in methods. 
Cells were counted with a neubauer chamber and cell numbers were volume-adjusted for 
labelling. After fixation with PFA, cells were read in FACS buffer on the flow cytometer. 
Compensation was done post-acquisition using BD Cell Quest. Gating was first applied on 
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Figure 5.11 – Pilot data suggested that hypercholesterolemia increased CD11b+ 
myeloid cells in whole blood. 
WT and ApoE-/- C57BL/6 mice were culled at age 20-25 weeks of age. Whole blood was 
collected by cardiac perfusion during terminal anaesthesia. Cells were lysed and stained for 
FACS using monoclonal antibodies as described in methods. Cells were counted with a 
neubauer chamber and cell numbers were volume-adjusted for labelling. After fixation with 
PFA, cells were read in FACS buffer on the flow cytometer. Compensation was done post-
acquisition using BD Cell Quest. Gating was first applied on total live cells, followed by the 
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5.6.4 CD200-Fc treatment did not affect tissue myeloid cell populations 
Higher CD200R expression was found on certain monocytes subsets 
depending on tissue (Chapter 4). Monocytes circulate from bone marrow to 
spleen and transverse into atherosclerotic lesions via the blood (Gordon and 
Taylor 2005). Based on this knowledge, it was important to study the different 
compartments where targeting CD200R could play a role on 
monocyte/macrophage population abundance. I began studying myeloid 
CD11b+ cells, and analysed the various subsets of myeloid CD11b+ cells.  
In the bone marrow, no changes were observed in CD200-Fc treated versus 
control treated mice as assessed by one-way ANOVA (p=ns). There was no 
evidence suggesting that myeloid cells egressed in higher proportion or 
became trapped in the bone marrow following CD200-Fc treatment  
(Table 5.1). After exiting the bone marrow, myeloid cells may have 
encountered the synthetic CD200R agonist in the circulation. To test for this 
effect, I collected and studied cell populations from the blood of ApoE-/- mice. 
Unfortunately, because of low blood retrieval yields from the experimental 
animals, samples had to be pooled from 2-3 donors to form a single FACS 
sample. This impaired the use of statistics on the blood samples dataset 
(Table 5.2).  
It has been reported that the spleen acts as a reservoir for monocytes from 
where they can respond to injury signals (Swirski, Nahrendorf et al. 2009). 
From this perspective, I wanted to assess the abundance of myeloid cells in 
the spleen during ApoE-/- induced hypercholesterolemia (Table 5.3). After 
testing 4-5 individual mice with vehicle control, IgG control or CD200-Fc, I 
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Parameter Bone Marrow ANOVA                 
(P-value) 
Vehicle control IgG control CD200-Fc 
CD11b+ 
% Cells 59.78 ± 8.92 55.7 ± 5.79 54.52 ± 5.90 0.149, ns 
  #Cells (10^5) 95.6 ± 43.3 110 ± 40.7 85.4 ± 32.9 0.611, ns 
  CD11b+CD115+   
% Cells 0.48  ± 0.15 0.48  ± 0.24 0.78  ± 0.51 0.339, ns 
# Cells (10^5) 0.71 ± 0.25 0.67 ± 0.19 0.85 ± 0.33 0.559, ns 
  CD11b+Ly6Chi   
% Cells 56.2 ± 10.2 66.7 ± 5.77 62.54 ± 7.39 0.205, ns 
# Cells (10^5) 88.6 ± 38.3 105 ± 38.8 79.1 ± 31.5 0.528, ns 
  CD11b+Ly6Clow   
% Cells n/a n/a n/a n/a 
# Cells (10^5) n/a n/a n/a n/a 
  CD11b+CD115+Ly6hi   
% Cells 56.2 ± 10.2 66.1 ± 5.77 62.5 ± 7.39 0.205, ns 
# Cells (10^5) 0.38 ± 0.11 0.44 ± 0.12 0.53 ± 0.22 0.404, ns 
  CD11b+CD115+Ly6Clow   
% Cells n/a n/a n/a n/a 
# Cells (10^5) n/a n/a n/a n/a 
 
Table 5.1 – Treatment with CD200-Fc did not induce significant changes in ApoE-/- 
bone marrow CD11b+ myeloid cells or subsets. 
ApoE-/- female mice were placed on a high fat diet for 9 weeks and injected twice weekly with 
vehicle control, IgG control or CD200-Fc drug. Bone marrow cells were harvested, lysed and 
counted for FACS staining. No bone marrow cells in the subtype Ly6Clow were encountered 
in either group (N=4-5; one-way ANOVA with Bonferroni’s post-test; ns =non-significant; 
n/a= non-applicable; mean ± SD; Data is representative of one single experiment). 
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Parameter Blood ANOVA 
(P-Value) Vehicle control IgG control CD200-Fc 
CD11b+ 
% Cells 1.23 ± 0.24 3.01 ± 1.93 4.29 ± 4.00 n/a 
# Cells (10^3) 8.65 ± 1.73 3.01 ± 1.93 3.87 ± 3.61 n/a 
  CD11b+CD115+   
% Cells 0.38 ± 0.04 1.39 ± 1.42 0.93 ± 0.93 n/a 
# Cells (10^3) 2.66 ± 0.29 1.39 ± 1.42 0.83 ± 0.84 n/a 
  CD11b+Ly6Chi   
% Cells 0.35 ± 0.09 0.71 ± 0.38 1.39 ± 1.30 n/a 
# Cells (10^3) 2.48 ± 0.66 0.71 ± 0.38 1.26 ± 1.17 n/a 
  CD11b+Ly6Clow   
% Cells 0.65 ± 0.32 1.48 ± 1.34 1.18 ± 0.71 n/a 
# Cells (10^3) 4.61 ± 2.23 1.48 ± 1.35 1.06 ± 0.64 n/a 
  CD11b+CD115+Ly6hi   
% Cells 19.7 ± 16.2 10.5 ± 4.95 16.7 ± 12.8 n/a 
# Cells (10^3) 0.52 ± 0.43 0.19 ± 0.08 0.24 ± 0.19 n/a 
  CD11b+CD115+Ly6Clow   
% Cells 34.8 ± 10.5 34.7 ± 15.1 23.7 ± 18.9 n/a 
# Cells (10^3) 0.93 ± 0.28 0.63 ± 0.27 0.34 ± 0.27 n/a 
 
Table 5.2 – Peripheral blood from ApoE-/- mice was recovered and monitored for 
myeloid cell populations after treatment with CD200-Fc. 
ApoE-/- female mice underwent surgery and were placed on a high fat diet for 9 weeks and 
injected twice per week with vehicle control, IgG control or CD200-Fc drug (10mg/kg). Blood 
cells were isolated and pooled from 2 or 3 donors to obtain one sample (n=2, pooled from 4-
5 mice; n/a=non-applicable). Data are presented as mean ±SD. No statistics were performed. 
Data is representative of one single experiment 
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Parameter Spleen ANOVA        
(P-value) 
Vehicle control IgG control CD200-Fc 
  CD11b+ 
 % Cells 6.45 ± 2.41 8.70 ± 3.16 8.83 ± 2.31 0.379, ns 
# Cells (10^5) 111 ± 102 171 ± 123 113 ± 45 0.533, ns 
  CD11b+CD115+   
% Cells 0.47 ± 0.31 0.95  ± 0.72 1.14  ± 1.85 0.511, ns 
# Cells (10^5) 0.91 ± 1.07 0.17  ± 0.12 0.16  ± 0.18 0.705, ns 
  CD11b+Ly6Chi   
% Cells 4.6 ± 1.66 6.97 ± 3.57 6.2 ± 1.29 0.379, ns 
# Cells (10^5) 7.49 ± 6.09 14.1 ± 12.0 7.91 ± 2.68 0.392, ns 
  CD11b+Ly6Clow   
% Cells 1.85  ± 2.12 2.27  ± 1.29 3.42  ± 2.97 0.562, ns 
# Cells (10^5) 4.25  ± 6.58 3.97  ± 2.25 4.38  ± 4.60 0.989, ns 
  CD11b+CD115+Ly6hi   
% Cells 63.9 ± 7.09 56.3 ± 2.99 57.3 ± 3.60 0.071, ns 
# Cells (10^5) 0.55 ± 0.58 0.95 ± 0.66 0.87 ± 0.98 0.723, ns 
  CD11b+CD115+Ly6Clow   
% Cells 25.2 ± 8.57 27 ± 8.06 29.4 ± 7.22 0.732, ns 
# Cells (10^5) 0.29 ± 0.42 0.47 ± 0.43 0.54 ± 0.69 0.781, ns 
 
Table 5.3 – ApoE-/- splenocyte expression of CD11b+ and other CD11b+ myeloid 
subsets did not display significant changes after treatment with CD200-Fc. 
After perivascular surgery, ApoE-/- female mice were placed on a high fat diet for 9 weeks 
and injected twice per week with vehicle control, IgG control or CD200-Fc drug (10mg/kg). 
Spleen cells were harvested, lysed and counted for FACS staining. (N=4-5). One-way 
ANOVA with Bonferroni’s post-test; ns=non-significant). Data are presented as mean ± SD. 
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5.6.5 Foam cell formation was not affected by CD200R 
 
To assess if CD200R affected hypercholesterolemia, BMDMs were matured 
with MCSF and incubated with oxLDL for 5 days on labtech slides. 
Subsequently, slides were fixed and stained with oil red O to determine 
oxLDL accumulation. Qualitative assessment revealed no observed changes 








Figure 5.12 – CD200R did not affect foam cell formation after oxLDL incubation.  
WT or CD200R-/- bone marrow derived macrophages were matured at a density of 1x106 
cells/ml for 7 days with MCSF (100 ng/ml). Cells were seeded onto labtech slides for 5 days 
with oxLDL at increasing concentrations (10 μg/ml, 40 μg/ml, 100 μg/ml). Slides were fixed, 
washed in PBS and stained with Oil Red O for lipid content. Quantifications of the different 
fields (A, B C) was determined using Image J. Images for WT macrophages at increasing 
dosage of oxLDL (D, E, F); Images for CD200R-/- at increasing dosage of oxLDL (G, H, I) 
and quantifications of single fields revealing percentages of WT or CD200R-/- at increasing 
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In this Chapter I have shown that systemic treatment of ApoE-/- mice for nine 
weeks with CD200-Fc fusion protein had no greater effect than IgG control or 
vehicle control treatment on the development of several atherosclerosis 
features. Readouts included lesion size assessment by intima/media ratios 
exhibiting no changes between treatment groups. The same occurred for 
collagen, lipids and macrophage content, which remained unchanged 
between treatment groups.  
Studies on myeloid cell populations showed no difference between treatment 
groups for the abundance of CD11b+, CD11b+CD115+, CD11b+Ly6Chi, 
CD11b+Ly6Clow, CD11b+CD115+Ly6Chi, and CD11b+CD115+Ly6Clow cells in 
the blood, spleen and bone marrow (where applicable) both in terms of 
percentages and cell numbers.  
The lack of changes in plaque size and morphology such as lipid and 
collagen content, after treatment with CD200-Fc, could be explained, first, by 
the possibility that CD200 provision is not per se sufficient to reduce 
macrophage activation and abundance in shear-induced atherosclerosis. 
This is consistent with the finding in Chapter 3 that the expression of 
CD200R is not modulated by shear stress, neither LSS nor OSS (Figure 3.8; 
Figure 3.9). Thus, further studies on native atherosclerosis are needed to 
investigate the potential effect of CD200/CD200R on native atherosclerosis. 
Secondly, I showed in Chapter 4 (Figures 4.8, 4.9, 4.11, 4.12 and 4.14) that 
CD200R expression is decreased in M1 and increased in M2 macrophages. 
Hence, provision of CD200 may not affect the most pro-inflammatory M1 
macrophages, which have lost their receptor and may be the important 
subset for atherosclerosis. In keeping with this interpretation, Figure 5.8C 
displays a trend for reduced macrophage content in the OSS region, which is 
not observed in the LSS region. This could be explained by a higher 
abundance of alternatively activated M2 macrophages in the OSS region, 
responding to treatment (Cho, Miyoshi et al. 2012). Inhibiting M2 
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macrophages may indeed not be beneficial for treatment of atherosclerosis. 
According to previous reports, M2 macrophages have been proposed to 
produce wound-healing or anti-inflammatory mediators, such as IL-10, 
previously shown to be protective in atherosclerosis (Mallat, Besnard et al. 
1999). In addition, production of tissue factor and fibrin has been reported to 
derive from M2 macrophages (Edin, Wikberg et al. 2012). These factors 
contribute towards collagen production (Mantovani, Sozzani et al. 2002). 
Notably the M2 macrophage subset population is more complex, with 
different subtypes, in comparison to M1 polarised macrophages (Mantovani, 
Sozzani et al. 2002). Thus, inhibition of M2 macrophages could have 
unexpected effects, depending on what M2 subset is affected by treatment.  
Thirdly, it is possible that the IgG structural modification of the fusion protein 
to avoid cross-linking carried out by Biogen Idec, Inc., modified the drugs’ 
efficacy (Chan and Carter 2010). Further studies comparing the Biogen form 
to the original Trillium Therapeutics, Inc. form (Simelyte, Criado et al. 2008) 
will be needed for understanding the differences in mechanism of action and 
efficacy. Studies involving the genetic deletion of CD200 and its receptors will 
help to clarify this point further. 
Moreover, a slight effect on the IgG control was observed in Figure 5.6A, 
Figure 5.6C, Figure 5.7A and Figure 5.8A, suggesting that a more suited 
control will be needed in future studies. Intravenous IgG (IVIg) is given to 
patients suffering from autoimmune and inflammatory disease such as 
Haemophagocytic lymphohistiocytosis (HLH) (Imashuku, Teramura et al. 
2001) and Kawasaki’s disease (Oates-Whitehead, Baumer et al. 2003). In 
autoimmune disease, IVIg works by dampening the overactive immune 
system (Hartung, Mouthon et al. 2009) and in Kawasaki’s disease IVIg 
treatment reduced the incidence of coronary aneurysms at day 30 after 
dosing patients with 2 g/kg (Oates-Whitehead, Baumer et al. 2003). Thus, 
IgG treatment could also have an effect on the myeloid cells in the ApoE-/- 
mouse and could be a reason for why there was no change observed 
between CD200-Fc treated and IgG treated groups. Several authors have 
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described this effect and its origin. Nicoletti et al and Persson et al have both 
proposed that treatment with IgG reduces atherosclerosis in ApoE-/- mice 
(Nicoletti, Kaveri et al. 1998) and ApoE-/-LDR-/- mice (Persson, Boren et al. 
2005), respectively. 
Published reports (Tacke and Randolph 2006; Swirski, Libby et al. 2007) 
have shown that there is an increase of pro-inflammatory Ly6Chi monocytes 
during hypercholesterolemia. CD200-/- mice are associated with an increase 
of CD11b+ microglia in the spinal cord and F4/80+ macrophages in the spleen 
(Hoek, Ruuls et al. 2000). However, in my experiments the provision of 
CD200-Fc to ApoE-/- mice failed to affect monocyte populations. This finding 
further supports previous studies indicating that the primary mechanism of 
CD200/CD200R1 signalling is to regulate pro-inflammatory cytokine 
signalling (Hoek, Ruuls et al. 2000). 
In conclusion, this chapter has demonstrated that treatment with the fusion 
protein CD200-Fc during atherosclerosis has:  
1) No impact on disease progression as determined by plaque 
macrophage, lipid and collagen content.  
2) No significant effect on myeloid and monocyte cell numbers as 
determined by flow cytometry.  
The reasons for this negative result could be several, including a reduced 
expression of the drug target during disease, as shown in Chapter 3; 
targeting of a macrophage/monocyte subset that is not relevant for disease 
progression. Possibly the treatment of the disease should begin earlier, as a 
prophylactic, targeting cells when they are in circulation, before they become 
resident in plaques. In view of this, the role of CD200R1 agonism on 
CD200R+ cells as a treatment modality for atherosclerosis could be further 
explored with larger cohorts of samples and different dosing regimens by 
itself. In view of the effect of M2 polarisation on the mRNA expression of 
CD200R1 in Chapter 4, the concomitant use of drugs that simulate the M2 
alternative activation pathway in macrophages could be beneficial to 
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overcome the reduced expression of CD200R1 in atherosclerosis and allow 
























Chapter 6  
General Discussion 





1. I have demonstrated that pro-inflammatory stimuli in vitro are strong 
modulators of the expression of CD200R1. In particular, classical M1 
polarisation with IFN-γ significantly inhibited expression of CD200R1 and 
the M2 marker CD206. Inhibition of CD200R1 expression occurred upon 
stimulation with TLR ligands for MyD88-dependent PRRs TLR2/6, TLR4 
and TLR7. The MyD88-independent TLR3 did not reduce CD200R1 
expression when stimulated with Poly(I:C) in vitro. Alternatively activating 
Th2 cytokines induced macrophage CD200R1 gene expression without 
significantly changing the protein levels.  
 
2. Oxidised LDL did not induce significant changes in CD200R1 expression 
nor did the absence of CD200R1 in BMDM affect lipid uptake in vitro.  
 
3. Monocyte subsets exhibit differences in expression of CD200R, with 
Ly6Cint displaying higher expression levels of CD200R in the blood.  
 
4. Shear stress generates atherosclerotic lesions during 
hypercholesterolemia. Macrophage uptake is an important component of 
atherosclerotic lesions. Utilising a model of atherosclerosis based on 
shear stress modulation, I demonstrated that CD200R is heterogeneously 
expressed by myeloid cells in atherosclerotic lesions. Its expression, 
however, was not related to a specific type of shear stress  
(oscillatory wall shear stress vs. low wall shear stress). 
 
5. In aortic lesions, CD200R1 gene expression did not change over time. 
However, I demonstrated a significant reduction of CD200R1 gene 
expression in the spleen at 35 weeks of disease. This correlated with the 
reduced expression of M2 macrophage marker CD206, in accordance 
with the in vitro data. 
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6. CD200-Fc agonism during shear stress-modulated atherosclerosis had 
no significant effect on lesion size and composition, nor systemic effects 
on monocyte subpopulations.  
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6.2 General Discussion 
 
CD200/CD200R1 signalling has been described as a powerful pathway for 
myeloid cell deactivation with a protective role in acute infection and 
autoimmune disease (Hoek, Ruuls et al. 2000; Simelyte, Criado et al. 2008; 
Snelgrove, Goulding et al. 2008). The receptor CD200R1 binds to the CD200 
ligand to control excessive inflammation (Wright, Cherwinski et al. 2003). 
Exploiting this regulatory pathway during inflammatory disease has shown 
benefit in a murine model of rheumatoid arthritis (Simelyte, Criado et al. 
2008).  Manufactured as a synthetic ligand for CD200R1, the CD200-Fc 
fusion was generated by fusing the Fc portion of human IgG1 and the murine 
CD200 ligand (Hatherley, Cherwinski et al. 2005).  
Atherosclerosis shares many features with chronic inflammatory diseases 
(Ross 1999). Inflammation and haemodynamic factors such as perturbations 
of shear stress imposed by the circulation on the endothelium are important 
components of the pathogenesis of atherosclerosis and as a result, 
cardiovascular disease (Cheng, Tempel et al. 2006; JM, Li et al. 2006; Cheng, 
Tempel et al. 2007; Helderman, Segers et al. 2007). 
My project attempted to characterise the expression of CD200R in the 
context of atherosclerosis disease and in particular in shear stress-modulated 
lesions. I showed that CD200R is expressed in shear stress-modulated 
atherosclerotic lesions, predominantly by CD68+ macrophages. Its 
expression by macrophages, however, was heterogeneous and was not 
associated with a particular type of shear stress. 
Seeking to establish an alternative mechanism for the heterogeneity found in 
tissues during disease, I studied the in vitro stimulation of BMDMs. I showed 
for the first time that M1 polarising stimuli, such as IFN-γ and TLR4, caused a 
significant decrease of CD200R1 expression. M2 polarising stimuli such as 
IL-4 caused a modest increase in CD200R1 gene expression, without 
significantly affecting protein levels. My data suggests that heterogeneity of 
CD200R expression in CD68+ cells in atherosclerotic lesions might be 
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related to the activation status of the macrophages. Preliminary analyses 
conducted by myself and other members of the group failed to show, 
however, any association between CD200R and M1 and M2 markers in the 
lesions, and further studies are needed on a broader range of polarisation 
markers to reach a conclusion on this point.  
MyD88 is a common adaptor protein for TLR signalling (Kawai and Akira 
2010). TLR4 was not the only TLR to regulate the expression of CD200R1. 
Stimulation of TLR2/6 and TLR7 also significantly reduced CD200R1 
expression, whereas TLR3 stimulation failed to reduce CD200R1 expression. 
My results were found to be in accordance with recent reports 
(Mukhopadhyay, Pluddemann et al. 2010), which established that the 
reduction in CD200R1 expression upon TLR stimulation was MyD88-
dependent in an infectious disease model (Mukhopadhyay, Pluddemann et al. 
2010). In the wider context, my findings are supportive of a view whereby the 
type of inflammatory stimulus may play a role in dictating the ability of the 
myeloid cells to terminate their own activation via CD200/CD200R signalling. 
Hence, chronic inflammation may be promoted by reduced presence of 
inhibitory signals leading to sustained, unresolved inflammation.  
As reported by Richard Williams’ group on their work on the CIA model 
(Simelyte, Criado et al. 2008), mice treated with CD200-Fc exhibited signs of 
disease improvement compared to controls. Nevertheless, this treatment was 
performed in the context of a disease model exhibiting significant positive 
expression of CD200R1 during the early and progressive phase of disease, 
as reported by Simelyte et al. (Simelyte, Alzabin et al. 2010). The expression 
of CD200R1 at the late stage appeared lowered, however, this aspect was 
not highlighted in their study. This could perhaps be a reason for why it also 
has minimal impact on the later induced adaptive immune response, as 
reported (Simelyte, Alzabin et al. 2010). Interestingly, Willams’ and Guaza’s 
group described CD200/CD200R in a chronic disease model of 
neuroinflammation called the Theiler’s virus-induced demyelinating disease 
(TMEV-IDD), and showed that in the spinal cord, where the macrophage 
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relative, the microglia, reside, expression of the CD200R/CD200 axis is 
reduced (Hernangomez, Mestre et al. 2012). The expression could be  
up-regulated by treatment with the endocannabinoid anandamide (AEA) 
(Hernangomez, Mestre et al. 2012), a cannabinoid neurotransmitter proven 
to exert anti-inflammatory effects (Rettori, De Laurentiis et al. 2012). Similar 
reductions were seen previously in the EAE mouse model, a model for the 
human disease multiple sclerosis (Koning, Bo et al. 2007). 
Myeloid cells are required for the development of atherosclerosis, as 
demonstrated for instance by the studies whereby MCSF-deficient op/op 
mice do not develop atherosclerotic lesions even in the presence of 
hypercholesterolemia (Smith, Trogan et al. 1995). Thus, it could be predicted 
that myeloid deactivation via ligation of a CD200-Fc to CD200R1 should 
reduce inflammation and reduce atherosclerosis. Perturbations of shear 
stress are considered a very important stimulus of the recruitment of myeloid 
cells to atherosclerotic lesions (Hsiai, Cho et al. 2003). Hence, I selected a 
model of shear-induced atherosclerosis to test the hypothesis that CD200R1 
engagement might reduce lesion formation. However, the result of the study 
was overall negative, with no reduction in lesion formation or inflammation.  
One of the first possible explanations of this negative result is my observation 
in Chapter 3 that CD200R does not appear to be modulated by changes in 
shear stress, with no difference between oscillatory and low shear stress 
regions. This data might indicate that CD200/CD200R1 signalling is 
redundant in a shear stress modulated model of atherosclerosis. Further 
studies in other models of atherosclerosis, such as arterial injury and 
hypercholesterolemia are warranted to clarify whether CD200R signalling 
may have a role in atherosclerosis. Nevertheless, I did not observe any effect 
of CD200R deletion in vitro on lipoprotein uptake and foam cell formation, 
suggesting that the effect of CD200R signalling is limited to inflammation. 
There are however, several other potential explanations. My in vitro work 
showed that the majority of pro-inflammatory stimuli decrease the expression 
of CD200R, in particular the stimuli deemed responsible for M1 polarisation. 
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The reduced expression of CD200R during inflammation could partially 
explain the failure of CD200-Fc treatment to decrease lesion formation as 
assessed by lipid, collagen and macrophage content in atherosclerotic 
lesions generated by shear stress. Furthermore, targeting of the monocyte 
subsets that can bind the CD200-Fc fusion protein due to a higher 
expression of CD200R might not reduce plaque size and composition in 
atherosclerosis.  
On the other hand, the artificial structure of the CD200-Fc used in these 
studies could have altered the experimental outcomes. Biogen Idec, Inc. (MA, 
USA), the supplier of the experimental CD200-Fc fusion protein, has recently 
aglycosylated sites of the fusion protein originally developed by Trillium 
Therapeutics (ON, Canada). The purpose of such modification is reportedly 
to minimise the effect of the Fc-portion (Chan and Carter 2010). As a result, 
the potency of the drug could be altered compared to the previous 
formulations in the Williams’ group’s studies (Simelyte, Criado et al. 2008). 
In the last months further supporting evidence has been published supporting 
the notion that the inflammatory environment reduces the expression of the 
CD200/CD200R axis. A recent publication by Ren et al argues that aberrant 
CD200/CD200R expression contributes to painful synovium hyperplasia in a 
patient with primary hypertrophic osteoarthropathy (Ren, Leng et al. 2013), 
giving support to the effect of the microenvironment on CD200R expression. 
A study on Parkinson’s disease by Zhang et al demonstrates that deficits in 
the CD200/CD200R system exacerbate microglial activation and 
dopaminergic neurodegeneration in rats with 6-OHDA-induced Parkinson’s 
disease. This suggests that the inflammatory disease state reduces CD200R 
expression in the brain (Zhang, Wang et al. 2011).  
In summary, CD200R expression on macrophages in atherosclerotic lesions 
is not modulated by the exposure to different types of shear stress, nor 
oxidised LDL, yet it is significantly affected by inflammatory and polarising 
stimuli. The type of inflammatory stimuli in the tissue microenvironment might 
determine the ability of a macrophage to regulate its own activity, with IFN-γ 
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and TLR2/6, TLR4 and TLR7 impairing the ability of macrophages to express 
CD200R, as summarised below in Figure 6.1.  
My studies set out to further our understanding of the mechanisms of 
macrophage regulation in atherosclerosis in order to better treat this 
prevalent disease. The engagement of CD200R via CD200-Fc did not reduce 
shear stress-induced atherosclerotic lesions in the current disease model.  
We don’t yet know whether CD200R is a potential drug target for this disease, 
and to answer this question, future experiments with other models are 
warranted to establish whether CD200/CD200R signalling is irrelevant in 
shear stress induced pathways only or in the atherosclerosis disease more 
generally.  
In conclusion, my work has laid foundation for understanding how CD200R 
expression and macrophages are regulated during inflammation and 
atherosclerosis. I have uncovered important subsets, tissues and molecular 
signals that regulate the receptor expression and have generated novel ideas 
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Figure 6.1 – Expression of CD200R is regulated by the microenvironment. 
This figure summarises the findings pertaining to the expression of CD200R1 and 
the possible causes of the down-regulation during disease. (A) Healthy artery.  
(B) Diseased artery with influx of inflammatory cells and a pro-inflammatory cytokine 
environment. (C) The expression of CD200R is increased by stimulation of the IL-4 
receptor, allowing the CD200/CD200R axis to function competently, inhibiting the 
production of pro-inflammatory cytokines. (D) Stimulation of pathogen recognition 
receptors and IFN-γR reduces the expression of CD200R. This could result in 
aberrant CD200/CD200R signalling, presumably allowing inflammation to progress 
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